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General Introduction, Review of the Literature 
and Aims of the Study 
The availability of systemic drugs like methotrexate and acitretin has changed the life 
of thousands of patients suffering from severe psoriasis and disorders of keratinization. 
On the other hand the potential side-effects of these drugs limit their application. In 
general severe forms of psoriasis and disorders of keratinization are chronic conditions 
requiring long-term treatment. Therefore, the cumulative toxicity potential of systemic 
therapies has to be balanced against their clinical efficacy. Methotrexate and acitretin 
are frequently used for long-term treatment. Cyclosporin A is especially indicated for 
more short-term interventions. 
In the present thesis the risks and benefits of methotrexate and acitretin treatment have 
been described and the guidelines for the use of these drugs in dermatology have been 
updated accordingly. 
A- PSORIASIS 
Definition 
Psoriasis is a common and chronic skin disease, characterized by cutaneous 
inflammation and epidermal hyperproliferation. The prevalence of psoriasis in 
Caucasians is between 1.5 and 3%.' The age of onset is variable, with two peaks 
between 16 and 22 years and between 57 and 60 years.2 The incidence of psoriasis is 
equally distributed between both sexes.3 The clinical course is unpredictable with 
remissions and exacerbations. 
Histopathology4 
The most important epidermal changes in a fully developed psoriatic lesion are 
elongation of the epidermal rete ridges and the dermal papillae with thinning of the 
suprapapillary plate. In the epidermis polymorphonuclear leucocytes (PMN's) 
accumulate into micropustules of Kogoj with their characteristic spongiform 
appearance. Absence of a granular layer, parakeratosis, and intracomeal "Munro 
microabscesses" filled with polymorphonuclear leucocytes (PMN's) constitute the 
changes of the suprabasal compartment. In pustular psoriasis macropustules, filled with 
PMN's, are present in the upper stratum spinosum. Figure 1 illustrates the histological 
appearance of the psoriatic plaque. 
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Fig. 1. Histological appearance of psoriasis. Epidermal acanthosis, focal parakeratosis, elongated dermal 
papillae with suprabasal thinning and a mixed inflammatory infiltrate at the dermo-epidermal junction. 
Pathogenesis 
Both exogenous and endogenous factors play a role in the pathogenesis of psoriasis. 
An important aspect is the genetic predisposition, which is supposed to be polygenic. 
Factors involved in the elicitation of psoriasis in a genetically predisposed individual 
are trauma (Köbner phenomenon), infection (streptococcus), endocrine factors, 
sunburn, metabolic factors, drugs and psychogenic factors.forrev,cw ' 
Genetic aspects 
Family studies and twin studies converge to a genetic nature of psoriasis. A 73% 
concordance amongst monozygotic twins was reported.5 Table 1 summarizes the risk 
of getting psoriasis. If both parents have psoriasis a child has a risk of 50% to develop 
clinical signs of psoriasis. If only one parent is affected the risk for the child to 
develop psoriasis is 10%. For second and third degree relatives the risk approaches the 
frequency in the normal population.6 
During the last decade important progress has been made by molecular geneticists and 
dermatologists on the insight of the puzzling genetics of psoriasis. Recently a 
predisposing gene has been mapped to the long arm of chromosome 17.7 However, 
recent information from Prof. E. Christophers, department of Dermatology, University 
of Kiel, Germany indicates that this gene is not involved in their families with 
psoriasis.8 Several genetic factors have been reported to contribute to an early onset 
and severe course of psoriasis. These include: 
S 
• HLA class I (CW6) and HLA class II (Dr7) antigens.9"17 
• Polymorphism in the apolipoprotein E gene'8, the alpha-1-antitrypsin inhibitor 
gene" and the interleukin-1 receptor antagonist gene.20 
Table 1. Risk of getting psoriasis 
Family members with Risk (%) 
psoriasis 
One parent, no siblings 10 
No parents, one sibling 7 
One parent, one sibling 16 
No parents, two siblings 16 
Both parents 50 
Second degree relatives 4 
Third degree relatives 1-2 
Adapted from: Zachariae H. Epidemiology and genetics. In: Textbook of psoriasis (Mier PD, 
Kerkhof PCM van de, eds.), Churchill Livingstone, Edinburgh, I986;4-12. 
The symptomless skin of patients with psoriasis 
Concerning the lesionai psoriatic skin many abnormalities have been reported. The 
symptomless skin of psoriatic patients shows far less abnormalities, but these are 
probably highly relevant to the pathogenesis of psoriasis. 
Earlier flow cytometrical studies and thymidin labelling experiments claimed that 
epidermal proliferation of the clinically uninvolved skin was abnormal compared to the 
skin of normal subjects.21,22 However, no information was provided whether these 
experiments were carried out on distant uninvolved skin and whether the patients were 
in a stable stage of their disease. Recently, it was shown that the "recruitment" of 
cycling epidermal cells from the resting G0 population is not increased and also that 
markers for keratinization such as involucrin, filaggrin and keratins are normal in the 
clinically uninvolved skin.23,24 
Although the histological appearance of the symptomless skin is essentially normal, 
some authors claim a slightly increased infiltration of lymphocytes into the 
symptomless skin.24,25 The uninvolved skin of psoriatics has been shown to contain 
small numbers of the HLA-DR+/CD la' subclass of antigen presenting cells.25 From 
these studies it cannot be concluded with certainty whether the symptomless skin of 
patients with psoriasis has an intrinsic defect. 
At the molecular level, however, various changes have been observed consistently in 
the clinically uninvolved skin of patients with psoriasis. The most important changes 
are: 
• increased release of arachidonic acid metabolites26,27 
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• increased phospholipase A2 activity2*"50 
• decreased protein kinase С (PKC) activity31 
• increased polyamine synthesis32"33 
We may conclude from these observations that the symptomless skin of psoriatic 
patients is abnormal with respect to molecular factors involved in epidermal growth 
and inflammation. These observations provide extra evidence that psoriasis is not only 
a local disease, but in part also a systemic disease. During the last decades systemic 
treatments constitute a major therapeutic approach. 
The lesionai skin of patients with psoriasis 
The psoriatic lesion is characterized by many changes in the epidermis and dermis. 
An increased recruitment of cycling epidermal cells from the resting G0 population 
constitutes the core mechanism of psoriatic hyperproliferation.M Abnormal 
keratinization in the psoriatic lesion comprises an increased transcription of involucrin, 
keratin 16, "skin associated anti-leukoproteinase" (SKALP) and the enzyme 
transglutaminase I, responsible for cross linking of involucrin which is an important 
component of the comified envelope.35'39 In contrast, the expression of filaggrin and 
loricrin, another constituent of the comified envelope are decreased.37·40 
Inflammatory changes comprise accumulation of PMN, T-lymphocytes, mast cells and 
macrophages.4142 So far, no consensus has been reached on the question of which cell 
type is the first to invade the dermo-epidermal compartment during the elicitation of 
the psoriatic process. 
The fully developed psoriatic lesion is "packed" with many different mediators of 
inflammation and growth factors.4345 The pathogenetic relevance of these mediators is 
still debated. 
More recent studies on PKC isoenzymes indicate that altered PKC signalling might be 
an important aspect of the pathogenesis of psoriasis.46,47 
Systemic abnormalities in psoriasis 
Endocrinological factors play a role in the elicitation of psoriasis. Impetigo 
herpetiformis may occur during pregnancy and is considered as a variant of 
generalized pustular psoriasis.48 After delivery the symptoms disappear. 
Discontinuation of systemic corticosteroids may result in a severe exacerbation of 
psoriasis. Following bacterial infections guttäte psoriasis is commonly induced, 
especially in children. Bacterial superantigens are supposed to be the immunological 
principle. In early psoriatic lesions a decrease of CD4 positive T-cells has been 
demonstrated.49 During immunosuppression in HIV positive psoriatics severe 
exacerbations of psoriasis are frequently observed.50 Various systemic drugs aggravate 
psoriasis: antimalarials, lithium, ß-adrenergic blockers.1 Psychologic factors have been 
shown to aggravate psoriasis in approximately 40% of the patients.51 
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Anti-psoriatic targets 
As psoriasis can be modulated by various endocrine and immunomodulatory 
mechanisms, it is feasible that hormonal intervention and immunotherapy might be 
approaches for systemic therapeutic intervention. Epidermal hyperproliferation and 
cutaneous inflammation are important targets for the topical treatment of psoriasis. 
Clinical features 
For a detailed description of the many clinical variants of psoriasis various reviews are 
available.U2 
Despite the fact that psoriasis has many different clinical presentations, it is regarded 
as a single entity. Different forms of psoriasis can coexist in one patient, or may 
appear at different moments in the same patient. In one family the members may show 
different forms. In brief, the most important clinical manifestations are described: 
1. Erythematosquamous variants 
• Chronic plaque psoriasis is the most common presentation, characterized by 
coin-sized to palm-sized erythematosquamous plaques with a sharply delineated 
edge (Figure 2). Annular lesions may occur as a result from central healing. 
Predilection sites are the scalp, the trunk, the sacral region and the extensor 
surfaces of knees and elbows. Guttäte psoriasis (Figure 3) is a variant with 
erythematosquamous papules. Systemic triggering factors often are relevant to 
this form. 
Fig. 2. Chronic plaque psoriasis 
// 
i 
Fig. 3. Guttäte psoriasis 
Fig. 4. Flexural psoriasis 
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• Palmoplanar psoriasis is rather common and may occur with or without 
psoriatic lesions on other parts of the skin. Characteristic features are sharply 
delineated erythematosquamous plaques with adherent scales and fissures. 
• Flexural psoriasis or psoriasis inversa occurs in 2-6% of the patients as an 
isolated symptom, much more frequently it occurs in association with non-
flexural symptoms of psoriasis. Scaling is mostly absent or minimal. (Figure 4) 
• Ervthrodermic psoriasis is the most severe form characterized by generalized 
erythema and scaling. Systemic disregulation with hypo- and hyperthermia, 
proteinloss, dehydration and even renal and cardiac failure may occur and 
hospitalization is indicated. 
2. Pustular variants 
• Persistent palmoplanar pustulosis occurs in up to 5% of all psoriatic patients. It 
is still a debate whether this is a manifestation of psoriasis or a separate entity. 
Two to 19% of the patients have other signs of psoriasis.53,54 Erythemato-
squamous plaques accompany the sterile pustulation (Figure 5). The disorder is 
very resistant to therapy. 
Fig. 5. Persistent palmoplantar pustulosis 
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Acrodermatitis continua of Hallopeau is a rare disorder with erythema, scaling 
and pustules on the distal phalanges of the fingers or toes, sometimes with nail 
deformation and bone changes. Treatment failures are common. (Figure 6) 
Generalized pustular psoriasis (Zumbush) is a relatively rare and severe form of 
psoriasis with erythema, scaling and the development of sterile pustels.55 (Figure 
7) Most patients have a history of chronic plaque psoriasis. There are systemic 
symptoms like malaise, fever and leukocytosis. Generalized pustular psoriasis is 
a serious disease with a considerable mortality. 
Fig. 6. Acrodermatitis continua of Hallopeau 
"&&~i 
Fig. 7. Generalized pustular psoriasis (Zumbush) 
,*' 
3. Extracutaneous symptoms 
• The nails are involved in 10-55% of the psoriatic patients.56 Pitting of the nails, 
subungual hyperkeratosis, distal onycholysis and brownish red discolorations due 
to accumulation of parakeratotic material in the nailbed are the most common 
features. (Figure 8) 
• Psoriatic arthritis is present in approximately 7% of the patients.57,58 Arthritis of 
the distal phalanges is the most characteristic manifestation. Although the 
incidence of peripheral oligoarthropathy is much higher, axial changes or severe 
deformities (arthritis mutilans) may occur in some patients.' 
Fig. 8. Psoriasis of the nails 
Treatment 
Many different topical and systemic anti-psoriatic treatments are available. No single 
drug treatment can produce definitive cure, but the clinical symptoms can be 
minimized. Treatment has to be individualized for each patient, depending upon factors 
like age, sex, occupation, general health, concomitant medication, personality, 
motivation and cutaneous symptomatology. The combination of different treatment 
modalities (topical and/or systemic) produces the best results in most patients. 
Attention to the general physical and psychological health is important, as the activity 
of psoriasis is influenced by these factors. Diets are not effective. A summary of 
different treatment modalities is presented.1·5' 
IS 
Topical treatment 
• Coal tar has been used for the treatment of psoriasis for more than a century and 
is a mixture of thousands of substances produced during the carbonization of 
coal.60 It is an anti-mitotic and anti-inflammatory agent.61 Coal tar preparations 
in concentrations varying from 3-10% are effective in psoriasis as monotherapy 
and in combination with ultraviolet light (Goeckerman regime).62 Coal tar mono­
therapy was reported not to be associated with increased malignancy of skin, 
bladder or any other organ.63 Disadvantages of coal tar treatment are staining of 
clothes and the typical odour. Side effects are folliculitis, phototoxicity (UVA), 
irritative or, very sporadically, allergic contact dermatitis. Coal tar is 
predominantly used in in-patient treatment settings and day care centres. 
• Dithranol (anthralin) is a synthetic analogue of chrysarobin, a tree bark extract. 
Its effectivity in psoriasis was discovered accidentally a century ago.64 Dithranol 
has anti-mitotic and anti-inflammatory properties.65,66 It is used as monotherapy 
and in combination with tar bath and ultraviolet В phototherapy (Ingram 
schedule).67 Until recently stiff dithranol pastes (with salicylic acid for 
stabilization of the dithranol) were most commonly used in stepwise increasing 
concentrations and with long application times (12-24 hrs). Nowadays 
preparations for short-contact treatment are available, that are equally effective 
and more convenient for the patients.68 Dithranol has no systemic side effects; 
local side effects are a brownish staining of the skin that disappears soon after 
treatment, purple and permanent staining of clothes, bath, furniture etc. and 
irritation of the skin. Although very effective and safe, treatment with dithranol 
is time consuming. Dithranol treatment is an important therapeutic approach at 
in-patient departments, daycare units and units for intensified out-patient 
treatment. 
• Topical corticosteroids are effective and convenient. They have anti-mitotic, anti­
inflammatory and immunosuppressive properties.6' Intermittent schedules and 
sparse use are mandatory to prevent local side effects: skin atrophy, striae, 
venectasias, tachyphylaxis and not infrequently allergic contact dermatitis. 
Inhibition of the adrenal axis is possible, but only after excessive use of potent 
preparations. Twice-weekly treatment with a potent topical corticosteroid under 
hydrocolloid occlusion is very effective and patient-friendly.70 
• Calcipotriol ointment (50 μg/g), a vitamin D3 analogue and a recently 
introduced treatment modality, is grosso modo equally effective as topical 
corticosteroids.71 This biologically active form of vitamin D3 has anti­
proliferative properties and stimulates terminal keratinization.n Irritative 
dermatitis is a local side-effect. Development of hypercalciemia is unlikely if the 
weekly amount of ointment does not exceed 100 gram.71 
• Bland emollients and topical keratolvtics containing salicylic acid, urea and/or 
lactic acid, are frequently prescribed. If thick scales are present keratolytic 
treatment has to precede other schedules to improve skin-penetration of the 
active agents. 
2. Photo(chemo)therapy 
UVB and PUVA (Psoralens plus UVA) treatment are approximately equally 
effective.73 Combination schedules with coal tar (Goeckerman regime),74 dithranol 
(Ingram regime)75 and oral retinoids76,77 further increase the effectivity of UV-
treatment. High cumulative dosages, however, are associated with an increased 
incidence of cutaneous malignancies.78 
3. Systemic treatment 
If topical agents and/or photo(chemo)therapy are not sufficiently effective or 
impossible for practical reasons, systemic treatment might be a good alternative. In 
general, systemic treatment is more effective than topical treatment and also very 
convenient for the patient. On the other hand, side effects are common and 
potentially dangerous. Intensive dermatological care and the availability of up-to-
date treatment protocols are important for the safe use of systemic drugs in 
psoriasis. A brief introduction to the different treatment modalities is presented.' 
• Methotrexate (MTX) treatment for psoriasis was introduced by Edmundson and 
Guy.79 Nowadays this antimetabolite is known as an established and highly 
effective drug.80 An improvement of at least 75% in 31-91% of the patients 
within several weeks or months has been reported, irrespective of the type of 
psoriasis.1" ГСУ1"¥ " The most important side effects are gastro-intestinal 
complaints, bone marrow suppression, leukopenia, anaemia, trombocytopenia 
and hepatic damage leading to hepatic fibrosis or cirrhosis. Subjective side 
effects like fatigue, headaches and general discomfort are relatively frequently 
encountered. Less frequent side effects are gastric ulceration and bleeding, 
mucosal ulceration and reversible alopecia. MTX pneumonitis is an extremely 
rare but dangerous complication, not related to the (cumulative) dose. 
Interactions with other drugs, especially with other folate antagonists like 
trimethoprim or trimetroprim-sulfamethoxazole and high dosages of nonsteroidal 
anti-inflammatory drugs, can be life threatening. As methotrexate is teratogenic 
and potentially mutagenic, both males and females have to refrain from 
reproductive activity during treatment and until 3 months after discontinuation of 
treatment.92 
• Oral retinoids are synthetic dérivâtes of vitamin A. Ott and Bollag first reported 
in 1975 on the effectivity of etretinate in psoriasis.*3 Although the working 
mechanisms of retinoids are not fully established, it is known that they influence 
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epidermal differentiation processes and that they have antiproliferative and 
immunomodulating properties.84 About 70% of the patients with plaque psoriasis 
respond favourably to etretinate monotherapy in dosages of 0.5-1.0 mg/kg/day.85 
Optimal results are reached in pustular forms of psoriasis.16 Acitretin, the free 
acid of etretinate, has recently become available and is much more hydrophylic 
than etretinate. Compared to etretinate, it is grosso modo equally effective87"", 
but it has a much shorter half-life of only about 50 h compared to 80 days for 
etretinate. However, reesterification of acitretin into etretinate has been well 
documented. In contrast to etretinate, acitretin does not accumulate in the fatty 
tissue during prolonged treatment.89 Combination therapy of oral retinoids and 
UVB (Re-UVB) or PUVA (Re-PUVA) increases the effectivity of 
monotherapy.90" The most important side effects are dryness of lips and mucous 
membranes, reversible hair-loss, elevated triglyceride and cholesterol levels, 
skeletal abnormalities and exceptionally hepatitis.84 The use of oral retinoids in 
fertile women is limited by their teratogenicity. Adequate contraception during 
treatment up to 2 years after discontinuation of treatment is necessary for both 
etretinate and acitretin.' 
• Cyclosporin A (3-5 mg/kg/day) has recently become available for patients with 
severe psoriasis.'2 The impressive effectiveness of this T-cell inhibitor in 
psoriasis has strongly influenced the insight into the pathogenesis of psoriasis.1,93 
The most important (long-term) side-effects are dose-related hypertension, 
nephrotoxicity and immunosuppression.' Cyclosporin is an important new 
therapeutic tool for recalcitrant psoriasis, although its long-term use is limited by 
nephrotoxicity. 
• Systemic corticosteroids nowadays have no place any more in the routine 
treatment of psoriasis, because of the well-known side effects and frequent 
clinical rebounds after discontinuation of treatment. Systemic corticosteroid are 
still used in exceptional circumstances, i.e. therapy-resistant erythroderma or 
generalized pustular psoriasis and severe psoriatic arthritis.' 
• Sulfasalazine94 and its active part 5-aminosalicylic acid95 are both moderately 
effective in psoriasis with only minor side-effects. They can be used as 
monotherapy in stable plaque psoriasis or in combination with topical agents. 
• Other systemic drugs like azathioprine96" and hydroxyurea,98,99 have been 
reported to be effective in psoriasis and can be a good alternative if more 
conventional treatments do not succeed because of lack of effectivity and/or 
side-effects. 
• Fumarie acid derivatives do not belong to the officially registered drugs, but 
these compounds have been used for the treatment of psoriasis for more than 30 
years.100'01 Fumarie acid esters have antiproliferating properties.102 The 
effectiveness of fumarie acid is comparable to that of other systemic drugs but 
its use is limited by nephrotoxicity and lymphopenia. Fumane acid should only 
be prescribed under well-controlled conditions. 
B. DISORDERS OF KERATINIZATION 
Introduction 
Many different disorders of keratinization have been described in the literature. At 
present approximately 70 different entities have been recognized and this number is 
expected to increase further in the near future.103 The majority of entities show 
monogenetic inheritance, a few are polygenic. The classification of the different 
disorders of keratinization is based upon clinical, genetical, histological, biochemical 
and molecular-biological studies. Important clinical factors for a correct diagnosis are 
the mode of inheritance, whether or not the disease is congenital, and the presence or 
absence of associated symptoms. Classification is very important for genetic 
counselling, information on the prognosis and for the choice of an optimal treatment. 
An overview concerning monogenic disorders of keratinization has been provided 
recently by Dr P.M. Steijlen in his thesis.104 In all disorders of keratinization 
hyperkeratosis of either the "retention-type" or the "hyperproliferative type" is the most 
prominent feature.105 This hyperkeratosis is the result of abnormal keratinization. 
Treatment is symptomatic and predominantly focused on the reduction of hyper-
keratotic symptoms. In mild cases topical treatment with emollients containing 
keratolytic agents like urea, lactic acid, salicylic acid and propylene glycol may be 
sufficient. Topical retinoid treatment with all-trans-retinoic acid (tretinoin) is effective 
in many cases, but its use is limited by irritation of the skin. Topical 13-cis-retinoic 
acid has been reported to be effective in ichthyoses and Darier's disease.106"107 The 
introduction of synthetic oral retinoids was a very important step forward for the 
treatment of patients with severe disabling disorders of keratinization.108""4 As most 
disorders of keratinization are chronic conditions requiring long-term treatment, it is 
important to focus attention on side- effects and optimal dosage schedules of oral 
retinoid treatment (part two of this thesis). Here, an introduction is presented regarding 
the symptomatology and therapeutic aspects of those disorders of keratinization that 
were studied in the present thesis. 
Darier's disease 
Darier's disease or keratosis follicularis is an autosomal dominant disorder of 
keratinization. 
The most typical clinical features are predominantly follicular (yellow)brown pruritic 
hyperkeratotic papules and plaques.117 (Figure 9) Secondary bacterial and herpes 
simplex infections are common."8"119 Predilection sites are the so-called "seborrhoeic 
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areas" of the trunk, face, neck, scalp and flexures. Pits or punctate keratoses may be 
present on the palms and soles.120 Some patients have linear Darier's disease.'21 
Lesions of the mucous membranes, consisting of "cobblestone" papules in the 
oropharynx, vulva, oesophagus or rectum can be present. Most patients have brittle 
nails, the most typical nail changes are red and white longitudinal bands with a V-
shaped nick at the free margin of the nail.122 
The histology shows focal hyper- and parakeratosis with dyskeratotic cells (corps 
ronds) and suprabasal acantholysis. '23 
Fig. 9. Darier's disease 
Therefore, research on the pathogenesis of Darier's disease is focused on the discovery 
of a genetic defect in the synthesis of one of the proteins of the desmosometono-
filament complex. Recently the Darier's disease gene has been mapped to chromosome 
12q.124 This genetic defect results in the formation of a decreased number of 
rudimentary desmosomes.125 
The prevalence of Darier's disease is 1 in 55,000 to 1 in ΙΟΟ,ΟΟΟ.120126 The onset is 
usually in early childhood and the course of the disease is chronic and in most cases 
slowly progressive. 
Treatment with emollients, topical antibacterial agents and topical corticosteroids is 
moderately effective in most patients. Both topical all-trans-retinoic acid and topical 
13-cis-retinoic acid have reported to be effective, the latter being much less irritative.107 
Oral retinoids are the first choice in severe disease, although the margin between the 
therapeutic and toxic dose is often narrow.108"3 In recalcitrant cases, dermabrasion can 
be tried.127 
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Ichthyosis bullosa of Siemens (IBS) 
IBS is a rare and rather mild form of non-erythrodermic congenital bullous ichthyosis. 
The inheritance is autosomal dominant. 
Typical clinical features are a brownish, rimpled hyperkeratosis with the joints, the 
shins and the periumbilical region as sites of predilection. Blistering occurs after slight 
mechanical trauma or after sweating, resulting in superficially denuded areas 
("Mauserung"). Some patients have chronic relapsing eruptions with sterile 
Fig. 10. Ichthyosis bullosa of Siemens 
The histologic appearance is characterized by epidermolytic hyperkeratosis limited to 
the upper layers of the stratum spinosum.128 
Recently it has been discovered that IBS is caused by a mutation in the keratin 2e 
gene. Keratin 2e is exclusively expressed in the upper layers of the stratum spinosum. 
It was also demonstrated by molecular analysis that "ichthyosis exfoliativa" is identical 
to IBS.130 
Treatment with topical keratolyses is moderately effective. 
Lamellar Ichthyosis 
The lamellar ichthyoses are a group of congenital, isolated non-bullous forms of 
ichthyosis.131132 With exception from the autosomal dominant lamellar ichthyosis 
(ADLI), the inheritance is autosomal recessive. In general, the clinical symptoms are 
extensive but they may vary considerably between patients. Williams and Elias 
introduced two main types of lamellar ichthyosis. They distinguished between 
Erythrodermic (Autosomal Recessive) Lamellar Ichthyosis (designated as ELI or 
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EARLI) and Non-Erythrodermic (Autosomal Recessive) Lamellar Ichthyosis 
(designated as NELI or NEARLY). These authors reported that ELI was associated 
with highly elevated n-alkanes in the corneal layer.133·134 However, the relevance of this 
observation to the pathogenesis of the ichthyoses is not clear. Recently a mutation in 
the transglutaminase-gene was reported in lamellar ichthyosis. Transglutaminase is an 
important enzyme for the development of the "cornified envelope", a membrane 
surrounding the corneocytes.135 A subdivision of lamellar ichthyosis in separate entities 
will probably be possible in the near future, based on location of the underlying gene 
defects. 
Patients with erythrodermic forms of lamellar ichthyosis (ELI or EARLI) are born 
erythrodermic. Sometimes at birth they have the appearance of a "collodion baby" with 
a collodion-like membrane covering their complete body. The severity of the 
erythroderma later in life is variable, as well as the amount of scaling and the 
thickness of the scales. Most patients show fine scaling with small white scales. 
Marked palmoplanar hyperkeratosis is usually present. In non-erythrodermic forms of 
lamellar ichthyosis (NELI or NEARLI) the scales are usually larger with a dark-brown 
color. There is no erythroderma, but some affected children are born as a collodion 
baby. (Figure 11) Palmoplantar hyperkeratosis is usually mild.136 
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The lamellar ichthyoses are rare congenital disorders with a prevalence of about 
1:100.000. The condition persists life-long with minimal fluctuations in severity. 
Histologic examination reveals orthohyperkeratosis, an increased granular layer, 
acanthosis and papillomatosis. The rete ridges are flattened and plump. The dermis 
usually shows a moderate perivascular infiltrate.117 
Moderate improvement can be reached with local therapy. Improvement is due to 
keratolysis and hydration of the stratum corneum. Fatty ointments containing 5-10% 
salicylic acid, urea and propylene glycol have predominantly keratolytic properties, 
whereas sodium chloride and lactic acid (5-10% in an emollient base) hydrate the 
epidermis. It is important to realize that vast amounts of salicylic acid applied on large 
body-surfaces can induce salicylate-intoxication, a potentially dangerous condition 
characterized by nausea, tinnitus, dyspnea and hallucinations. "* Especially in children, 
preparations containing salicylic acid should only be used intermittently on small parts 
of the skin. Topical tretinoin (all-trans-retinoic acid) is effective in concentrations 
varying from 0.025 to 0.1%, but irritation is common. Recently, topical 13-cis-retinoic 
acid 0.1% was reported to be effective and less irritative than all-trans-retinoic 
acid.106107 Systemic retinoids have been reported to be very effective in most patients 
with lamellar ichthyosis.10g"5116 Because of the potential side-effects of retinoids, 
treatment should be restricted to patients with severe ichthyosis. In some patients 
intermittent therapy for example during the summer season can be a good alternative. 
Clinical studies concerning the development of optimal dosage schedules for different 
form of lamellar ichthyosis are important. 
Keratodermia palmaris et plantaris transgrediens et progrediens Greither U9,l4° 
Greither's disease is one of the hereditary diffuse palmoplantar hyperkeratoses. It was 
first described in a family by Aloys Greither in 1952.''" Its inheritance is autosomal 
dominant. The hyperkeratosis is often fissuring and painful and has a transgredient 
nature, which means that it extends to the extensor surfaces of the hands, feet, Achillus 
tendons, knees and elbows. Erythema and hyperhidrosis are common features. (Figure 
12) Symptoms usually start in the first decade of life and are slowly progressive, 
however, the disease tends to regress after the fifth decade. 
The histological appearance is non-specific: hyperkeratosis, acanthosis and a prominent 
stratum granulosum without any acanthokeratolysis. In the dermis a sparse mono-
nuclear infiltrate is present.139 
The genetic defect has not yet been localized. 
Treatment with topical keratolytics and fatty ointments has only a moderate effect. 
Mal de Meleda140·142 
Mal de Meleda or "keratosis extremitatum hereditaria transgrediens et progrediens" 
also belongs to the heterogeneous group of palmoplantar hyperkeratoses. Its inheritance 
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is autosomal recessive. This rare genodermatosis is named after the Adriatic island of 
Mljet, where it is an endemic disease because of inbreeding. 
Fig. 12. Greither's disease 
Patients with Mal de Meleda suffer from a diffuse palmoplanar hyperkeratosis. The 
hyperkeratosis extends to the extensor surfaces of the hands and feet and can involve 
the knees and elbows (transgredient). The hyperkeratosis usually has a smooth (cheese-
like) surface and erythema is substantial. Hyperhidrosis is a prominent feature. 
Secondary bacterial and fungal infections are common and produce an unpleasant 
odour. Constricting ainhum-like bands around the digits can result in spontaneous 
amputation. Perioral erythema and hyperkeratosis may be present. Nail changes may 
consist of koilonychia, thickening of the nails or subungual hyperkeratosis. Symptoms 
start in early infancy with palmoplanar erythema, followed by the development of 
hyperkeratosis. (Figure 13) The course is usually slowly progressive. 
The histology is again aspecific and shows orthokeratotic hyperkeratosis, 
hypergranulosis, slight acanthosis and a superficial perivascular infiltrate.143 
The pathogenesis of Mal de Meleda is still unknown. 
Topical treatment with keratolyses, antibacterial and anti-mycotic agents is important 
but usually not sufficiently effective. Etretinate treatment has been reported to be 
effective, but an increase of the erythematous component was observed if the daily 
dose exceeded 0.5 mg/kg.108 
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Fig. 13. Mal de Meleda 
Pityriasis rubra pilaris (PRP) 
Griffiths classified PRP into two adult types (classic and atypical) and three juvenile 
types (classic, circumscribed and atypical). The classic adult type accounts for more 
than 50% of the cases.144 PRP can occur at any age and affects both sexes equally. 
There are two peaks between 40 and 60 years and a smaller one in the first decade. 
Classical adult onset PRP (type I) is characterized by follicular erythematous and 
hyperkeratotic papules typically distributed on the trunk and extensor surface of the 
extremities (Figure 14). Extensive erythema and scaling or even erythroderma may 
occur, interspersed with sharply demarcated "island" of normal skin. Typically the 
disease progresses in cephalocaudal direction. Palmoplantar keratoderma is common 
and often has a yellowish color (PRP "sandal").145 The nail plates are usually thickened 
with distal splinter haemorrhages. Spontaneous resolution occurs in about 80% of 
patients in 1-3 years and relapses are uncommon.146 
Atypical adult onset PRP (type II) affects approximately 5% of the patients. The 
clinical symptoms are less typical; some skin areas show follicular hyperkeratosis and 
other areas a more lamellar scaling or eczematous changes. Erythroderma is 
uncommon. Patients with classical juvenile PRP (type III) have the same symptoms as 
those with type I PRP, but the age of onset is usually between 5 to 10 years. 
Spontaneous resolution within 1-2 years is common. In circumscribed juvenile PRP 
(type IV) well-demarcated plaques with erythema and follicular plugging are present on 
the knees and elbows. Atypical juvenile PRP (type V) \s a severe form with little 
tendency to spontaneous clearing. Clinical symptoms are often extensive and 
25 
keratoderma is common. As there is a considerable overlap in clinical symptoms in 
patients with PRP, the clinical importance of this classification is rather limited. 
The most characteristic histological changes are hyperkeratosis and follicular 
hyperkeratotic plugging with parakeratotic "shoulders". Acanthosis is usually present. 
The dermis shows a lymphohistiocytic infiltrate.147 
The pathogenesis of PRP is unknown and probably multifactorial.145 Possibly the 
different forms of PRP represent more than one single entity. Recently it has been 
suggested that the classic type of PRP is caused by a defect in the "retinol binding 
protein", the transport protein of vitamin A. This defect possibly induces a disturbance 
in control mechanisms of epidermal turnover, resulting in hyperproliferation and 
subsequently abnormal keratinization.148 The effectivity of synthetic retinoids in PRP 
emphasizes an important regulating function of vitamin A dérivâtes in the 
keratinization process. Vitamin A and Vitamin D are both ligands of the steroid-
receptor superfamily. These ligands work closely together ("as a family"). Topical 
calcipotriol has also been reported to be effective in some patients with PRP.150 
Satisfactorily therapeutic results of oral retinoids in this condition have been reported, 
although not all patients benefit from this treatment. 15<M54 The juvenile forms tend to 
have a better response to retinoid treatment than the adult forms.152154 Alternative 
treatment possibilities are azathioprine and MTX.150155"157 
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С. MODE OF ACTION OF METHOTREXATE AND ACITRETIN 
Many different treatment modalities are available for the management of psoriasis and 
disorders of keratinization. In this thesis we have restricted to highly effective systemic 
treatments for chronic and severe manifestations of these diseases. The clinical studies 
presented in this thesis have been focused on systemic treatment with methotrexate and 
acitretin. 
Methotrexate 
As the present thesis does not directly address the question of modes of action, the 
reader is referred to extensive reviews in the literature for detailed information.8081·158 
Here, general principles concerning the working mechanism of MTX are highlighted. 
MTX, a folic acid antagonist, has many different effects on various cell systems. It 
inhibits DNA synthesis by competitive inhibition of dihydrofolate reductase and 
inhibition of thymidynic acid.15' Especially cells in S phase are highly susceptible to 
this antimetabolitic effect. MTX inhibits the Chemotaxis of polymorphonuclear 
granulocytes (PMN's).160 MTX inhibits T-cell activation by antigen presenting cells. It 
has been suggested that inhibition of interleukin-1 bioavailability is of relevance in this 
respect.161162 To the best of our knowledge no direct effect of MTX on the process of 
keratinization has been demonstrated. The anti-inflammatory, anti-proliferative and 
immunomodulating effects of MTX have resulted in broad clinical application of this 
drug in both dermatology and rheumatology. MTX has been reported to be effective in 
rheumatoid arthritis, systemic lupus erythematosus, polyarteritis nodosa, Wegener's 
granulomatosis and recently also in systemic sclerosis.163"164 
It may be hypothesized that MTX exerts its antipsoriatic action via non-specific 
mechanisms interfering with epidermal cell proliferation and various aspects of 
cutaneous inflammation. 
Acitretin 
In this thesis we have focused on therapeutic effects of the most recent oral synthetic 
retinoid acitretin. The safety aspects were evaluated over prolonged periods of time 
and therefore regard both acitretin and its pro-drug etretinate. 
The mode of action of synthetic oral retinoids is not fully established. Retinoids 
regulate epidermal differentiation, resulting in normalization of disturbed keratinocyte 
differentiation and keratolysis. Retinoids have also antiproliferative, anti-neoplastic and 
immunomodulating properties.84 On the other hand, the intra-epidermal accumulation 
of polymorphonuclear leukocytes is inhibited by acitretin, demonstrating the anti­
inflammatory potential of this retinoid.168,169 At the molecular level a general principle 
is relevant for these cellular end-effects. Retinoids belong to the ligands of the "steroid 
receptor superfamily".170 This steroid receptor superfamily consists of specific receptors 
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which bind retinoids, vitamin D3, estriol, androgens and thyroxin. The complex of a 
ligand and its receptor modulates the transcription of various genes, ultimately 
resulting into modulation of epidermal proliferation and keratinization. 
Acitretin has been shown to modify the profile of epidermal cytokeratin expression. '7I 
In particular, the expression of keratin 4 and 13, normally only expressed in fetal skin, 
illustrates this effect. The transcription of type I (epidermal) transglutaminase mRNA 
is inhibited by oral retinoids.m This enzyme is relevant to the formation of the 
cornified envelope. Intracellular deposition of glycoconjugates (mucin-like substances) 
has been reported causing loosening and fragility of the stratum comeum.m 
The broad action spectrum of acitretin is reflected in its effectivity in inflammatory 
conditions such as pustular psoriasis, pityriasis rubra pilaris, lichen planus and 
cutaneous lupus erythematosus as well as in various disorders of keratinization.174 In 
this respect acitretin has a markedly different action spectrum compared to MTX 
which is not effective in the monogenic disorders of keratinization. 
D. AIMS OF THIS THESIS 
This thesis comprises a number of clinical studies concerning the effectivity, side 
effects and treatment guidelines of two systemic drugs that are frequently used in 
severe psoriasis or disorders of keratinization. The aim of the present thesis was a 
risk-benefit evaluation of these drugs in the treatment of psoriasis and disorders 
of keratinization. 
The following questions were addressed: 
1.1. What is the effectivity and side-effect profile of long-term treatment with 
MTX in psoriasis? 
1.2. Does interruption of long-term MTX treatment in psoriasis result in a 
substantial dose-reduction? 
1.3. Can we develop alternative approaches to detect MTX-induced liver damage 
in psoriatic patients that are reliable, but less invasive compared to liver 
biopsies? 
2.1. What is the efficacy and side-effect profile of acitretin in severe psoriasis 
and disorders of keratinization and which are optimal dosage schedules? 
2.2. What is the influence of oral retinoid treatment on the prevalence and 
severity of bone abnormalities? 
Based on the observations in studies addressing these questions, an update of 
guidelines for long term treatment with MTX and acitretin in dermatology is 
provided. 
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PARTI 
Methotrexate in Severe Psoriasis 

Chapter 1 
Introduction 
For several decades MTX has been an established drug for prolonged treatment of 
severe psoriasis. Unfortunately, it is not a focal point of clinically and basic oriented 
research, as pharmaceutic companies are more interested in the development and 
marketing of newer and more profitable systemic drugs. As MTX in our opinion 
remains to be a very effective, relatively safe and cheap drug for long-term treatment 
of severe psoriasis, a "reappraisal" of the clinical effects of this drug is necessary. In 
chapter 2 the clinical effectivity and side-effect profile of long-term MTX treatment 
were retrospectively analyzed in a group of 113 patients over a period of 22 years and 
compared to data presented in the literature. 
In general, psoriatic patients on long-term MTX treatment are "easy" patients for 
dermatologists. They are seen at regular intervals of 6-8 weeks for evaluation of the 
clinical effectivity and possible side-effects and if necessary the weekly dose is 
adjusted. Most patients are very satisfied with MTX treatment, despite the fact that 
they are aware of its potentially serious side-effects. In general, they are reluctant to 
interrupt treatment because of fear for a severe relapse or aversion to the more 
cumbersome and time-consuming topical therapy. In chapter 3 it was investigated 
whether it is possible to reduce the cumulative dose and toxicity of MTX by interrupti-
on of long-term treatment in 10 patients. 
According to the international guidelines provided by Roenigk, the performance of 
percutaneous liver biopsies is necessary in the initial phase of treatment and 
subsequently after each cumulative dose of 1.5 gram. Because of fear for possible 
complications and for a painful procedure, patients (and doctors) regularly refrain from 
MTX treatment, despite its effectiveness. In chapter 4 the value of two non-invasive 
tests for the detection of early MTX-induced liver damage was prospectively evaluated 
in a study designed and carried out in cooperation with the Department of Nuclear 
Medicine, the Department of Hepatology and Gastroenterology and the Department of 
Clinical Chemistry. 
39 

Chapter 2 
Methotrexate Revisited: 
Effects of long-term Treatment in Psoriasis 
RJ van Dooren-Greebe 
ALA Kuijpers 
J Mulder 
Th de Boo 
PCM van de Kerkhof 
Br J Dermatol 1994; 130: 204-210 
SUMMARY 
In the past 22 years, 113 patients with severe psoriasis have been treated with low-
dose methotrexate (MTX) in our department. The maximum weekly dosage was 15 mg 
(Weinstein schedule), the estimated mean cumulative dose 4803 mg and the estimated 
mean duration of therapy 8 years and 11 months. In 81% of the patients, prolonged 
clearance or almost clearance was reached, indicating the potent and sustained potential 
of MTX in the treatment of both pustular and erythematosquamous variants of 
psoriasis. 
Eighty-three patients (73%) had side-effects, most frequently abnormal liver function 
tests, nausea and gastric complaints. Apart from hair loss in seven patients, there were 
no mucocutaneous side-effects, probably because of the low-dose treatment schedule. 
In 71 patients MTX therapy was discontinued; in 33 patients because of side-effects. In 
55 patients one or more liver biopsies were performed. Fibrosis was seen in seven of 
these patients (13%) and cirrhosis in two (4%). There was no relation between liver 
biopsy classification and cumulative dosage or duration of MTX therapy, nor was there 
any relation between liver histology and abnormal liver function tests. During this 22-
year period, there were no deaths or life-threatening side-effects attributable to MTX 
treatment. 
We conclude that low-dose MTX (< 15 mg/wk) is a relatively safe therapy for severe 
psoriasis, if patients are carefully selected beforehand and regular monitoring for side-
effects and drug interactions is performed during therapy. A liver biopsy during the 
first 3 months of treatment, and subsequently after each 1.5 g of MTX, should be part 
of the treatment protocol, until equally reliable non-invasive screening methods for 
liver damage are developed. 
Methotrexate (MTX) is an established and highly effective systemic drug for the 
treatment of severe psoriasis. It is indicated in patients with psoriasis which is resistant 
to topical therapy or photo(chemo)therapy, and also when the response to other 
systemic treatments such as oral retinoids is unsatisfactory.1'3 Compared with other 
treatments, MTX is particularly effective in psoriatic arthritis and psoriasis of the 
nails.4·5 
The use of MTX in psoriasis has a long history. In 1951 Gubner noted a beneficial 
effect from the folic acid antagonist aminopterin,6 and in 1958 MTX treatment was 
introduced by Edmundson and Guy.7 MTX seemed to be somewhat less effective than 
aminopterin, but it had fewer and less severe side-effects. From 1971 onwards the 
weekly divided oral "Weinstein schedule" was generally used, i.e. three dosages per 
week at 12-hour intervals.8 Despite the clinical efficacy of MTX, dermatologists have 
developed a cautious attitude towards this drug because of many reports concerning 
long-term hepatotoxic side-effects.*"14 Because of the introduction of newer systemic 
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treatments such as retinoids and cyclosporin, a re-evaluation of MTX therapy is 
appropriate. 
In our department 113 patients with severe psoriasis have been treated with MTX 
during the past 22 years. In 1982, clinical efficacy and side-effects were reported in 
some of these patients,15 and we now present the results of a retrospective study 
concerning the efficacy and side-effects of MTX in psoriatic patients attending the 
department of dermatology at the Nijmegen University Hospital. Special attention was 
focused on the relation between liver biopsy classification and disturbances of liver 
function tests, and the relation of liver histology to cumulative dose or duration of 
MTX therapy. 
METHODS 
All records of patients with psoriasis treated with MTX in the period between August 
1970 and July 1992 were reviewed. The indication for MTX therapy was severe 
psoriasis unresponsive to local therapy, photo(chemo)therapy or oral retinoids. The 
patients were treated with the oral schedule described by Weinstein and Frost.8 
Treatment was started with 3x5 mg/week or 3x2,5 mg/week (from 1986 onwards), and 
thereafter gradual dosage adjustments were made until a satisfactory minimum 
maintenance level was reached. The maximum dosage was 15 mg/wk. Before starting 
MTX treatment, liver function tests (including transaminases, alkaline phosphatase and 
gamma-glutamyltranspeptidase), serum creatinine, full blood count and chest X-ray 
were performed. Contra-indications to therapy were a history of alcoholism, severe 
liver disease, renal failure and gastric ulceration. Patients with cytopenia, abnormal 
liver function tests, infectious diseases, those receiving concomitant medication which 
might interact with MTX, pregnant women and those wishing to become pregnant (and 
male partners of women wishing to become pregnant) were also excluded. 
From 1983 onwards it was our policy to perform liver biopsies before treatment or 
during the first 3 months of treatment, and subsequently after each 1.5 g of MTX. 
Liver histology was graded as follows: 0, not évaluable; grade I, normal histology or 
minimal disturbances; grade II, moderate to severe fatty infiltration; grade IIIA, mild 
portal fibrosis; grade HIB, moderate to severe portal fibrosis, and grade IV, cirrhosis.16 
During MTX-therapy, all patients attended the out-patient department at 6-weekly 
intervals for evaluation of clinical efficacy and side-effects (more frequently during the 
initial period of therapy). Laboratory investigations were repeated and, if necessary, 
adjustments in the weekly dosage were made. 
For this retrospective study, clinical and laboratory data were collected from the 
patients' records. The following lists the details elicited in the case history. 
1 Details on patients and MTX intake. Date of birth, sex, type of psoriasis, risk factors 
for hepatotoxicity (alcoholism, obesity, diabetes mellitus, history of arsenic intake), 
cumulative dose of MTX, duration of therapy. 
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2 Efficacy. The efficacy was considered good if the skin was clear or almost clear, 
moderate if recurrences were seen during treatment, and poor when there was no 
improvement. 
3 Side-effects. Clinical side-effects, abnormal laboratory findings and liver biopsy 
features, including the corresponding cumulative dose and duration of therapy. 
4 Post-treatment follow-up. Reasons for discontinuation of treatment, and clinical 
course after cessation of therapy. If applicable, the cause of death was recorded. 
To estimate the mean cumulative dose and duration of treatment, we used the Kaplan-
Meier method." The reason for using this method was that patients still using MTX at 
the end of the study, or patients lost to follow up have to be included in the estimation 
procedure as "censored observations". A method based exclusively on data derived 
from patients who discontinued MTX treatment would underestimate the mean 
cumulative dose and duration of treatment. 
RESULTS 
General data 
One hundred and thirteen patients (66 males, 47 females) with a mean age of 45.5 
years at the onset of therapy (age range 17-81 years), were treated with MTX between 
August 1970 and July 1992. Ninety-five patients (84%) were suffering from 
recalcitrant psoriasis vulgaris, 10 (9%) were erythrodermic, five (4%) had palmoplantar 
pustulosis, two (2%) had generalized pustular psoriasis (Von Zumbush type) and one 
patient (1%) annular pustular psoriasis. In 108 out of the 113 patients concomitant 
topical treatment was intermittently given in limited amounts, e.g. topical 
corticosteroids (105 patients), home treatment with short contact dithranol (15 patients) 
and coal tar products (10 patients). Twenty-five patients were still taking MTX at the 
end of the study; treatment was discontinued in 71 cases and 17 patients were lost to 
follow-up. The retrospective analysis revealed that 2 patients died during MTX 
therapy. Causes of death were carcinoma of the lung and myocardial infarction. 
Cumulative dose of MTX and duration of therapy 
The cumulative dose ranged between 90 mg and 16,580 mg, the estimated mean 
cumulative dose was 4803 mg (Figure 1). The estimated mean duration of therapy was 
8 years and 11 months with a range of 8 weeks - 20 years. The weekly dosage did nor 
exceed 15 mg in any patient. 
Efficacy 
In 92 patients (81%) the response was good, in 19 (17%) moderate, and in two (2%) it 
was poor. Table 1 summarizes the efficacy of MTX in the various types of psoriasis. 
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The frequency of hospital admissions during treatment with MTX decreased by a 
factor of 10 compared with the pre-treatment situation. Before MTX therapy the mean 
number of hospital admissions was 0.4/patient/year, and during therapy it was 0.04. 
% of patients 
100 л 
6 8 10 12 
Cumulativa dose of MTX (g) 
14 16 18 
Fig. 1 Cumulative dose of MTX (n=113) 
Table 1. Efficacy of MTX in the various types of psoriasis (n=113) 
Type of psoriasis 
Plaque psoriasis 
Erythrodermic psoriasis 
Palmoplanar pustulosis 
Generalized pustular 
psoriasis 
Annular pustular psoriasis 
Total 
No. of 
patients 
95 
10 
5 
2 
1 
113 
Good 
78 
9 
3 
1 
1 
92 
Efficacy 
Moderate 
15 
1 
2 
1 
19 
Poor 
2 
2 
Clinical course after discontinuation of MTX therapy 
Seventy-one patients discontinued MTX therapy for different reasons (see below). 
Thirty-two of these 71 patients (45%) subsequently required hospital admission, PUVA 
therapy, oral retinoids or cyclosporin within the first 6 months after cessation of 
therapy, and another nine patients (13%) required such treatment between 6 months 
and 1 year after stopping MTX. 
4S 
Side-effects 
During treatment with MTX 83 patients (73%) showed one or more clinical side-
effects, or abnormal laboratory data, at some time during the treatment period. Table 2 
summarizes the side-effects. 
Table 2. Patients with one or more side-effects during MTX therapy (n=83) 
Side-effect 
Abnormal liver function tests 
Gastro-intestinal 
Nausea 
Gastral complaints 
Abdominal discomfort 
Vomiting 
Gastric ulcer 
Subjective 
Fatigue 
Headache 
Dizziness 
Haematopoietic suppression 
Leucopenia 
Thrombopenia 
Anaemia 
Hair loss 
Minor infection 
Neoplasm 
η 
37 
36 
20 
6 
3 
3 
15 
7 
5 
10 
6 
3 
7 
6 
5 
% of total 
group (n=113) 
33 
32 
18 
5 
3 
3 
13 
6 
4 
9 
5 
3 
6 
5 
4 
Gastro-intestinal side-effects 
The most frequent side-effect was gastrointestinal discomfort. The complaints usually 
were restricted to the first 2-3 days following MTX ingestion. In three patients a 
gastric ulcer occurred, and this required temporary cessation of MTX treatment. 
Subjective side-effects 
Episodes of fatigue, headache and dizziness were occasionally experienced by several 
patients. 
Haematopoietic suppression 
Haematopoietic suppression occasionally occurred during MTX treatment. 
Normalization of blood counts was seen in all patients following reduction of the 
dosage or (temporary) discontinuation of therapy. 
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Mucocutaneous side-effects 
Apart from some hair loss in seven patients, no mucocutaneous side-effects were 
encountered. There were no complaints of ulceration of mucosal membranes or a 
"burning sensation" of the skin. 
Infections 
Six patients had minor infections. They were no more serious than might be seen in 
normal individuals not receiving MTX treatment. 
Neoplasms 
In five patients, a malignancy was diagnosed during therapy. Two patients developed a 
basal cell carcinoma, one patient had a cutaneous melanoma, one patient a sigmoid 
carcinoma and one patient had both a basal cell carcinoma and a lung tumour. 
Liver impairment 
Risk factors for hepatotoxicity, as indicated by Roenigk16, were present in some of our 
patients. Five patients consumed more than one unit of alcohol daily during treatment 
with MTX, 12 patients were obese, five had diabetes mellitus, and one had a history of 
arsenic intake. 
In total, 105 liver biopsies were performed in 55 patients. Pre-MTX data were 
available in 12 patients. The results of liver biopsy classification (LBC) are shown in 
Table 3. In patients who underwent consecutive biopsies, the highest histology grade is 
presented in the Table. Nine of the 55 patients had a LBC grade IIIA, HIB or IV once, 
or more frequently. In seven patients (13%) fibrosis was seen, and there was cirrhosis 
in two patients (4%). 
Tsble 3. Results of liver biopsy classification (LBC); for each patient, the highest histology grade 
is presented (n=55) 
LBC η % 
0 2 4 
1 35 62 
II 9 17 
IIIA 6 I 
HIB 1 2 
IV 2 4 
Total 55 100 
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Fig. 2 Relation between liver biopsy classification and a. cumulative dose (n=48) b. duration of therapy 
(n=49) 
There was no clear relation between liver biopsy classification and cumulative dosage 
or duration of therapy (Figure 2). In this Figure the cumulative dose and duration of 
therapy corresponding to the highest LBC was used (mean cumulative dose 4622 mg, 
and mean duration of therapy 91 months). Four patients in whom only a pre-MTX 
biopsy was performed, two patients with a LBC grade 0 and one patient with a LBC 
of I on an unknown dose of MTX, were excluded. 
There was also no clear relation between liver histology and liver function tests: in 28 
of the 46 patients with a normal LBC (grade 0,1 and II), LFTs were normal and in 18 
they were abnormal. Of the nine patients with LBC grade IIIA, HIB and IV, only five 
had abnormal LFTs. 
We could not find any relationship between the incidence of side-effects and the 
patients' age at the start of MTX therapy. In the patients with side-effects, MTX 
therapy was started at the mean age of 45.6 years, and in the patients without side-
effects it was 45.2 years. 
Reasons for discontinuation of MTX 
Seventy-one patients discontinued MTX therapy, 33 because of side-effects. In seven 
patients the reason for discontinuation was unknown, and in 11 a combination of 
factors was involved. The most frequent reasons were psychological (mostly patients 
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who developed adverse feelings towards systemic therapy) and an inadequate clinical 
response. Table 4 shows the reasons for discontinuation of MTX. 
Table 4. Reasons for discontinuation of MTX (n=71) 
Reason for discontinuation 
Psychological reasons 
Poor clinical result 
Gastrointestinal disturbances 
Abnormal LFTs 
Haematopoietic suppression 
Abnormal liver biopsy classification 
Desire for pregnancy 
Contraindication to liver biopsy 
Unknown 
η 
20 
16 
12 
12 
5 
5 
4 
1 
7 
% (n=71) 
28 
23 
17 
17 
7 
7 
6 
1 
10 
DISCUSSION 
The present study confirms the potent and sustained efficacy of MTX in psoriasis. In 
113 patients with severe, widespread and/or disabling psoriasis, MTX was prescribed 
according to a weekly divided dose schedule, with an absolute maximum of 15 
mg/week. Clearance or near clearance, of prolonged duration, was achieved in 81% of 
patients with this maximum weekly dose. The number of hospital admissions was 
reduced by a factor 10, compared with the situation before MTX treatment. The 
estimated mean treatment period was 8 years and 11 months, and the estimated mean 
cumulative dose was 4803 mg. 
Although Baker reported that only six of 21 patients with persistent palmoplantar 
pustulosis responded favourably to MTX treatment," the present study shows 
comparable efficacy of MTX in the different types of psoriasis, but also a good 
response in three out of five patients with persistent palmoplantar pustulosis. 
In a previous study we reported that the relapse rate following discontinuation of MTX 
is comparable with the relapse rate following clearance with dithranol.15 In the present 
study, 45% of the patients experienced a full relapse in the first 6 months after 
cessation of MTX therapy. This "therapeutic half-life" of 6 months is again comparable 
with that of dithranol treatment. Following discontinuation of acitretin, the relapse rate 
was reported to be 41% in the first 6 months." 
Etretinate and acitretin have a failure rate of 30% in chronic plaque psoriasis.19 In 
contrast, cyclosporin and MTX seem to be equally effective in all types of psoriasis.20, 
pire« itody j 0 m e j j ^ 0 f o u r knowledge data o n the management of psoriasis with oral 
retinoids over treatment periods of 1-2 decades are not yet available. The history of 
cyclosporin use in psoriasis is still too short for conclusions to be made about long-
term efficacy and safety. 
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Because of reported side-effects, dermatologists have adopted a cautious attitude 
towards MTX. The repertoire of side-effects observed in the present study confirms 
and extends previous reports.1-21 The results described in this communication 
demonstrate that prolonged low-dose MTX treatment (up to 20 years) is relatively safe, 
as long as patients are treated according to the international guidelines.1,16 In our study, 
there was no apparent relation between the cumulative dose or duration of therapy and 
the frequency of side-effects. Side-effects may occur in any phase of MTX treatment 
and it is important to realize that patients who have been on MTX for some years 
without serious problems do not have a guarantee that they are "protected" from side-
effects. 
As the present study is a retrospective analysis without a control group, a clear 
interpretation of the causal relation of adverse events to MTX therapy is not possible. 
In particular, this concerns the neoplasms observed during MTX treatment (5/115 
patients). We have previously reported a seven-fold increase in non-melanoma skin 
cancers in a group of patients treated with MTX or photochemotherapy.22 In these 
patients, previous exposure to arsenic, radiotherapy and photochemotherapy proved to 
relevant factors. As patients with severe psoriasis usually have been exposed to 
treatments with a carcinogenic potential, the individual influence of MTX on the 
development of skin cancers is difficult to estimate. The incidence of internal 
malignancies following treatment with MTX has been reported to be equal or lower 
than that in a matched control population.23'24 
Side-effects such as erosions of skin and mucosal membranes, as reported in the 
literature, were not seen in the present series, nor did we encounter "MTX-
pneumonitis". There were no deaths attributable to MTX. It is attractive to hypothesize 
that the relatively low maximum dose of 15 mg/week might be relevant in this respect. 
The incidence of severe liver fibrosis and cirrhosis was relatively low compared with 
most other series (Table 5). There was no relation between hepatic damage and 
cumulative dose or duration of treatment. Again, it might be of relevance that 15 
mg/week was the maximum dose in this population. Alternatively, the lack of a dose 
relationship with respect to hepatotoxicity might be the result of a multifactorial 
pathogenesis of liver fibrosis and cirrhosis. Another explanation for the relatively low 
incidence of hepatic damage in the present series could be the strict rule with regard to 
alcohol consumption in MTX-treated patients in our department. 
Monitoring of liver enzymes was found to be of limited value in the detection of 
histological liver damage, as in four out of nine patients with fibrosis or cirrhosis 
(44%) the liver function tests were normal. Although the progression of cirrhosis is 
slow during continuation of MTX,31 and although histological damage was uncommon 
in the present series, a liver biopsy before or during the first 3 months of treatment and 
subsequently at intervals of 1.5 g of MTX, remains mandatory. 
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Table 5. Liver biopsy findings during MTX therapy using treatment protocols with one single oral 
dose per week (oral WS) and 3 weekly doses at 12-h intervals (oral WD) 
Schedule 
Oral WS 
Oral WD 
Reference 
Nyfors - Poulsen25 
Roenigk et al.26 
Nyfors "> 
Mitchell et al.27 
Zachariae et al.2* 
Roenigk et al.26 
Robinson et al.29 
Zachariae et al." 
vd Kerkhof et al.12 
Themido et al.'° 
Present study 
No. of 
pts. 
88 
92 
68 
51 
96 
15 
43 
183 
9 
44 
30 
55 
Duration 
(months) 
26 (mean) 
2 - 105 
62 (median) 
25.9 ± 1.9 
8 -79 
12-84 
>60 
78 ± 13 
91 (mean) 
Cumulative 
dose (g) 
0.175 - 4.590 
0.050 - 5.075 
0.325 - 8 
2.538 (median) 
1.164 ± 0.098 
0.35 ± 3.56 
3.624 ± 2.929 
0.2 - 10.650 
4.622 (mean) 
% 
fibrosis 
6 
16 
7 
24 
20 
11 
40 
26 
16 
50 
13 
% 
cirrhosis 
7 
0 
1 
20 
6 
6 
0 
0 
10 
25 
4 
10 
4 
Further studies are indicated on the reliability of non-invasive methods for detection of 
liver damage, such as serum type III procollagen peptide, magnetic resonance imaging, 
ultrasound, and dynamic hepatic scintigraphy.27,32"40 
Subjective side-effects are seen frequently (Table 2). These symptoms could not be 
related to MTX-induced psycho-organic dysfunction, as we have demonstrated in a 
previous study/1 
We conclude that low-dose MTX treatment is relatively safe, provided that the 
treatment is carried out according to established guidelines.116 The long-term clinical 
efficacy, and relative safety of MTX, remain impressive. 
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Chapter 3 
Interruption of long-term Methotrexate 
Treatment in Psoriasis 
Evaluation of Clinical Course and Laboratory 
Parameters after Discontinuation and 
Re-introduction of weekly oral Methotrexate 
RJ van Dooren-Greebe 
ALA Kuijpers 
F Termorshuizen 
PCM van de Kerkhof 
Acta Derm Venereol 1995; in press 
The effects of interval treatment were evaluated in 10 psoriatic patients on long-term 
treatment with low-dose oral methotrexate (MTX). In all patients, the dosage of MTX 
had already been tapered off as much as possible. After interruption of MTX 
treatment, the clinical course and changes in laboratory parameters were evaluated. The 
mean MTX-free period was 17 weeks and the mean reduction in cumulative MTX 
dose was 76 mg (p=0.05). However, only 3 patients preferred interval treatment to a 
continuous schedule. During the first 3 weeks of discontinuation, a significant decrease 
in the serum transaminases was observed, indicating a direct toxic influence of MTX 
on the liver parenchyma. 
We conclude that interruption of long-term MTX treatment leads to a substantial 
reduction of the cumulative MTX dose and reduces the hepatotoxic load of MTX. It is 
necessary to motivate patients on long-term MTX treatment for regular treatment 
interruptions to establish a further reduction in their cumulative MTX dose. 
The efficacy of low-dose oral methotrexate (MTX) in severe psoriasis is well 
established.1,2 Beside gastro-intestinal complaints, the most notorious side-effects of 
MTX therapy concern haematological abnormalities and hepatic damage.2'7 For the 
treatment of psoriasis MTX is often continued for many years, especially when the 
achieved clinical result is satisfactory and no major side-effects occur. However, a high 
cumulative dose of MTX is associated with an increased frequency of liver damage/·8 
The aim of the present study was to investigate whether treatment with MTX in 
intervals is better than a continuous schedule. The MTX regimen was temporarily 
discontinued in 10 psoriatic patients on long-term treatment with oral MTX according 
to the Weinstein-schedule.9 At the moment of discontinuation all patients were in a 
stable clinical condition with minimal skin-lesions and their weekly MTX dose had 
already been tapered off to an optimal dose with respect to efficacy and side-effects. 
The clinical course after discontinuation and re-introduction of MTX was evaluated. 
MTX was re-introduced at the moment of a partial relapse, according to well defined 
criteria. The possible reduction in cumulative dose of MTX due to the temporary 
discontinuation was calculated as well as effects on important laboratory parameters. 
The opinion of the patients concerning the interruption and re-introduction of treatment 
was evaluated by means of a short questionnaire. 
PATIENTS AND METHODS 
Patients 
The study was carried out in the period June 1993 - May 1994. Eight males and 2 
females with severe psoriasis vulgaris for 25-55 years, were included. The age of the 
patients was 51-72 years and the mean treatment period was 12.7 years (0.8-21.5 
years). All patients had been treated according to the "Weinstein-schedule" (a weekly 
divided oral dose with a maximum of 15 mg per week).910 All patients responded well 
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to MTX therapy, and the weekly dose was individualized by tolerance and efficacy in 
each patient. The mean cumulative dose of MTX at the moment of discontinuation was 
6,471 mg (400-10,790 mg). As it was our purpose to reach maximal similarity to the 
treatment situation in daily practice, the patients were allowed to continue their topical 
anti-psoriatic treatment in the same amounts as before interruption of MTX treatment. 
This topical treatment comprised sparse use of topical corticosteroids or calcipotriol 
and unlimited use of bland emollients. 
Assessment of disease progress 
At discontinuation and subsequently every 2 weeks during the first 2 months and later 
every 4 weeks, the area (percentage of total body area) and the severity of the psoriatic 
lesions were estimated by one and the same clinician. The area involved was assessed 
by using the "rule of hand", in which the area covered by the examiner's hand 
represents roughly 1% of the skin surface." The severity score was assessed by 
grading erythema, scaling and thickness of the psoriatic lesions on a 3-point scale: 
0=absent, l=mild, 2=moderate and 3=severe. By summation of these three scores the 
severity score was calculated. The Psoriasis Severity Score was calculated according to 
the next formula (modified after Perkins12): 
Psoriasis Severity Score (PSS) = 
Erythema (0 - 3) + Scaling (0 - 3) + Thickness (0 - 3)
 χ % s u r f a c e ^ i n v o , v e d 
9 
This scoring-method is analogous to the PASI-score," but the impact of the surface 
area on the overall score is more decisive in this calculation model. Treatment was re­
introduced when a partial relapse of psoriasis occurred. A partial relapse was defined 
as an area score reaching a value of twice the initial area score with a minimum of 3% 
and a severity score reaching a value of more than 3 points. 
Calculation of the modulation of the cumulative MTX dose due to temporary 
discontinuation of treatment 
For each patient the difference between the expected and the real cumulative MTX 
dose was calculated. The expected cumulative dose is the cumulative dose that the 
patient would have received if treatment had not been interrupted. For patients who 
restarted and continued on the same dose schedule as prescribed before the 
discontinuation, this difference was computed by multiplying the pre-study weekly 
dose by the number of MTX-free weeks. For patients with severe relapsing psoriasis 
who needed a temporary "loading-up" dose after re-introduction to get a favourable 
clearing of their lesions, this additional MTX was comprised in the calculation. If the 
expected cumulative dose was higher than the real cumulative dose, this resulted in a 
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reduction in cumulative dose due to treatment interruption. However, if the expected 
cumulative dose was lower than the real cumulative dose, the patient eventually 
received more MTX than he or she would have received without treatment 
interruption. 
Additionally, it was investigated whether a higher number of MTX-free weeks was 
attended by a larger "loading-up" dose and consequently by an annulling of the "gain" 
in cumulative MTX dose. A possible predictive value of the pre-study MTX dose for 
the number of MTX-free weeks was also assessed. 
Evaluation of laboratory parameters before and after discontinuation of MTX 
treatment 
At the moments of clinical assessment (PSS) the following laboratory parameters were 
recorded: hemoglobin, erythrocyte mean cell volume (MCV), leucocyte count, 
trombocyte count, serum folate, alkaline phosphatase, serum-transaminases (SGOT and 
SGPT) and gamma-glutamyltranspeptidase (gamma-GT). The values before 
discontinuation and possible changes during discontinuation of the MTX regimen were 
established. 
Patients ' opinion on treatment in intervals 
Whether the patients preferred a continuous treatment schedule to a treatment in 
intervals was investigated by means of a short questionnaire. The reason for this 
preference was also evaluated. 
Statistics 
Whether the mean difference between the expected and the real cumulative dose 
differed significantly from 0 was tested with a paired t-test. Possible correlations 
between the number of MTX-free weeks, the pre-study MTX dose and the difference 
between the expected and the real cumulative dose were assessed and tested using a 
Spearman's rank correlation coefficient. Changes in laboratory parameters were 
assessed by univariate linear regression analyses for each patient separately, with the 
value of a certain laboratory parameter as the dependent and the time period following 
discontinuation of MTX as the independent variable. Whether the mean change of the 
laboratory parameter concerned differed significantly from 0 was tested by means of a 
Wilcoxon signed rank test or in cases of a normal distribution a paired t-test. 
RESULTS 
Clinical relapse 
Three patients experienced a quick relapse and MTX was re-introduced within 4 
weeks. In 7 patients the MTX-free interval was at least 11 weeks. One patient did not 
relapse at all within a follow-up period of 41 weeks. In 3 patients the MTX treatment 
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had to be re-introduced before the criteria for a partial relapse were met, because of 
recurrence of skin lesions at cosmetically disturbing localizations or because of rapidly 
progressing pin-point lesions, indicating the onset of a severe relapse. The clinical 
course (PSS) of the 7 patients with a MTX-free period of 11 weeks is shown in Figure 
1. The mean MTX-free period of these patients was 23 weeks (11-41, n=7) The 
number of MTX-free patients in relation to the time after discontinuation of the 
treatment is shown in Figure 2. The 'overall' mean MTX-free period was 17 weeks (2-
41 weeks, n=10). 
Cumulative MTX dose 
The individual reduction or increase in cumulative MTX dose due to interruption of 
MTX treatment is shown in Figure 3. One patient had to be excluded in this 
calculation because it appeared that she had previously been treated with arsenic; 
acitretin was prescribed at the moment of a relapse. The mean reduction of the 
cumulative MTX dose was 75 mg (-67.5-255 mg, p=0.05). Recalculation for those 
patients with a MTX-free period of at least 11 weeks resulted in a mean reduction of 
the cumulative MTX dose of 117.5 mg (-23.8-255 mg, p=0.03). 
It appeared that a lower MTX dose before discontinuation of the MTX regimen 
permitted a higher number of MTX-free weeks (r(Spearman)=-0.64, p=0.05). A 
positive correlation was observed between the number of MTX-free weeks and the 
difference between the expected and the real cumulative MTX dose (r(Spearman) 
=+0.64, p=0.06). 
Laboratory parameters 
At the moment of discontinuation 3 patients showed an elevated MCV (>100 fl), the 
other patients showed a MCV in the high normal range (92-100 fl), one patient had a 
lowered trombocyte-count (<120xl0'/l), all patients had serum folate levels in the low 
but normal range (5.7-14 nM/1), one patient had both an elevated SGOT (27 U/l), 
SGPT (48 U/l) and gamma-GT (85 U/l), one patient showed an elevated SGPT 
(33 U/l) and one patient an elevated gamma-GT (69 U/l). 
The mean changes in laboratory parameters during the whole period of discontinuation 
in patients with a number of MTX-free weeks >11 (n=7) were evaluated. A small but 
statistically significant increase of serum folate was observed (0.166 nM/week, 
p<0.05). During the first 3 weeks after discontinuation a statistically significant mean 
decrease of 2.09 U/l/week in SGOT and 4.46 U/l/week in SGPT could be 
demonstrated (p<0.05, n=9; the data of one patient were not complete). Higher 
transaminases at the moment of discontinuation were associated with a more prominent 
decrease during the first MTX-free weeks. In the first weeks after re-introduction a 
mean increase of 1.30 U/l/week in SGOT (p=0.09) and 2.31 U/l/week in SGPT 
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(p=0.06) were observed. In the other laboratory parameters no important changes were 
observed. 
The patient with a low trombocyte count and the two patients with an elevated 
gamma-GT did not show an improvement into the normal range during discontinuation 
of MTX. 
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Fig. 1. Psoriasis Severity Score after discontinuation ( ) and re-introduction ( ) of MTX in 
patients with a MTX-free period >11 weeks (n=7). 
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Fig. 2. Number of MTX-free patients in relation to the time after discontinuation of treatment. 
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Fig. 3. Reduction (positive values) or increase (negative values) in cumulative MTX dose due to 
interruption of treatment for each patient (n=9). 
Subjective assessment 
The 3 patients resuming their MTX regimen shortly after discontinuation (within 4 
weeks) all preferred a continuous treatment. Of the 7 patients with prolonged MTX-
free periods, 3 patients preferred interval treatment because of the reduced toxicity 
potential of such a regimen. The other patients preferred a continuous treatment in 
spite of a long MTX-free period because of fear of a relapse and practical problems 
with the more cumbersome local therapy. 
DISCUSSION 
Clinical severity scores and safety parameters after interruption and re-introduction of 
long-term MTX treatment were evaluated in 10 psoriasis patients. The MTX-free 
period was assessed and it was evaluated whether treatment interruption resulted in a 
substantial reduction of the cumulative dose. To our knowledge no similar study has 
been reported so far. 
A considerable mean number of 17 MTX-free (2-41) weeks could be reached. Three 
patients asked for re-introduction of MTX treatment before the defined criterion of a 
relapse was met. This problem is characteristic to clinical studies and links up with 
day-to-day medical practice. Seven patients had a MTX-free period of at least 11 
weeks. Two patients were still free of MTX after 6 months; one of them did not get a 
relapse at all (Figures 1 and 2). Relapse-periods of 1 year or even more have been 
reported by other authors.10,13 There was a negative correlation between the weekly 
MTX dose before discontinuation and the number of MTX-free weeks. The mean 
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reduction in cumulative dose due to this single interruption of treatment was 76 mg. 
Only in 2 patients treatment interruption resulted in a small increase in cumulative 
MTX dose, because they needed a "loading-up" dose to reach the same clinical 
situation as before the treatment interruption (Figure 3). For patients with at least II 
MTX-free weeks the mean reduction was 117 mg. A positive correlation was observed 
between the number of MTX-free weeks and the reduction in cumulative dose. This is 
an important observation and means that the "gain" in cumulative MTX dose due to 
treatment interruption was not annulled by high "loading up" doses after re-
introduction of treatment. 
The only laboratory parameters showing significant changes during discontinuation of 
MTX treatment, particularly in patients with abnormal pre-study values, were the 
serum transaminases. After re-introduction of MTX a borderline significant increase in 
SGOT and SGPT was observed. The relatively high MCV values at the beginning of 
the study probably indicate a macrocytogenic impact of MTX on the erythrocytes. '^15 
The low normal serum folate values before discontinuation of MTX treatment and the 
small but statistically significant increase during discontinuation indicate a suppressive 
effect of MTX on the serum folate level. This is in accordance with reports in the 
literature.1617 Despite the fact that all patients in the present study were in a stable 
clinical situation without important side-effects, they showed clear changes in liver 
parenchyma derived transaminases, reflecting a direct hepatotoxic effect of MTX. 
Although a mean MTX-free period of 17 weeks could be reached after interruption of 
MTX treatment, 7 patients preferred continuous treatment because of fear of a relapse 
or because local treatment was less convenient. This indicates that patients have to be 
carefully instructed and persuaded to become motivated for an interval treatment 
schedule. 
In this study it was shown that treatment of severe psoriasis with MTX in intervals is a 
good alternative to a continuous dose schedule. Treatment interruption results in a 
substantial reduction of the cumulative dose and reduces the hepatotoxic load of MTX. 
Patients on a low maintenance MTX dose may particularly benefit from regular 
interruptions of their MTX regimen. It is necessary to persuade patients on long-term 
MTX treatment to interrupt their regimen at regular intervals to achieve a further 
reduction in their cumulative dose. 
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SUMMARY 
Oral methotrexate (MTX) is a highly effective drug for the treatment of severe 
psoriasis. A limitation of this treatment is its potential hepatotoxicity. 
In the present prospective study the value of dynamic hepatic scintigraphy (DHS) and 
serum aminoterminal propeptide of type III procollagen (PIIINP) were investigated as 
screening methods for early detection of MTX-induced hepatic damage. These 
relatively non-invasive procedures were compared with the liver biopsy classification, 
until now the gold standard to assess MTX-induced liver damage. 
Twenty-five MTX patients were studied. The mean cumulative MTX dose was 3.9 
gram ( 0.2-11.1 gram). Twenty-one patients had a normal liver histology (grade I), 3 
patients had steatosis (grade II) and one patient mild fibrosis (grade Ilia). Seven 
additional patients with non-MTX related hepatic cirrhosis were included as disease 
controls. 
The DHS showed a clear-cut separation between the portal contribution of the MTX 
patients with grade I liver histology and that of all other patients. A portal contribution 
larger than 52% was associated with a >95% chance to a normal liver histology. If this 
cut-off value would have been used to postpone the liver biopsy, this would have 
resulted in a reduction of at least 55% of the biopsies in patients with a normal liver 
histology. DHS appeared to be very promising as a screening test to differentiate 
between the presence or absence of MTX-induced hepatic damage, but appeared not 
suitable to grade severity of hepatic damage. 
Although a global relationship was demonstrated between serum PIIINP concentrations 
and hepatic damage, single measurements in individual patients were not reliable. The 
combination of PIIINP measurements with DHS had only a limited additional value 
above DHS alone. 
The present study indicates that DHS has great promise as a method for detection of 
early MTX-induced hepatic damage. Pending further studies, regular liver biopsies 
remain mandatory for safe prolonged use of MTX in psoriasis patients. 
Oral methotrexate (MTX) is a highly effective drug for the treatment of severe 
psoriasis.M MTX treatment, however, is associated with potential hepato-
toxicity/" rcview 3 Conventional serum liver function tests are not reliable as indicators of 
hepatic damage. According to the international guidelines a liver biopsy has to be 
performed in the initial phase of treatment and subsequently after each cumulative dose 
of 1.5 gram.2,3,5 At present histological evaluation of liver biopsies is the gold standard 
to assess MTX-induced liver damage. However, serious complications like 
hemorrhage, pneumothorax and sepsis may occur incidentally. The reported morbidity 
figures range from 0.02-10%6for rcvKw7 and the mortality rate is 0.01-0.1%.for rcvKW 7g 
Liver biopsies are relatively expensive and uncomfortable for the patients. Magnetic 
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resonance imaging,9 ultrasound scanning'°·** """' " and static scintigraphy of the liver"* 
rcview
 '
2
 have been reported as not sufficiently reliable. 
Recently, McHenry et al.13 reported promising results on dynamic hepatic scintigraphy 
(DHS) according to the methodology of Ferguson et al.M In short: the uptake of " T c 
sulphur colloid in the spleen is proportional to the arterial uptake by the liver. By 
subtracting this arterial contribution from the total liver uptake, the portal contribution 
to the total liver flow can be computed. The low-pressure portal vene system is more 
sensitive for changes in the structure of the liver parenchyma than the high-pressure 
arterial system and the portal contribution decreases in case of fibrosis or cirrhosis. 
Another interesting screening test is the measurement of serum aminoterminal 
propeptide of type III procollagen (PIIINP).15"18 Hepatic fibrosis is characterized by 
increased synthesis and deposition of collagen, predominantly type III. Collagen 
molecules are derived from procollagen molecules by cleaving the terminal peptides, 
which are subsequently released into the circulation. " Measurement of PIIINP with a 
radioimmunoassay20 may be suitable to detect and monitor liver damage.21 This test is 
not organ-specific, as increased PIIINP levels have also been demonstrated in systemic 
sclerosis, localized scleroderma and rheumatoid arthritis.22,23 
In the present study the value of both DHS and serum PIIINP alone and in 
combination for the detection of MTX-induced hepatic damage were prospectively 
investigated. The liver biopsy results were used as gold standard. A small group of 
patients with non-MTX related hepatic cirrhosis were included as disease controls. 
PATIENTS AND METHODS 
Patients 
In the period September 1993 - October 1994 all MTX patients who were scheduleds 
to undergo a liver biopsy were asked to participate in the study. AH patients were 
treated according to the Weinstein schedule (maximum weekly dose 15 mg/day).4 All 
investigations in individual patients were completed within a period of 10 weeks. DHS 
was performed > 2 weeks after the liver biopsy. Details on age and gender of the 
patients, indication for MTX treatment, duration of treatment, cumulative dose and the 
presence or absence of arthritis were obtained from the medical records. Several 
patients from the department of gastroenterology with non-MTX related liver cirrhosis 
were included as disease controls. The study was approved by the hospital's Medical 
Ethical Committee and all patients gave written informed consent. 
Liver biopsies in MTX patients 
Liver biopsies were performed according to the Menghini technique at the department 
of gastroenterology. The biopsies were prepared and classified according to the 
guidelines of Roenigk5 by one pathologist: LBC Grade I - no abnormalities or mild 
steatosis, nuclear variability or portal inflammation. LBC Grade II - moderate or severe 
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steatosis, nuclear variability portal inflammation or necrosis. LBC Grade IIIA - mild 
fibrosis, LBC Grade HIB - moderate to severe fibrosis. LBC Grade IV - cirrhosis. 
Dynamic hepatic scintigraphy (DHS) 
After overnight fasting the patient was positioned supine on the couch of the dual 
headed gamma camera, connected to an ICON computer (MultiSPECT II, Siemens, 
Hofmann Estates, IL). The gamma camera was equipped with "Low Energy High 
Resolution" collimators. The liver and spleen were positioned in the centre of detectors 
measuring 53 χ 39 cm. Immediately after a rapid injection of 111 MBq " T c sulphur 
colloid with a particle size of about 30 nm, dynamic planar gamma camera images 
were recorded for 160 frames of 0.5 seconds each in a 64 χ 64 matrix. Analysis was 
performed according to the method of McHenry and Ferguson.1314 Regions of interest 
were drawn around the liver on an anterior sumimage and around the spleen on a 
posterior sumimage. Time activity curves for both organs were generated and 
smoothed. The ratio of liver to spleen activity for the first 80 seconds p.i. was also 
generated. On the basis of this curve the onset of portal input was estimated as the 
moment when the ratio curve started to rise, followed by a plateau. The value of the 
ratio just before the curve started to rise was used to normalize the liver to the spleen 
curve over the complete duration of the study. The spleen curve was subtracted from 
the normalized liver curve, resulting in the portal curve. The portal contribution at 25, 
30, 35 and 40 seconds post injection (p.i.) was calculated as the ratio between the 
activity in the portal curve and the normalized liver curve and expressed as percentage 
of the total liver curve. All studies were analyzed blinded by three observers (the first 
three authors). The results of W.B., physicist at the department of nuclear medicine, 
were used for further analysis. The inter-observer variability was evaluated. The 
radioactive dose was 1.1 mSv per scan (the background radiation on earth is 2 mSv 
per year). 
Serum aminoterminal propeptide of type III procollagen (PIIINP) 
Sera were collected and stored at -20°C until analysis. PIIINP concentrations were 
measured with a radioimmunoassay based upon the human propeptide (FARMOS 
Diagnostica, Espoo, Finland).20 The reference range for adults (based on healthy 
Finnish blood donors) as provided by the manufacturer is 1.7-4.2 μg/l. 
Patient questionnaire 
After completion of the liver biopsy and DHS a questionnaire was sent to all MTX 
patients. A subjective judgement of mild, medium or strong discomfort scored 1-3 
points and a judgement of absent, minimum, medium or strong fear scored 0-3 points. 
The patients were asked which procedure they preferred. 
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Statistical methods 
In order to distinguish patients with a LBC grade I from the other patients, linear 
discriminant analysis was used.24 With this method, posterior probabilities for a grade I 
LBC can be computed, given the values of one or more discriminating variables and 
given the prior probability (i.e. the probability without any further knowledge). As 
possible discriminating variables the portal contribution (DHS) and the ΡΙΙΓΝΡ were 
used. A minimal prior probability of 66% for a grade I LBC was used; this percentage 
originates from an earlier study.3 When the corresponding posterior probability, given 
the cut-off value of a discriminating variable (for example the portal contribution) 
exceeds 95%, this means that at most 5% of the patients with such a high portal 
contribution have a higher LBC than grade I. The inter-observer variability of the DHS 
was evaluated by recomputing the posterior probabilities for a grade I LBC, using the 
values of the portal contribution as they were measured by the two other observers 
(RvDG and AK). 
RESULTS 
Patients 
Twenty-five MTX patients (12 males and 13 females) could be included in the study. 
Twenty-four patients had severe psoriasis and one patient had Reiter's disease. The 
mean age of the patients was 52 yrs (31-75 yrs). The mean cumulative MTX dose was 
3.9 gram (0.2-11.1 gram) and the mean duration of treatment was 90 months (4-288 
months). Six of the 25 patients also had psoriatic arthritis. In 7 patients (3 males and 4 
females) with a non-MTX related hepatic cirrhosis DHS and/or ΡΙΙΓΝΡ determinations 
were performed. Their mean age was 53 yrs (43-75 yrs). In 4 patients cirrhosis was 
induced by alcohol abuse and in 3 patients by auto-immune hepatitis. 
Liver biopsies in MTX patients 
Twenty-one patients (84%) had a liver biopsy classification (LBC) grade I, 3 patients 
(12%) had grade II and one patient (4%) grade IIIA. No complications occurred during 
or after the liver biopsies. 
Dynamic hepatic scintigraphy (DHS) 
DHS could be performed in 22 of the 25 MTX patients. The portal contribution 
computed at 35 s p.i. had the highest discriminating power and was used for further 
analysis. The mean portal contribution at 35 s was 50.4% (SD 13.1). In the 18 patients 
with LBC grade I the mean portal contribution was 54.8% (SD 9.5), the 3 patients 
with LBC grade II had portal contributions of 20.4%, 28.9% and 38.0% and the patient 
with grade III LBC had a portal contribution of 37.0%. Figure 1 shows the portal 
contribution of all patients in relation to their LBC (grade I-III). There was a clear 
separation between the portal contribution of the patients with a normal liver histology 
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(grade I) and all other patients. The values of the patients with grade II and grade III 
LBC were in the same range. The portal contributions of 5 cirrhosis patients are shown 
in a separate column of Figure 1 (grade IV). Their mean portal contribution (31%), 
was in the same range as that of the MTX patients with grade II-III LBC. 
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Fig. I. Portal contribution in relation to histological classification of liver biopsies (grade I-III). Non-
MTX related cirrhosis patients are included in a separate column (grade IV). 
Serum aminoterminal propeptide of type III procollagen (PIIINP) 
The mean PIIINP in all 25 MTX patients was 3.8 μ^Ι (SD 1.3). In the patients with a 
LBC grade I the mean PIIINP was 3.6 μg/l (SD 1.0), the 3 patients with LBC grade II 
had PIIINP values of 3.2 μg/l, 3.0 μg/l and 7.0 μ^Ι and the patient with LBC grade III 
had a PIIINP value of 6.2 μg/l. Figure 2 shows the PIIINP values of all patients in 
relation to their LBC (grade I-III). Although the mean PIIINP values in patients with 
grade II-III LBC were significantly higher than those of the patients with grade I LBC, 
isolated values did not discriminate between individuals with and without hepatic 
damage. The six patients with psoriatic arthritis all had a LBC grade I and their mean 
PIIINP was 3.7 μ%ίΙ. The PIIINP values of 5 cirrhosis patients are shown in a separate 
column of Figure 2 (grade IV). Their mean PIIINP (8.0 μg/l), was significantly higher 
than that of the MTX patients, with an overlap the individual results. If the MTX and 
the cirrhosis patients are combined, three of the 9 patients (33%) with abnormal 
histology had normal PIIINP values. 
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Fig. 2. Serum ΡΙΙΓΝΡ values in relation to histological classification of liver biopsies (grade I-II1). Non-
MTX related cirrhosis patients are included in a separate column (grade IV). 
Discriminant analysis (DHS and PIIINP) for MTX patients 
The cut-off value of the portal contribution (DHS), corresponding to a >95% posterior 
probability to a LBC grade I was 52% (Figure 3). Of the 18 patients with a normal 
liver histology, 10 (55%) had posterior probabilities >95%, while none of the patients 
with abnormal histology met this criterium (Figure 3). 
Subsequently it was investigated whether addition of the PIIINP as second 
discriminating variable could enlarge the posterior probabilities. This appeared to be 
the case: now 14 (78%) of the 18 patients with normal liver histology had posterior 
probabilities >95%, while still none of the patients with abnormal histology did (Figure 
3). The variable PIIINP on itself did not produce a useful cut-off point. 
The cirrhosis patients are included in Figure 3 to illustrate that their position in the 
figure is clearly left of the cut-off limits; in the discriminant analysis, however, only 
the MTX patients were included. 
To evaluate the inter-observer variability of the DHS after performance of discriminant 
analysis, it was computed wether the two other observers would have reached other 
conclusions concerning the percentage of patients with a >95% chance to a LBC grade 
I. It is important that none of the observers produced any false negative results 
(computed posterior probability >95% and abnormal liver histology). The percentage 
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of false-positive results (computed posterior probability <95% and normal liver 
histology) differed between the 3 observers (WB 45%, AK 22% and RvDG 17%). 
Adding the PIIINP as a second discriminating variable, only the percentage false 
positive results for observer WB changed, namely from 45% to 22%. If the decision 
was made to postpone the liver biopsy in case of a portal contribution >52%, the 
number of biopsies in patients with a normal liver would have been reduced with 55% 
to 83%, depending on the observer. 
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Fig. 3. Liver biopsy classification (0= grade I, * = grade II/III, *= cirrhosis patients), portal contribution 
and PIIINP values of all 32 patients. Discriminant function lines (cut-off lines) for DHS only 
(continuous vertical line), and for both DHS and PIIINP (interrupted diagonal line). Dotted line parallel 
to Y-axis: patients with unknown portal contribution. Dotted line parallel to X-axis: patients with 
unknown PIIINP value. 
Patient questionnaire 
The questionnaire was returned by 17 of the 25 MTX patients (68%). The total 
"discomfort-score" was 28 points for the liver biopsy and 20 points for the DHS. The 
total "fear-score" was 10 points for the liver biopsy and 6 points for the DHS. Fifteen 
out of the 17 patients (88%) preferred the DHS. 
DISCUSSION 
In the present study a clear-cut separation between the portal contribution of the MTX 
patients with a LBC grade I and all other patients could be demonstrated. DHS 
appeared not to be suitable for the determination of the severity of hepatic damage. 
The patients with steatosis (grade II) had a much lower mean portal contribution than 
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the patients with grade I LBC (29.1% vs. 54.8%), this suggests that a grade II LBC 
indeed reflects early MTX induced hepatic damage. McHenry et al.1314 performed 87 
paired DHS and liver biopsies in 63 psoriatic MTX patients. The authors reported a 
high predictive value of a normal DHS for fibrosis grade 0-1 (98.5%) and a low 
predictive value of an abnormal DHS for fibrosis of grade 2 or worse (25%). McLaren 
et al.25,26 reported a significant reduction in the portal contribution in 41 non-MTX 
related cirrhosis patients compared to 33 healthy controls. 
By means of discriminant analysis it was demonstrated in our study that a portal 
contribution of >52% in a MTX patient was associated with a >95% chance to a LBC 
grade I. If this cut-off value of 52% would have been used to postpone the liver 
biopsy, this would have reduced the number of biopsies with at least 55% in the 
patients with a normal liver histology. None of the 3 observers produced any false 
negative results. 
Zachariae et al.1516 reported on PIIINP levels in 170 patients with psoriasis. Patients 
with liver fibrosis or cirrhosis and patients with psoriatic arthritis had significantly 
elevated mean PIIINP levels. The authors claimed that the number of liver biopsies 
performed on MTX patients might be reduced to a minimum in case of normal PIIINP 
levels. In concert with Kanzler and Gorsulowsky" we cannot confirm their 
conclusions, as a considerable number (6-8/24, 25-33%) of patients without arthritis 
and with fibrosis had normal values of PIIINP. Furthermore, 4/18 (22%) of patients 
with both arthritis and liver fibrosis had normal PIIINP values. Risteli et al." reported 
elevated PIIINP levels in 8/9 patients with fibrosis or cirrhosis and concluded that the 
number of biopsies could be significantly reduced in patients with normal PIIINP 
values, despite the fact that 6/15 patients (40%) with PIIINP values in the normal 
range had fibrosis or cirrhosis. Mitchell et al.17 reported on a controlled study with 51 
MTX-treated psoriatics and concluded that isolated PIIINP measurements can not 
discriminate between individuals with and without significant liver pathology. The 
conclusion from the present study is in accordance with Mitchell et al.17: There was a 
global relation between PIIINP values and hepatic damage, but one-off readings 
appeared to be unreliable for the screening of individual patients. The patients with 
psoriatic arthritis had PIIINP levels in the same range as the other patients. Probably, 
there is scope for the use of PIIINP values for regular monitoring of individual 
patients. 
The additional value of PIIINP measurements to DHS in individual patients was very 
limited in the present study, and could be demonstrated only in 1 of the 3 observers 
(WB). 
The subjective judgement of both procedures by the MTX patients was clearly in 
favour of the DHS. 
The present study indicates that the relatively non-invasive DHS procedure is very 
promising for the detection of early MTX-induced hepatic damage. This approach may 
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lead to a considerable reduction of the number of liver biopsies in the near future. 
Pending further studies, the performance of liver biopsies according to the international 
guidelines5 remains the gold standard for safe prolonged use of MTX in the treatment 
of psoriasis. 
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PART II 
Acitretin in Severe Psoriasis and 
Monogenic Disorders of Keratinization 

Chapter 1 
Introduction 
The efficacy and side-effects of acitretin in plaque psoriasis have been documented in 
several recent reports in the literature. Data on treatment with acitretin in disorders of 
keratinization and unusual presentations of severe psoriasis, however, are very limited 
or absent. 
The development of new therapeutic approaches for these rare but extremely disabling 
conditions is hampered by the fact that the assembling of large series is almost 
impossible and also because drug development is directed towards dermatoses with a 
high prevalence. 
Therefore, we have carried out an investigation on the clinical efficacy of acitretin 
within the broad spectrum of these rare diseases, using a case-oriented approach. The 
results of this study have been reported in several publications (see the authors's "list 
of publications"). 
In chapter 2-7 of this thesis a compilation of the original manuscripts is presented. In 
the "Nederlands Tijdschrift voor Geneeskunde" the author has reported on the clinical 
observations in 37 patients treated with acitretin. The profile of side-effects was 
included in this review. Table 1 summarizes these side-effects and presents a com-
parison with the literature. It appears that the side effect profiles of acitretin and 
etretinate are highly comparable. In the Nijmegen study group of 37 patients no spinal 
abnormalities occurred after a treatment period of 6-8 months. 
Hepatotoxicity and skeletal hyperostoses are serious side effects which may occur in 
patients treated with acitretin. In chapter 8 a severe hepatotoxic reaction after the use 
of acitretin was reported and chapter 9 concerns extensive extra-spinal hyperostoses 
after long-term retinoid treatment in a patient with pityriasis rubra pilaris. As the lack 
of clear and definitive guidelines to asses retinoid-induced bone toxicity is a major 
practical problem, special attention was focused in chapter 10 to the relation between 
spinal abnormalities and oral retinoid use in a group of 135 patients with psoriasis and 
disorders of keratinization. 
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In the Discussion of this thesis these experiences will be compared and contrasted with 
the available information in the literature, resulting in adapted guidelines for long-term 
use of acitretin in dermatology. 
Table 1. General profile of acitretin side effects (%) in the present study population (n=37). 
Comparison to side-effects of acitretin and etretinate as reported in the literature. 
SIDE EFFECT 
Hps/mucosal membranes 
cheilitis 
dry mouth 
gingivitis/stomatitis 
dry nose 
epistaxis 
dry eyes/conjunctivitis 
skin and appendages 
xerosis 
palmoplanar scaling 
scaling total skin 
mild hair loss 
severe hair loss 
mild/severe hair loss 
brittle nails 
fragile skin 
"sticky" skin 
pruritus 
other side effects 
fatigue 
hyperhidrosis 
headache 
dizziness 
arthralgia/myalgia 
nausea 
gastrointestinal symptoms 
visual disturbances 
otitis 
elevation of serum 
cholesterol and/or 
triglycerides 
reversible elevation 
of liver enzymes 
severe hepatotoxic 
reaction 
ACITRETIN 
Van Dooren-Greebe 
et al. 1990 (n=37) 
90 
50 
3 
33 
6 
28 
33 
33 
28 
39 
17 
56 
22 
0 
11 
11 
11 
3 
6 
3 
3 
6 
3 
0 
0 
17 
5 
3 
Geiger et al* 
1988 (n=518) 
82 
30 
6 
34 
2 
17 
30 
26 
28 
20 
10 
5 
3 
16 
5 
9 
5 
1 
7 
2 
3 
1 
1 
14 
8 
0 
ETRETINATE 
Geiger et al* 
1988 (n=69) 
85 
36 
3 
42 
0 
14 
36 
19 
19 
19 
16 
10 
3 
20 
0 
1 
3 
1 
3 
1 
4 
1 
0 
Geiger JM, Czamclzlu BM 
1988,176 182-190 
Acitretin (Ro 10-1670, elretin) Overall evaluation of clinical studies. Dermatologica 
Adapted from: Dooren-Greebe RJ van, Kerkhof PCM van de, Steijlen PM, Happle 
Acitretinetherapie bij verhoomingsstoomissen. Ned Tijdschr Geneeskd 1990;134:1995-2000. 
R. 
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Chapter 2 
Acitretm Monotherapy in 
Acrodermatitis Continua Hallopeau 
RJ van Dooren-Greebe 
PCM van de Kerkhof 
A Chang 
R Happle 
Acta Derm Venerol (Stockh) 1989; 69: 344-346 
In a patient affected with acrodermatitis continua Hallopeau, acitretin (Ro 10-1670) 
monotherapy resulted in a complete clearance of pustulation at a dosage of 45 mg per 
day. At this dosage the leukotriene B4-induced intra-epidermal accumulation of 
polymorphonuclear leukocytes was markedly inhibited. 
Successful treatment with the aromatic retinoid etretinate in Acrodermatitis continua 
Hallopeau (ACH) has been reported in a few cases.1,2 In this communication we 
describe the clinical results of acitretin (Ro 10-1670) in a case of ACH. In this patient 
the influence of acitretin therapy on the chemotactic response of polymorphonuclear 
leukocytes (PMNs) was assessed in an in vivo assay. 
CASE REPORT 
A 69-year-old white man presented with a 2-year history of progressing redness, 
scaling and pustulation of his fingertips. The second and third finger of the right hand 
as well as the second finger of the left hand were involved. At first he had noticed a 
roughening of the nail plates and subsequently complete onycholysis occurred. Due to 
extreme tenderness and itching of the skin lesions the patient was severely 
handicapped. The family history was non-contributory. Several types of treatment, such 
as oral sulfones and topical corticosteroids, had been tried, but without any success. 
Physical examination showed severe erythema, scaling and pustulation of the distal 
parts of the affected fingers. The nail plates were absent and the nail beds were 
covered with pustules (Figure la). There was no involvement of the interphalangeal 
joints. Further inspection of the skin did not show any psoriatic lesions. The mucous 
membranes were unaffected. 
Blood examination before initiation of acitretin therapy showed no abnormalities, 
except for a slight elevation of transaminases, presumably attributable to an increased 
alcohol intake during the weeks before. Abstinence from alcohol was strongly advised. 
At monthly intervals the clinical responses were monitored using a 4-point scale for 
erythema, scaling and pustulation and routine blood examinations were repeated. 
During the first 3 months the dosage was 35 mg per day (= 0.5 mg/kg). At the end of 
this period pustulation had disappeared almost completely, whereas erythema and 
scaling were less pronounced, but still present. Side effects were limited to a mild 
cheilitis. In order to further improve the response we increased the dosage to 45 mg 
per day. This resulted in total disappearance of pustulation and a further decrease in 
erythema and scaling during the following month (Figure lb). 
On this dosage, this excellent result could be maintained up to the end of the treatment 
period (6 months). Apart form the mild cheilitis, no other side effects were observed 
and the initially increased transaminases normalized completely during the therapy. 
Within 2 weeks of discontinuation of acitretin therapy, the patient experienced a 
recurrence of pustulation. Etretinate was now prescribed, starting with 50 mg per day. 
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Subsequently the dosage had to be increased to 75 mg per day to achieve a similar 
response, as shown in Figure lb. 
Fig. 1. Acrodermatitis continua Hallopeau: a. before treatment; b. after 4 months of treatment with 
acitretin 
125 -
100 -
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f 
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Fig. 2. Intra-epidermal accumulation of PMN 
following application of 10 ng LTB4 before 
and during treatment with acitretin. 
Effect on intra-epidermal accumulation of PMNs 
The intra-epidermal accumulation of PMN following topical application of leukotriene 
B4(LTB4) was used as an in vivo model for pustule formation.3,4 In this patient the 
effect of acitretin therapy on this phenomenon was quantified. Before treatment with 
acitretin and subsequently after 1, 4 and 6 months of treatment, aliquots of 10 ng LTB4 
in ethanol were applied on the clinically uninvolved dorsal skin through glass cylinders 
5.5 mm in diameter. The ethanol was evaporated with a stream of nitrogen. Razor 
blade biopsies of LTB4-treated areas, containing mostly epidermis, were taken 24 h 
after these applications. In these biopsies, PMN were quantified using the marker 
enzyme elastase.5 
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The LTB^-induced PMN accumulations are shown in Figure 2. It can be seen that a 
profound inhibition occurred after 1 month of treatment with acitretin (35 mg per day). 
Increasing the dosage to 45 mg per day did not achieve further inhibition. 
DISCUSSION 
The present observation indicates that acitretin monotherapy is effective in the 
management of ACH. A further reduction of the dosage needed might be achieved by 
combining retinoids with classical topical antipsoriatics. 
The LTB4-induced intra-epidermal accumulation of PMN is a practical approach to 
study the migration of PMN through the skin. Already after 1 month of acitretin 
treatment at a dosage of 35 mg per day, the migration of these cells proved to be 
markedly inhibited. This observation further illustrates the effectivity of relatively low 
doses of acitretin. 
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Chapter 3 
Acitrctin Monotherapy in Darier's Disease 
RJ van Dooren-Greebe 
PCM van de Kerkhof 
R Happle 
Br J Dermatology 1989; 121: 375-379 
SUMMARY 
The dose response relationship to acitretin in five patients with Darier's disease was 
investigated. The patients received in the first 3 months 35 mg daily, and the dose was 
adjusted according to the clinical response. Four of the five patients showed a marked 
improvement with up to total clearance, although in two patients isomorphic reactions 
due to a relative overdose were seen. These isomorphic reactions improved with a 
reduction of dose. We suggest that treatment with acitretin is initiated at 10-25 mg 
daily with gradual adjustment of the dose. 
Darier's disease (DD) or keratosis follicularis is inherited as an autosomal dominant 
trait and is characterized by predominantly follicular pruritic hyperkeratotic papules. 
The onset is usually in late childhood and the course of the disease is chronic and in 
most cases slowly progressive. 
Before oral retinoids became available, the response to different kinds of treatment was 
poor. The use of oral vitamin A was limited by toxicity and topical retinoic acid was 
usually unsuccessful due to local irritation.1 Etretinate has been found to be effective in 
the treatment of DD,2"* but is difficult to find an optimal dosage schedule for this 
drug2·3'5,6 and even a slight overdosage may result in an isomorphic reaction with 
consequent deterioration. Despite this, etretinate has become the first choice in the 
therapy of this condition. 
The new oral retinoid acitretin (Ro 10-1670) has been found to be effective in 
psoriasis and various disorders of keratinization.7"9 Acitretin is the free acid of 
etretinate and the main metabolite of etretinate. It has an elimination half-life of 
approximately 50 h, in contrast to that of etretinate of 80-160 days. 
We investigated the dose-response relationship of five patients with DD during 
treatment with acitretin to determine the practical management of this disorder using 
this retinoid. 
METHODS 
Two women and three men with moderate to severe DD were treated with acitretin 
capsules (Hoffmann-La Roche, Basle, Switzerland). Female patients of child-bearing 
age were not included unless using reliable contraceptive methods, and patients with 
concomitant diseases, such as disturbances of the lipid metabolism, were also excluded. 
No additional therapy was allowed apart from emollients. Three patients were 
previously treated with etretinate and this was discontinued at least 4 weeks before the 
trial. 
Before therapy and each month thereafter blood investigations were performed, 
including renal and liver function tests and the lipid levels. The patients were seen 
monthly and more frequently if necessary. The clinical results were scored using a 4-
point scale for erythema, scaling, hyperkeratotic papules and pruritus (0=not present; 
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l=mild; 2=moderate; 3=severe). The total severity score refers to the sum of all 4-
points scales. Photographs of each patient were taken several times during the trial, 
and at each visit the patients were asked about side-effects. Treatment with acitretin 
was continued for at least 6 months. The initial dosage was 35 mg per day and after 1 
month the daily dose was adjusted according to efficacy and in relation to the side 
effects. 
RESULTS 
The clinical results are summarized in Figure 1. 
total »«verity i c o n tot*! Mwrlty «cor· 
12 
10 
8 
β 
4 
2 
0 SBmg 
і н ч Ш 
case 4 
""""' 
Stag 
0 1 2 S 4 
Fig. 1. Total severity score in five cases of Darier's disease during treatment with acitretin. The scoring 
refers to the sum of erythema, scaling, hyperkeratotic papules and pruritus. 
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Case 1 
A 47-year-old woman had a history of slowly progressive DD for 20 years. The initial 
severity score was 9. Acitretin treatment was started at an initial dosage of 35 mg per 
day and after 1 month the erythema and the hyperkeratotic papules improved but her 
pruritus was the same. During the next 2 months she was treated with 25 mg acitretin 
per day, and the clinical picture did not change. Increasing the dosage to 35 mg per 
day resulted in an exacerbation of symptoms over the next 2 weeks, probably due to 
an isomorphic reaction. Subsequently the dosage was reduced to 10 mg per day with 
improvement, and on increasing to 20 mg per day there was a slight exacerbation. She 
has been on 10 mg acitretin per day for 7 months and remains improved without any 
exacerbations. 
Case 2 
This 41-year-old woman first developed symptoms of DD when she was 6 years old. 
The patient had a severity score of 11 and was initially treated with 35 mg acitretin per 
day with some improvement. Increasing the dose after 3 months to 60 mg per day 
produced a mild exacerbation with later a distinct improvement, although the disease 
continues to be very active. 
Case 3 
A male patient, 39 years of age, had severe DD since late childhood. The severity 
score prior to treatment was 12. The patient received 35 mg acitretin daily during the 
first 3 months, and a mild improvement was noticed. During the fourth month the dose 
was increased to 45 mg per day. His itching became worse and we decided to decrease 
the dosage to 25 mg per day. This resulted in a marked improvement, although a 
satisfactory result was not achieved. 
Case 4 
A 36-year-old male patient had DD of moderate severity. The first symptoms started at 
the age of 29. The initial severity score was 9. During the first 2 months the patient 
was treated with 35 mg acitretin daily. This resulted in a complete clearance but 
decreasing the dosage to 25 mg was followed by a slight exacerbation. On 
maintenance therapy with 35 mg acitretin the patient has remained free of symptoms. 
Case 5 
A 47-year-old male had a 10-year history of moderate DD. The initial severity score 
was 8, and his initial dose of acitretin of 35 mg daily resulted after 1 month in a 
marked improvement. On 25 mg per day there was a slight exacerbation but increasing 
the dose to 35 mg resulted in total clearance after 3 months (Fig. 2.). This clearance 
was maintained with a dosage of 25 mg per day. 
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Fig. 2. Darier's disease (Case 5) a. before treatment; b. after 5-months treatment with acitretin. 
Side-effects 
Treatment with acitretin was well tolerated by all the patients. A mild to severe 
cheilitis was noticed by each patient and two of them complained of a dry mouth and 
one patient had a dry skin. In two cases there was a mild elevation of the serum 
triglycerides during the trail period. 
DISCUSSION 
In this trial all the patients with DD improved during treatment with acitretin. In two 
there was complete clearance of the eruption and two showed a marked improvement. 
In the remaining case there was only a moderate improvement of the disease. 
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The dose of retinoids in the treatment of DD is a problem. The initial dosage of 
etretinate has been suggested as between 0.5-1.0 mg/kg,2·3 but a lower dosage of 0.3-
0,5 mg/kg has been advocated.4*·10 This is because severe isomorphic reactions have 
been reported with high dose etretinate therapy.3"6 With acitretin an initial dose of 25-
35 mg per day has been suggested for the treatment of various disorders of 
keratinization.' This study shows that the therapeutic safe range of acitretin in DD is 
limited and that isomorphic reactions can occur on relatively low doses. However 
maintenance therapy in four of our five patients with 10-35 mg per day proved to be 
effective, and this is similar to another study on DD" which showed that acitretin in a 
dose of 20 mg per day improved the majority of 13 patients. We consider that it is 
probably advisable to start with 10-25 mg acitretin per day and then to adjust the dose 
by gradual increments up to the optimal therapeutic level for the individual patient. 
The relatively short half-life of acitretin compared to etretinate is a major advantage, 
particularly with regard to the period of strict contraceptive precautions that are 
necessary after stopping therapy. A second advantage is the prompt response with a 
reduction in the dose when side-effects have occurred.12 This is important in those 
diseases where slight overdosing results in serious adverse reactions. Our study 
indicates that acitretin appears to be of value in the treatment of DD and superior to 
etretinate in the practical management of this disorder. 
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Chapter 4 
Ichthyosis Bullosa of Siemens Responds 
Well to Low-Dosage Oral Retinoids 
PM Steijlen 
RJ van Dooren-Greebe 
R Happle 
PCM van de Kerkhof 
Br J Dermatol 1991; 125: 469-471 
SUMMARY 
Two patients with ichthyosis bullosa of Siemens (IBS) and one patient with bullous 
ichthyosiform erythroderma of Brocq (ΒΙΕ) were treated with etretinate. Two 
additional patients with IBS received acitretin. All patients had a marked improvement 
when on retinoids and the maintenance dose required was for IBS 10-25mg per day. 
The patient with ΒΙΕ was on a maintenance dose of 40-60 mg per day. 
Bullous ichthyosisform erythroderma is a relatively rare but severe and incapacitating 
type of congenital ichthyosis. This type of epidermolytic hyperkeratosis has been 
described by Brocq1 and further delineated by Lapière.2 However, in 1937 Siemens 
distinguished a particular type of congenital bullous ichthyosis without erythroderma.' 
Over the years this type of ichthyosis has been described as having a relatively mild 
involvement of the skin and the epidermolytic hyperkeratosis has been restricted to the 
upper part of the epidermis/·5 
Aromatic retinoids have been effective in the treatment of various forms of congenital 
ichthyosis,6"8 but the treatment of bullous ichthyosis erythroderma of Brocq with oral 
retinoids has been difficult.9'12 Although a marked reduction of the hyperkeratosis can 
be achieved, exacerbation of the blistering is a serious complication and often limits 
the dose of the drug. As yet there have been no reports of the use of retinoids in the 
treatment of ichthyosis bullosa of Siemens (IBS). This present study was to compare 
the responses of these two types of bullous ichthyosis to therapy with oral retinoids. 
CASE REPORTS 
The clinical and histological aspects of Case 1 to 4 have been previously described.' 
All the patients were monitored at 4-weekly intervals while on treatment. 
Case 1 
A 27-year-old woman weighing 63 kg had superficial blistering of the skin on the 
extensor surfaces of the arms and legs in addition to ichthyosis (Figure la). Her father 
(Case 3), uncle (Case 4), sisters and son were also affected. At no time she had an 
erythroderma. A skin biopsy showed mild acanthokeratolysis of the epidermis 
restricted to the region of the stratum granulosum and upper part of the stratum 
spinosum. 
The patient was given acitretin in a dosage of 35 mg daily and after 4 weeks there was 
marked reduction of the scaling that was virtually absent after 8 weeks of therapy. The 
dose was reduced after 12 weeks of treatment to 30 mg and further reduced after 16 
weeks to 25 mg (Figure lb). The dosage of acitretin was again reduced at 20 weeks 
because of some hair loss and slight elevation of the liver transaminases. A further 
reduction of the dose was at 24 weeks when she was on 10 and 20 mg on alternate 
days. During the follow-up period of 95 weeks no blistering of the skin had occurred. 
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Fig. 1. Ichthyosis bullosa of Siemens: a. Before treatment; b. After 16 weeks of treatment with acitretin 
(25 mg/day). 
Case 2 
A 21-year-old woman weighing 77 kg presented with the same degree of involvement 
as seen in Case 1. The patient was given acitretin in a dosage of 35 mg daily and the 
hyperkeratosis diminished and was virtually absent after 8 weeks of therapy. The 
dosage was reduced to 30 mg and an excellent response was maintained from 13 
weeks with a dosage of 25 mg. During the follow-up period of 22 months no blistering 
of the skin has occurred. 
Case 3 
The 51-year-old father of Cases 1 and 2 and weighing 77 kg had suffered from a scaly 
skin since birth. From the age of 15 he also had chronic relapsing pustular eruptions 
and a biopsy showed a subcorneal blister that was filled with numerous 
polymorphonuclear leukocytes. He was given etretinate in a dosage of 35 mg daily and 
after 4 weeks the skin had improved and there was no further pustulation. After 8 
weeks of treatment the hyperkeratosis was hardly noticeable and the dosage was 
further reduced to 25 mg per day. In the 22nd week the dosage was further reduced to 
25 mg on alternate days and by the 28th week to 10 mg daily. There was mild scaling 
of the arms but over the observation period of 14 months there was no blistering or 
pustulation of the skin. 
Case 4 
A 40-year-old uncle of Case 1 weighing 65 kg had the same disorder with relapsing 
pustular eruptions and was given etretinate in a dosage of 35 mg daily. After 4 weeks 
of treatment the hyperkeratosis and pustulation had resolved and the dosage of the 
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retinoid was reduced to 25 mg daily. A further reduction to 10 mg daily resulted in an 
exacerbation with pustulation and scaling. Over a follow-up period of 12 months a 
good response was maintained with him having 10 and 20 mg of etretinate on alternate 
days. 
Case 5 
A 15-year-old male weighing 67 had severe hyperkeratotic (Figure 2a) that covered the 
entire surface of the body apart from the face, palms and soles. The condition had been 
present since birth, but because the patient was an orphan it was uncertain about his 
first year of life and a family history was not available. A skin biopsy from the left 
forearm showed features of an epidermolytic hyperkeratosis that involved the entire 
epidermis. 
He was treated with etretinate in a dosage of 75 mg daily and within 4 weeks there 
was a marked improvement. However, a skin biopsy showed even more pronounced 
histological features despite the clinical improvement. During the subsequent 6 months 
he was treated with etretinate in a dosage of between 40-60 mg daily and apart from 
slight recurrence of mild hyperkeratosis with bulla formation he was otherwise 
satisfactory (Figure 2b). 
Fig. 2. Bullous ichtyosiform erythroderma of Brocq: a. Before treatment; b. After 10 weeks of treatment 
with etretinate (50 mg/day). Note the appearance of some blisters. 
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DISCUSSION 
Ichthyosis Bullosa of Siemens is a relatively mild condition as compared to bullous 
ichthyosiform erythroderma. However, the extent of the lesions and the discomfort 
caused by scaling and pustulation in our cases justified the administration of oral 
retinoids. As yet there are no other reports on the response of this disorder to systemic 
retinoids. None of our patients showed any sign of blistering 
of the skin during the follow-up period of 12-95 weeks. The maintenance dose was 
much lower than that required for bullous ichthyosiform erythroderma. 
The efficacy of etretinate in the treatment of ΒΙΕ is shown in our Case 5, though the 
maintenance dose of the drug was high at 40-60 mg daily, A maximum dose of 
retinoids is limited by introduction of blisters in this disorder9 and it has also been 
reported that the blister formation was not inhibited by therapy with etretinate11 as we 
found in our case. 
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SUMMARY 
Etretinate and its metabolite acitretin have been shown to be highly effective in the 
treatment of various disorders of keratinization, including lamellar ichthyosis. The aim 
of the present study was to provide further information on acitretin dosage regimens in 
the management of acitretin in lamellar ichthyosis. 
Seven patients with classical manifestations of lamellar ichthyosis participated in the 
study. Five patients improved markedly, and the remaining patients showed mild to 
moderate improvement. Two patients improved following gradual incremental increase 
in dosage (>35 mg/day). Four patients, including a patient with the erythrodermic 
variant, required low-dose acitretin treatment (<25 mg/day), as higher doses resulted in 
a marked deterioration in their skin condition. The dichotomy with respect to the 
response to acitretin suggests that lamellar ichthyosis is a spectrum of at least two 
conditions. 
In severe disorders of keratinization retinoids constitute a well-established and highly 
effective treatment.1,2 In monogenic disorders of keratinization, however, information 
on dosage regimens is sparse. 
We report the results of acitretin treatment of lamellar ichthyosis. The principal aim of 
the study was to establish the dose-response relationship in this disorder. 
METHODS 
Patients 
A total of seven patients with lamellar ichthyosis participated in the study. Table 1 
summarizes the patient details. All patients had a history of ichthyosis from birth. 
Patient 3 had a life-long history of erythroderma. In one patient (patient 7) the family 
history revealed that two nephews suffered from the same condition. In the other cases 
family history was negative. 
Table 1. Patients details 
Patients 'itS Bodyweight Erythroderma Congenital 
ichthyosis 
+ 
+ 
+ + 
+ 
+ 
+ 
+ 
In six patients the classical picture of non-erythrodermic autosomal recessive lamellar 
ichthyosis was seen, and in one case (patient 3) erythrodermic autosomal recessive 
ichthyosis was diagnosed. Flexural involvement, and palmoplanar keratoderma was 
2. 
3. 
4. 
5. 
6. 
7. 
9 
9 
9 
6 
9 
δ 
i 
40 
39 
59 
51 
57 
59 
76 
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present in all patients. In patient 1 the condition was associated with almost total 
alopecia. Two patients (patients 1 and 3) suffered from pruritus. In all patients the 
severity of the skin condition required systemic treatment with retinoids. 
In four out of seven patients, treatment was initiated with etretinate, resulting in a 
moderate to good clinical improvement. Apart from mild to moderate cheilitis, no 
mucocutaneous side-effects occurred in these patients. Table 2 summarizes the results 
with etretinate. In these patients etretinate was discontinued for 1 month before the 
initiation of acitretin therapy. This resulted in a deterioration of skin symptoms during 
the first 2-3 weeks. 
Table 2. Response to etretinate 
Patient 
2. 
3. 
4. 
5. 
6. 
7. 
Duration 
(years) 
7 
6 
7 
5 
Optimal dose 
(mg/day) 
25 
20 
25 
50-75 
Improvement 
moderate 
good 
good 
moderate-good 
Mucocutaneous 
side effects 
mild 
mild 
moderate 
mild 
Treatment 
All patients were initially treated with acitetrin 35 mg daily for 4 weeks. Thereafter, 
the dose was individualised on the basis of efficacy and tolerability in each patient. 
Before treatment, and at monthly intervals, blood investigations were carried out (full 
blood count, bilirubin, creatinine, urea, uric acid, blood sugar, alkaline phosphatase, 
transaminases, gamma-glutamyl transpeptidase, cholesterol, triglycerides). Before 
treatment, after б months treatment, and subsequently at yearly intervals, an X-ray of 
the spine was performed. 
Table 3. Response to acitretin 
Patient 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
Duration 
(years) 
4 
4 
5 
5 
V4 
4 
V4 
Optimal dose 
(mg/day) 
35 
25 
10-25 
25 
35 
10-20 
55 
Improvement 
marked 
marked 
marked 
marked 
mild 
marked 
moderate 
Mucocutaneous 
side effects 
mild 
moderate 
moderate-severe 
moderate 
severe hairless 
moderate 
moderate 
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Results 
Acitetrin therapy produced a marked improvement in most patients. Table 3 shows the 
results in individual patients. Figure 1 illustrates the clinical improvement (patient 1). 
The optimal dose varied considerably between individual patients (Table 3). The 
dynamics of dosage adjustments, however, provided two distinct response patterns. 
Some patients improved following each dosage increment (patients 1 and 7: Figure 2). 
Fig. I, Lamellar ichthyosis before treatment (a) and after 6 months treatment (b) with acitretin 
(35 mg/ day, patient 1) 
In these patients the maximum dose was limited by mucocutaneous side- effects 
(cheilitis, epistaxis or hair loss). The remaining patients worsened at a dosage of 35 
mg/day, and required lower doses (10-25 mg/day, Figure 3). Reduction of the dosage 
below 35 mg/day resulted in an improvement of scaling, pruritus and tenderness of the 
skin. The patient with erythrodermic lamellar ichthyosis (patient 3) showed the most 
remarkable dose-response relationship in this respect. Figure 2 illustrates dose response 
relationship of a "high-dose profile" and Figure 3 the dose-response relationship of a 
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"low dose profile". After 4 years treatment there was cosmetically acceptable hair 
regrowth in patient 1, who had suffered from severe alopecia. 
Apart from some degree of cheilitis, epistaxis or hairloss, there were no other side-
effects. 
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DISCUSSION 
The efficacy of acitretin in the treatment of lamellar ichthyosis has been reported 
previously.2 The present study confirms this report, and suggests that two distinct 
response patterns may occur: (i) a high-dose response, in which maximum efficacy is 
limited by the tolerance of the individual patient to acitretin; (ii) a low-dose response, 
in which maximum efficacy is reached at a low dose. In the latter response type, 
increasing the dose results in more scaling and pruritus. Erythrodermic autosomal 
recessive lamellar ichthyosis is characterized by a low-dose response-pattern. However, 
3 of the patients who responded optimally to the low-dose regimen had clinical and 
histological features which were similar to those observed in the patients requiring 
higher doses. 
The clinical appearance of lamellar ichthyosis is highly variable.3 Patients with 
lamellar ichthyosis may manifest erythroderma, or they may have the non-
erythrodermic variant. In addition, patients may appear non-erythrodermic, but have a 
previous history of erythroderma. At the cellular level, patients with erythrodermic 
manifestations tend to have increased labelling indices in the epidermis in combination 
with parakeratosis.4"6 There is some overlap at the cellular level. At the molecular 
level, patients with erythroderma have increased levels of n-alkanes in the epidermis, 
in contrast with the normal levels observed in the non-erythrodermic individuals.7 
It has been suggested that heterogeneity exist within the lamellar ichthyosis group, 
based on clinical, histological ultrastructural, cellular and biochemical studies. The 
present study demonstrates that the patient with erythrodermic lamellar ichthyosis 
responded optimally to the low dose regimen. The remaining patients who had clinical 
and histological features of the non-erythrodermic type showed a differential retinoid 
sensitivity. 
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ABSTRACT 
Keratodermia palmaris et plantaris transgrediera et progrediens can invalidate patients 
to the extent that normal walking is impossible. The present case report describes the 
beneficial response of two patients with Greither's disease to acitretin 25-35 mg/day. 
Keratodermia palmaris et plantaris transgrediens et progrediens has been described as a 
distinct disorder of keratinization by Greither in 1952 (Greither's disease)'. Greither's 
disease is an autosomal dominant trait. The hyperkeratosis is not restricted to the palms 
and soles but transgredes to the dorsal surfaces. The hyperkeratosis has a Assuring 
appearance.1'6 In addition, hyperkeratotic lesions can be seen on the elbows, the knees 
and the region of the Achilles tendon. Greither's disease and keratosis palmoplantaris 
diffusa (Unna Thosts disease) are both diffuse palmoplantar keratodermias. In Unna 
Thosts disease, however, hyperkeratosis is smooth and restricted to the palmar and 
plantar surfaces. 
In Unna Thosts disease acitretin has variable results; a marked improvement was 
observed in one patient and no effect at all could be shown in two patients.7 To the 
best of our knowledge no reports are available yet on the efficacy of acitretin in 
Greither's disease. 
In this communication we report on the clinical efficacy of acitretin in two patients 
with Greither's disease. 
CASE REPORTS 
Case 1 
A 39-year-old man presented with a hyperkeratosis of the palms and soles. During the 
year before presentation, the patient complained of pain, due to fissuring of the 
hyperkeratosis. Normal walking was impossible. The family history was negative for 
palmoplantar keratosis. A diffuse fissuring hyperkeratosis was observed on the palms 
and soles (Figure 1), which transgreded to the dorsal surfaces. Hyperkeratotic plaques 
were present around the Achilles tendon and at the right elbow. No erythema was 
observed at the involved areas. Histological investigation of a biopsy taken from the 
area above the Achilles tendon revealed hyperkeratosis of the orthotype, a prominent 
stratum granulosum and acanthosis. There were no foci of acanthokeratolysis and the 
dermis did not show abnormalities apart from a sparse mononuclear infiltrate. 
Acitretin was instituted at a dosage of 35 mg per day. After 8 weeks a clear 
improvement (Figure 1) was seen with respect to hyperkeratosis and fissuring. During 
treatment hyperkeratosis and fissuring were assessed using a 4 point scale (0= no 
abnormality; 1= mild expression; 2= moderate expression; 3= severe expression). The 
response had its maximum effect after 12 weeks treatment. At that time only a 
minimal hyperkeratosis remained (Figure 2). Walking was not painful anymore. After 
20 weeks of treatment acitretin was discontinued and a relapse of fissuring 
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hyperkeratosis occurred within one week. The patient did not experience any subjective 
side effects, apart from a mild cheilitis. Serum cholesterol, triglycerides and 
transaminases remained within the normal range. 
Fig. 1. Case 1: transgreding hyperkeratosis of the sole. Note the fissuring aspect of the hyperkeratosis. 
a. before treatment; b. after 9 weeks treatment with acitretin 
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Fig. 2. A schematic representation of the response to acitretin. a. Case 1; b. Case 2. 
0 0 = palmoplanar keratodermia; 0—0 = fissuring; sfc = pruritus; X = hair loss 
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Case 2 
A 30-year-old woman presented with a hyperkeratosis of palms and soles, which had 
been present since birth. During the years a gradual aggravation of this disorder 
occurred. The patient complained of pain caused by fissuring. Two brothers, the father 
and grandfather of the patient suffered from a similar hyperkeratotic disorder on palms 
and soles. A diffuse hyperkeratosis, partly verrucous and partly fissuring was observed 
of the palms and soles (Figure 3). The hyperkeratosis transgreded to the dorsal surface 
of the fingers and to the region of the Achilles tendon. Histopathologic^ investigation 
of a biopsy taken from the right palm showed hyperkeratosis of the orthotype, a broad 
stratum granulosum and acanthosis. The dermis did not show any abnormality. 
Figure 2 illustrates the response to acitretin. Following one month of treatment with 
acitretin 35 mg/day the fissuring hyperkeratosis improved. However, pruritus 
necessitated a dosage reduction to 25 mg on alternate days. After 8 weeks treatment 
extensive hairloss was observed and the dosage was reduced to 10 mg on alternate 
days. A fast relapse was seen at this low dosage. Upon a dosage of 30 mg/day for 2 
weeks and subsequently 25 mg/day an excellent response was observed (Figure 3): 
only a minimal hyperkeratosis remained and no pain was experienced. Subsequently 
the patient continued with acitretin treatment during one year. Further reduction below 
25 mg/day resulted in an immediate relapse of the hyperkeratosis. Serum cholesterol, 
triglycerides and transaminases remained within the normal range. Treatment was 
discontinued because of the narrow margin between side effects (hairloss; pruritus) and 
clinical efficacy. 
DISCUSSION 
Keratodermia palmaris et plantaris transgrediens and progrediens Greither is supposed 
to be a rare disorder.'9 Hamm et at. reviewed a group of 26 patients with diffuse 
palmoplantar keratodermia and 4 of these patients were classified as Greither's 
disease.10 It is also our impression that the frequency of Greither's disease is 
underestimated. Aware dermatologists working in private practice could certainly 
detect this disorder more frequently. 
Acitretin was effective in both patients. Hyperkeratosis had decreased substantially and 
the patients were relieved of pain. In case 2 side effects limited acitretin treatment. 
The response of palmoplantar keratodermias to acitretin is highly variable.7 Very good 
improvement has been reported in Papillon-Lefèvre syndrome.7 The present report 
demonstrates that acitretin can induce an excellent improvement in Greither's diseases. 
In this condition acitretin is best initiated at a dose of 35 mg per day. 
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Fig. 3. Case 2: Transgreding hyperkeratosis of the palm a. before treatment; b. after 6 weeks treatment 
with acitretin. 
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Sir, Mal de Meleda is an autosomal recessive keratoderma of the palms and soles. This 
relatively rare condition is characterized by a diffuse hyperkeratosis which extends on 
to the dorsal surfaces of the hand and feet, and may affect the knees and elbows. 
Sometimes the forearms and lower legs are also involved. Other abnormalities which 
have been described in mal de Meleda include nail thickening or koilonychia and 
hyperkeratosis. This disorder originally was described on the Dalmation island of Mljet 
(Meleda). ' The efficacy of the aromatic retinoids etretinate and acitretin in disorders of 
keratinization is well established,2,3 and they usually, but not invariably, produce 
improvement of palmoplantar keratoderma. In Papillon-Lefèvre syndrome a highly 
successful response has been documented by several groups.3"* In contrast, although 
hereditary epidermolytic palmoplantar keratoderma (Vomer type) consistently showed 
a reduction of the hyperkeratosis during retinoid therapy, increased fissuring and 
blistering accompanied by tenderness always necessitated discontinuation of treatment 
at an early stage.7,8 Information on the efficacy of acitretin in other types of 
palmoplantar keratoderma is limited, and in the more rare disorders such as mal de 
Meleda information is not yet available. We report the response to acitretin in two 
patients with mal de Meleda. 
A 70-year-old female complained of thickening of the palms and soles which had been 
present since birth. She had extensive, diffuse hyperkeratosis which extended on to the 
dorsa of the hands and feet (Figure 1). The nails showed a subungual hyperkeratosis. 
Seven months before presentation the lesions had extended to the distal parts of the 
lower legs and lower arms as sharply demarcated erythematosquamous plaques. This 
extension had been noticed following treatment of hypertension with Captopril. 
Although cultures of scrapings had all been negative for fungi, a culture of a skin 
biopsy grew trichophyton rubrum. A biopsy taken from the margin of the extending 
lesion on the lower arm revealed epidermal acanthosis and hyperkeratosis, with areas 
of orthokeratosis and parakeratosis. There was a perivascular mononuclear infiltrate in 
the dermis. PAS-positive spores were present in the stratum comeum. Acitretin 
treatment was started at a dosage of 35 mg/day and increased to 50 mg/day. Topical 
treatment with ketoconazole cream twice daily was also commenced. Acitretin 
treatment resulted in a marked reduction of the hyperkeratosis, however, blistering and 
tenderness of the affected skin necessitated reduction of the dosage to 30 mg/day. 
After 4 months' treatment with acitretin and topical ketoconazole, a marked reduction 
of hyperkeratosis and a modest improvement of erythema were observed (Figure 2). 
Unfortunately, severe hair-loss necessitated discontinuation of acitretin, and within 5 
days the hyperkeratosis of the palms and soles reappeared. 
A 59-year-old female presented with a hyperkeratotic disorder of the palms and soles, 
which had been present from birth. On examination there was diffuse hyperkeratosis of 
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the palms and soles, which extended on to the dorsal surfaces of the hands and feet. 
There was pseudo-ainhum of the 5th finger of the left hand. Mild erythema and a 
moderate palmoplanar hyperhidrosis were additional features. Cultures from the 
hyperkeratotic areas repeatedly grew Candida albicans and Trichophyton rubrum. His-
topathology of a biopsy taken from the palm showed a marked ortho-hyperkeratosis 
and PAS staining demonstrated Candida hyphae. The hyperkeratotic areas were treated 
topically with ketoconazole cream, and acitretin was started at a dose of 35 mg/day. 
After 4 weeks' treatment, the hyperkeratosis was markedly reduced. The erythema, 
however, was more intense and the patient experienced an unpleasant tenderness of the 
palms and soles. A dosage of 20 mg/day and 10 mg/day on alternate days was found 
to be the best compromise. The pseudo-ainhum of the 5th finger had completely 
resolved after 6 months treatment. 
Fig. 1. Clinical appearance of the hand in Case 1 Fig. 2. Clinical appearance of the hand in Case 1 
before treatment
 a f t e r 4 m o n t h s 0f acitretin (30 mg/day) 
The clinical picture in both patients is compatible with the diagnosis mal de Meleda. 
Both patients were severely incapacitated by their skin disorder, and we therefore 
considered that treatment with acitretin was warranted. Jee et al.9 have previously 
reported the efficacy of etretinate in mal de Meleda. Treatment with acitretin resulted 
in a marked reduction of the keratoderma in both cases. Erythema, however, was 
prominent and became more evident following resolution of the hyperkeratosis. The 
optimal dosage proved to be between 10-30 mg/day. Higher dosages resulted in a 
113 
marked tenderness of the skin and in Case 1 blistering was observed at a dosage of 
50 mg/day. Improvement occurred within the first month of treatment. In Case 1 
discontinuation of acitretin resulted in relapse within days. In various forms of 
palmoplantar keratoderma cultures of hyperkeratotic material have revealed fungi,10"12 
and fungal infection can be demonstrated in up to 60% of patients with palmoplantar 
keratoderma.12 Although it is difficult to estimate to what extent the fungal infection is 
responsible for the hyperkeratosis and inflammation, the beneficial effect of 
monotherapy with itraconazol suggests that fungal infection contributes to the 
symptoms." For this reason, combined treatment with acitretin and topical 
ketoconazole was prescribed in the present cases. 
In conclusion, acitretin can be of benefit in cases of mal de Meleda. However, 
treatment should be initiated with a relatively low dose (10 mg/day) which should be 
gradually increased in order to reach an optimal dose which does not result in 
discomfort or blistering. It is important to be aware of the possibility of a concomitant 
fungal infection, which requires additional antifungal treatment. 
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Chapter 8 
Severe Hepatotoxic Reaction with Progression to 
Cirrhosis after use of a Novel Retinoid (Acitretin) 
ThJM van Ditzhuijsen 
UJGM van Haelst 
RJ van Dooren-Greebe 
PCM van de Kerkhof 
SH Yap 
J Hepatol 1990; 11: 185-188 
We report the case of a 50-year-old female who suffered from severe palmar and 
plantar pustulosis. During treatment with acitretin, a novel oral retinoid, which is the 
main derivative of etretinate, the patient developed a severe hepatotoxic reaction. 
Subsequent histological studies strongly suggested the development of liver cirrhosis. 
Reversible elevation of serum aminotransferase values during treatment with acitretin 
has been reported. However, the present observation indicates that severe hepatotoxic 
injury may also follow treatment with this agent. 
Chronic use of vitamin A causes toxic manifestations which have limited its 
therapeutic usefulness. Nevertheless, vitamin A dérivâtes are still used, especially in 
Europe, for the treatment of keratinizing disorders. The aromatic retinoid etretinate 
(Figure 1) structurally is quite similar to retinol, which has been shown to induce 
severe hepatotoxic reactions.M Etretinate is a potent teratogen. Because of its extended 
half-life (120 days6), women of childbearing age must avoid pregnancy for a long 
period after discontinuation of the drug. This is a serious disadvantage. Its main 
metabolite, acitretin (Figure 1), with a half-life of only 50 h, is now under 
investigation for the treatment of psoriasis and other treatment-resistant dermatoses. 
We report the first case of severe hepatotoxic reaction to this novel retinoid. 
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Fig. 1. Etretinate and acitretin, its main metabolite. 
CASE REPORT 
A 50-year-old Caucasian female presented with severe palmar and plantar pustulosis. 
Treatment with acitretin was started in April 1987. Prior to treatment she had been in 
good health and had normal serum aminotransferase levels (Figure 2). During the first 
3 months of treatment her liver enzyme parameters were still normal, but at 4 months 
an elevation of serum aminotransferase values was noted: serum alanone aminotrans­
ferase (ALT), 125 IU/1 (normal value <30); serum aspartate aminotransferase (AST): 
90 UI/1 (normal value <25). Her physical condition remained unchanged. She did not 
use other drugs or abuse alcohol. Despite a dose-reduction during the following weeks 
(Figure 2), ALT values rose to 790 IU/1 and the patient began to complain of vague 
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abdominal discomfort, malaise, hair loss and a dry mouth. The drug was discontinued 
and she was referred to our out-patient department. On her first visit, 11 days after 
discontinuation of the drug, her main complaints were: poor appetite, tiredness and 
vague abdominal discomfort. There was no history of blood transfusion, illicit drug 
abuse or jaundice. Her stools and urine were normal. 
At physical examination, the liver was found to be tender and enlarged to four 
centimeters form the costal margin, the spleen was not felt. Spider naevi were noted 
on the trunk, and pustules within sharply defined erythematosquamous plaques were 
present on palms and foot soles. 
Laboratory studies revealed a normal erythrocyte sedimentation rate (4 mm in the first 
hour), hemoglobin concentration and white blood cell an platelet counts. 
Aminotransferase values were still markedly elevated. ALT and AST were, 
respectively 790 and 635 IU/1. Gamma-GT level was 166 IU/1 (normal value <120); 
bilirubin levels were normal. 
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Fig. 2. Correlation of serum alanine aminotransferase (ALT) and serum bilirubin levels with intake of 
acitretin. 
Serologic examination was negative for hepatitis A, hepatitis B, cytomegalovirus, 
Epstein-Ватт virus, herpes simplex, toxoplasmosis, brucellosis and syphilis. No 
antibodies against smooth muscles, mitochondria, parietal cells or antinuclear 
antibodies were present. Ultrasound studies of the liver revealed no abnormalities. 
Despite a gradual clinical improvement and a fall in serum aminotransferase values 
during the following weeks, a slight elevation of serum bilirubin was noted. At that 
time, 2 months after discontinuation of the drag, a liver biopsy was performed. 
Histological examination showed severe acute hepatitis with mainly porto-portal and to 
a lesser extent porto-central necrosis, eosinophilic infiltrates and slight 
intrahepatocellular cholestasis (Figure 3). In ultrastructural studies, no accumulation of 
fat-storing cells, as described after vitamin A intoxication, was observed. In view of 
these findings the patient was admitted to hospital. Serum aminotransferase values 
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improved gradually and her symptoms diminished. A second liver biopsy, 1 month 
later, demonstrated evident regression of the inflammatory component but also some 
nodularity with portal fibrosis and the formation of fine portal septa (Figure 4). Nine 
months after discontinuation of acitretin when, the patient was in good health, except 
for vague abdominal discomfort, and all liver parameters had normalized, a third 
biopsy was performed. Histology revealed even more convincing pseudolobular 
transformation with portal fibrosis and fine broad septa featuring the development of 
cirrhosis (Figure 5). 
Fig. 3. Liver biopsy 2 months after discontinuation of etretin. Note severe inflammatory features with 
porto-portal bridging necrosis. (Laguesse reticulin stain; original magnification χ 160). 
Fig. 4. Liver biopsy 3 months after discontinuation: some nodularity with portal fibrosis and formation 
of slender subdividing septa can be demonstrated. (Laguesse reticulin stain; original magnification 
xl60). 
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Fig. 5. Liver biopsy 5 months after discontinuation of the etretin therapy. Note macro-micronodular 
cirrhotic transformation. (Van Gieson stain; original magnification x40). 
DISCUSSION 
The hepatotoxic effects of the chronic use of vitamin A are well known and 
characterized histologically by perisinusoidal fibrosis, central vein sclerosis, focal 
congestion and massive accumulation of fat-storing cells.7,8 Since the early seventies, 
vitamin A dérivâtes have been used in the treatment of keratinizing disorders. The 
aromatic retinoid, etretinate, has probably been studied most extensively, and was 
implicated in reversible serum aminotransferase elevations, acute hepatitis and chronic 
active hepatitis.1"4 Moreover, reversible non-cirrhotic portal hypertension, probably due 
to an increase in number and size of fat-storing cells has been described.5 However, 
other studies on the liver toxicity of etretinate therapy have shown no consistent liver 
function abnormalities. In their controlled study, Foged et al. found no significant 
histological differences before and after etretinate therapy.10 Transient elevations of 
liver enzymes (serum aminotransferases and alkaline phosphatase) have also been 
reported during treatment with the main metabolite of etretinate, acitretin, the drug 
under study in this report.""15 However, this case report shows that a severe 
hepatotoxic reaction with progression to liver cirrhosis may occur during treatment 
with this agent. We therefore believe that acitretin should be added to the list of 
potentially hepatotoxic drugs. 
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Chapter 9 
Extensive Extraspinal Hyperostoses after 
long-term Oral Retinoid Treatment in a 
Patient with Pityriasis Rubra Pilaris 
RJ van Dooren-Greebe 
PCM van de Kerkhof 
JAAD 1995;32:322-325 
ABSTRACT 
We describe a patient with severe pityriasis rubra pilaris in whom extensive extra-
spinal hyperostoses developed after 13 years of oral retinoid treatment. The most 
prominent abnormality was a bridging exostosis between the left acetabulum and 
collum. X-ray examinations of the spine during retinoid therapy showed no 
abnormalities. During oral retinoid treatment it is important to ask the patient on a 
regular basis about any skeletal pains or mobility restriction. Normal spinal X-ray 
results are no guarantee that a patient is free of hyperostoses. 
Discontinuation of acitretin therapy resulted in a severe exacerbation of the patient's 
pityriasis rubra pilaris after 2 weeks. The clinical response to administration of 
azathioprine was clearly inferior to that of acitretin. However, low-dose oral 
methotrexate therapy appeared to be a good alternative in this patient, with a clinical 
result comparable to acitretin and no side effects after 6 months of therapy (JAAD 
1995;32:322-325). 
Pityriasis rubra pilaris (PRP) is characterized by follicular erythematous and 
hyperkeratotic papules typically distributed on the trunk and extensor surfaces of the 
extremities. Extensive erythema and scaling or erythroderma may occur, interspersed 
with sharply demarcated "islands" of normal skin. Keratoderma of palms and soles is 
common; the hyperkeratosis often has a yellowish color.1'3 
Griffiths4 classified PRP into two adult types (classical and atypical) and three juvenile 
types (classical, circumscribed and atypical). The classic adult type accounts for more 
than 50% of cases.4 Satisfactory results with oral retinoid therapy have been reported,1" 
3,5-7
 although not all patients benefit from such treatment. Juvenile forms of PRP tend 
to have a better response to retinoid treatment than adult forms of the disease.5,6 
Skeletal abnormalities with changes similar to DISH (cñffuse idiopathic skeletal 
hyperostoses), extraskeletal ossification, premature epiphyseal closure, and osteoporosis 
have been reported as long-term side effects of oral retinoid therapy. *"14 These skeletal 
changes strongly resemble those observed in hypervitaminosis A syndrome.15 
According to most authors, the spine is the site of predilection for retinoid-induced 
hyperostoses. 
We describe a patient with PRP and extensive extraspinal hyperostoses after long-term 
retinoid treatment. 
CASE REPORT 
A boy bom in 1959 had severe classic juvenile PRP that first started at age 9 years 
and consisted of a persistent erythroderma (except for some small "islands" of normal 
skin), hyperkeratotic follicular papules, and diffuse palmoplantar hyperkeratosis 
(Figure la). 
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Histologie examination showed a slightly acanthotic epidermis and diffuse and 
follicular hyperkeratosis and parakeratosis. There was follicular plugging and 
perifollicular parakeratosis. The papillary dermis showed a predominantly lymphocytic 
infiltrate. 
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Fig. 1. a. PRP before treatment with acitretin; b. After 6 months of treatment with acitretin 35-
50 mg/day 
Local therapy and UVB irradiation were ineffective. Oral retinoid treatment was 
started in 1977 and continued until January 1992 (retinóte acid 25 to 50 mg/day from 
1977 to 1979, etretinate, 50 to 75 mg/day from 1979 to 1987; acitretin, 35 to 
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50 mg/day after 1987). This regimen resulted in marked clinical improvement (Figure 
lb). Side-effects were limited to cheilitis and some alopecia. Attempts to lower the 
dosage of oral retinoids to less than 35 mg/day (0.3 mg/kg/day) were unsuccessful. 
Additional routine X-ray examinations of the spinal column showed no abnormalities. 
In August 1990 the patient reported progressive pain and restricted mobility in his left 
hip. Radiographs showed extensive periostal hyperostoses of both hips and, to a lesser 
extent, of the shoulders. A bridging exostosis was present between the left acetabulum 
and collum (Figure 2). 
Fig. 2. Extensive periostal hyperostoses and a bridging exostosis between the left acetabulum and 
collum after 13 years of oral retinoid treatment 
Successful surgery was performed on the left hip. Acitretin treatment was discontinued 
after surgery and PUVA therapy was started. Two weeks later treatment with acitretin 
was restarted because of a severe exacerbation. In January 1992 acitretin therapy was 
again discontinued. Azathioprine therapy was introduced with an initial dosage of 50 
mg/day and a maintenance dosage of 200 mg/day. The clinical response was inferior to 
that of acitretin therapy, but treatment was continued for 10 months. In October 1992, 
the erythroderma became more pronounced and the patient reported malaise, thirst and 
chills. Azathioprine therapy was discontinued and a 2-week course of prednisone 
(30 mg/day) was prescribed. Subsequently methotrexate (MTX) was given according to 
the divided schedule proposed by Weinstein and Frost.16 The dosage was gradually 
increased from 7.5 mg/week to 15 mg/week. Laboratory investigations were performed 
¡24 
according to the international MTX guidelines.17 In general, the response to treatment 
with MTX has been satisfactory and comparable with the response to acitretin therapy. 
After 6 months of therapy there have been no clinical or laboratory side effects. 
DISCUSSION 
Many reports have appeared about retinoid-induced skeletal abnormalities,8"14 but the 
true incidence and severity of skeletal problems are not yet sufficiently established. A 
major problem is the differentiation of retinoid-induced bone changes from those 
induced as a result of aging or unrelated diseases. It is generally accepted that retinoid-
induced skeletal abnormalities predominantly affect the spinal column. Exclusively 
extraspinal abnormalities have been reported only occasionally. ' · 1 β 1 ' 
Further prospective and controlled studies of retinoid-induced skeletal abnormalities are 
necessary before definitive guidelines for the surveillance of patients before and during 
retinoid treatment can be established. Currently most authors advise pre-treatment and 
annual radiographs of the lateral spine with additional views of symptomatic 
areas.
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 Others recommend additional screening of the pelvis, calcaneus, and long 
bones.1214 Finally, there are some authors who do not recommend any routine 
screening but only obtain radiographs of symptomatic areas in addition to radiographs 
of the spine (and calcaneus) before treatment.22"23 
A complete response to azathioprine therapy (50-200 mg/day) in four out of five 
patients with wide-spread PRP was reported by Hunter and Forbes.24 Griffiths4 reported 
a satisfactory response in seven of eight patients. There are several reports on the 
efficacy of MTX in PRP.4,25"27 Usually daily or weekly schedules were used in dosages 
similar to the psoriasis schedule. In their review of PRP, Cohen and Prystowsky ' stated 
that "although most patients with PRP respond to methotrexate, many relapse when 
therapy is discontinued; reinstitution of the drug usually results in rapid clinical 
improvement". Griffiths4 was less optimistic; combining his own data with those in the 
literature, he reported that of 44 patients treated with MTX only 17 showed any 
response. 
Azathioprine therapy was not successful in our patient, but low-dose oral MTX therapy 
was comparable to acitretin in efficacy. 
This article illustrates the problems in management of patients with retinoid-induced 
skeletal abnormalities. Discontinuation of retinoid therapy is not always possible; if it 
cannot be discontinued, more hyperostoses are likely to develop. It is important to be 
aware that normal results of spinal X-ray studies do no guarantee that a patient is free 
of hyperostoses. It is also important to ask about skeletal pains and mobility problems 
regularly during oral retinoid treatment, because patients do not usually connect these 
symptoms with retinoid treatment and therefore do not always indicate them 
spontaneously. 
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SUMMARY 
It is generally accepted that the spine is a predilection site for retinoid-induced skeletal 
abnormalities. The reported prevalence of skeletal problems, however, is widely 
variable. 
To investigate the frequency and severity of retinoid-induced spinal abnormalities, all 
records of patients who underwent spinal radiographs on request of the department of 
dermatology between 1983 and 1993 were reviewed. This group of 135 patients 
comprised the total population of retinoid-treated patients and those patients who were 
investigated for possible future retinoid treatment. The mean treatment period in the 
total group was 30 months and the mean cumulative dose was 31 gram. In 50 patients 
the treatment period was > 24 months; 30 patients were treated for more than 48 
months. From 26 patients baseline radiographs were available and these were 
compared with the most recent X-rays during treatment. The mean treatment period in 
this "prospective group" was 25 months and the mean cumulative dose was 25 gram. 
The prevalence of DISH, degenerative changes and osteoporosis in the total group was 
respectively 16, 53 and 29%. There was no statistical significant relation between the 
duration of treatment or the cumulative dose and the prevalence or severity of DISH, 
degenerative changes and osteoporosis. Only the age of the patients was significantly 
related to the frequency and severity of skeletal abnormalities. In the "prospective 
group", again, no important changes were observed between the radiographs at baseline 
and during treatment. 
In this study no relation whatsoever between spinal abnormalities and prolonged oral 
retinoid treatment could be established. The performance of annual routine spinal 
radiographs during retinoid treatment is not necessary in our opinion. Additional 
controlled and prospective studies on spinal and extra-spinal skeletal abnormalities are 
required to develop definitive screening guidelines for patients submitted to long-term 
retinoid treatment. 
During the last two decades, oral retinoids have acquired an indispensable place in the 
therapeutic arsenal of modem dermatology. The most notorious side-effects of oral 
retinoids, in adults as well as in children, are spinal- and extra-spinal skeletal 
abnormalities. Retinoid-induced skeletal abnormalities resemble the symptoms 
described in chronic vitamin A intoxication. ' In adults the described abnormalities are 
highly identical to those of "diffuse idiopathic skeletal hyperostosis" (DISH) and 
consist of spinal- and extra-spinal hyperostosis (spurs) and calcification of tendons and 
ligaments. Other abnormalities include slender long bones and possibly osteoporosis.1'0' 
revi« 2-4 j n ^ ¡ ¡ ^ η thickening of periost, bone resorption, disc narrowing and premature 
closure of epiphyses have also been reported.5,6 The prevalence of retinoid-induced 
skeletal abnormalities, as mentioned in the literature, is widely variable and many of 
the communications on skeletal abnormalities in retinoid patients are casuistic. In table 
128 
1 the population studies in adults (n>5) are summarized.7'" In our department we have 
a longstanding experience with long-term retinoid treatment. 
The aim of this study was to investigate the extent of retinoid-induced spinal 
abnormalities in a large patient population and to contribute to the development of 
screening guidelines for long-term retinoid treatment. The available spinal radiographs 
of our retinoid patients were studied with regard to the frequency and severity of 
DISH, degenerative changes and osteoporosis, using well-defined radiological criteria. 
The results were related to duration of treatment, cumulative dose and age of the 
patients. Pre-treatment radiographs were available in 26 patients and these were 
compared with the most recent X-rays during treatment. 
METHODS 
The records of all patients who underwent spinal radiographs on request of the 
department of dermatology during the period 1983-1993 were reviewed. Radiographic 
examination of the spine is part of our protocol for oral retinoid treatment. Patients 
who underwent pre-treatment screening were also included in the study. The duration 
of treatment and the cumulative dose of etretinate and acitretin were calculated in each 
patient. For all calculations we chose as referring point the moment of the most recent 
radiographic survey. From the total group a "prospective group" was identified who 
had pre-treatment radiographs as well as one ore more X-ray surveys during retinoid 
therapy and a minimal treatment period of 9 months. 
Both the available pre-treatment radiographs and the most recent radiographs of each 
patient (anterior-posterior as well as lateral views) were evaluated by the same 
radiologist (JAML). The radiographs were reviewed in arbitrary sequence and in 
chronologic order for each patient. The radiologist was not conversant with details 
from the patient records. The vertebral levels C3-C7, Th3-ThI2 and Ll-Sl of all 
radiographs were investigated for osteophytes (small, medium or large), 
syndesmophytes (1/3, 2/3 or 3/3 bridging), osteoporosis, narrowing of the intervertebral 
discs and ligament calcification. Triangular outgrowths located several millimeters 
from the edge of the vertebral bodies were defined as osteophytes and vertical 
outgrowths extending from the edge of one vertebral body to the next were defined as 
syndesmophytes.20 DISH was diagnosed when the spinal radiographs showed a flowing 
ligament calcification and syndesmophytes along the anterior aspect of at least three 
vertebral bodies, a relative preservation of intervertebral disc height in the involved 
vertebral segment and absence of osseous fusions.21 Osteophytes and narrowing of the 
intervertebral discs were defined as degenerative changes. Beside a "yes or no" 
classification of DISH, degenerative changes and osteoporosis, total severity-scores for 
DISH and degenerative changes were defined for each reviewed spinal radiograph. To 
compute the severity score of DISH (0-84 points), syndesmophytes with an extension 
of less dan 1/3 of the intervertebral disc height scored 1 point per vertebral level, 
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syndesmophytes with an extension between 1/3 and 2/3 scored 2 points per vertebral 
level and when more than 2/3 of the intervertebral disc height was involved, the score 
was 3 points per vertebral level. Ligament calcification was scored with 1 point per 
vertebral level. To compute the severity score of degenerative changes (0-84 points), 
small, medium or large osteophytes were scored with respectively 1,2 or 3 points per 
vertebral level and disc narrowing was scored with 1 point per vertebral level. 
Osteoporosis was assessed only as present or absent. A severity score was not used, as 
plain radiography is considered an inaccurate method to evaluate the severity of 
osteoporosis.22 The prevalence and the severity scores of DISH, degenerative changes 
and osteoporosis were assessed and related to duration of retinoid treatment, 
cumulative dose and age of the patients. For the "prospective group" the prevalence 
and severity scores of DISH, degenerative abnormalities and osteoporosis in the pre-
treatment situation were compared with the most recent radiographs during retinoid 
treatment. 
Possible dependencies of the prevalence of DISH, degenerative changes and 
osteoporosis on one hand on duration of treatment, cumulative dose and age on the 
other hand were investigated using stepwise logistic regression with the latter three 
parameters as independent variables. The relationship between the severity scores of 
DISH and degenerative changes and duration of treatment, cumulative dose and age 
was investigated using Spearman's rank correlation coefficient. 
RESULTS 
Patients 
The spinal radiographs of 135 patients (81 men and 54 women) were studied. The 
mean age of the patients was 46 years. The population consisted of 77 patients with 
psoriasis, 31 patients with a monogenic disorder of keratinization, 6 patients with 
lichen planus, 5 patients with cutaneous lupus erythematodes, 4 patients with mycosis 
fungoides, 3 patients with pityriasis rubra pilaris and 9 patients with different chronic 
hyperkeratotic skin diseases. The mean treatment period in the total group was 30 
months (0-200 months) and the mean cumulative dose was 31 gram (0-230 gram). In 
50 patients the treatment period was ä 24 months; 30 patients were treated for more 
than 48 months. 
Prevalence of DISH, degenerative changes and osteoporosis 
The prevalence of DISH, degenerative changes and osteoporosis in the total group was 
respectively 16, 53 and 29%. No statistically significant relation between these 
prevalences and the duration of treatment or the cumulative dose could be shown. In 
using stepwise logistic regression, it appeared that the only significant relation of each 
of these three parameters that could be established was that with the age of the 
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patients. This dependency is best shown by computing the prevalence of DISH, 
degenerative changes and osteoporosis for different age classes (Table 2). 
Table 2. Incidence of spinal abnormalities in relation to age of the patients 
N 
DISH (%) 
Degenerative changes (%) 
Osteoporosis (%) 
<35 
36 
3 
19 
14 
Age (years) 
35-45 
29 
3 
52 
21 
45-55 
23 
9 
52 
35 
55-65 
32 . 
38 
81 
38 
>65 
IS 
33 
80 
53 
Total 
135 
16 
53 
29 
Severity scores of DISH and degenerative changes 
The mean severity scores for DISH and degenerative changes were respectively 2.0 
(0-41 points) and 2.8 (0-38 points). There was no significant correlation 
(Spearman's rank correlation coefficient) between the severity scores of DISH 
(Figure 1) and degenerative changes and the duration of treatment or the cumula­
tive dose. The correlation coefficients of the severity scores of DISH and 
degenerative changes with age, however, appeared to be highly significant: r=0.39 
(p<0.01) for DISH and r=0.61 (pO.01) for degenerative changes. 
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Fig. 1. Severity score of DISH in relation to duration of retinoid treatment 
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"Prospective group" 
In the "prospective group" (n=26), the mean duration of treatment was 25 months (9-
61 months). The mean cumulative dose was 25 gram (6.6-61.2 gram) Before treatment 
2/26 patients had DISH versus 4/26 patients during treatment. The two patients who 
developed DISH during treatment had treatment periods of 14 and 29 months. Their 
severity score was only 4 points (maximum DISH score 84 points). Before retinoid-
treatment 14/26 patients had degenerative changes; during treatment 15/26 patients. 
Osteoporosis was diagnosed in 9/26 patients before treatment and in 10/26 patients 
during treatment. These differences were too small to be meaningful analyzed statis-
tically. 
The two patients with DISH before treatment did not show any progression during 
treatment (treatment period 10 and 12 months). Three of the 14 patients with 
degenerative changes before treatment showed a slight progression (1-2 points) of the 
severity score during treatment (treatment period 14, 19, and 53 months). 
DISCUSSION 
Many reports have appeared in the recent literature on retinoid-induced skeletal 
abnormalities (Table l).2"" However, no consensus has been reached on the frequency 
and magnitude of these side-effects. Most of the communications are anecdotal, the 
population studies are predominantly uncontrolled and prospective studies on 
prolonged treatment with oral retinoids are not available. A major problem in these 
studies is the differentiation of retinoid-induced from age-induced bone changes. The 
reported prevalence of DISH in the normal population varies from 2.6% to 28%.""" It 
is very complicated to conduct an extensive placebo-controlled study for practical and 
ethical reasons.15 Furthermore, there is no consensus on the definitions of the kind and 
severity of retinoid-induced spinal abnormalities. In the present study we used the 
definitions that are now generally accepted in the radiological world.21'22 The design 
of the present study is retrospective, concerning the spinal abnormalities of our retinoid 
population and of those patients who underwent pre-treatment X-ray screening. This 
approach provided the opportunity to relate the frequency and severity of the various 
spinal abnormalities to the duration of treatment, the cumulative dose and the age of 
the patients. As this could be a possible reason for bias, it is important that not a single 
patient was excluded from retinoid treatment because of pre-existing skeletal abnor-
malities. The mean age of the patients in relation to the duration of treatment showed a 
rather homogeneous distribution and all patients suffered from severe psoriasis or other 
disorders of keratinization. The present study is extensive (135 patients), especially in 
comparison with the available reports in the literature (Table 1) and includes a 
"prospective" sample of 26 patients. A mean duration of treatment of 30 months and a 
mean cumulative dose of 31 gram are considerable, 50 patients were treated for more 
than 24 months and 30 patients for more than 48 months. Another advantage of this 
133 
study is the fact that the results concern all retinoids used by the patients, so that 
possible bias induced by retinoid treatment in the past is avoided. 
The conclusion which is reached from the data presented in this communication is 
simple and clear. There was no relation whatsoever between the duration of retinoid 
treatment or the cumulative dose and the prevalence and severity of DISH, degenerati-
ve changes and osteoporosis. The only significant variable in this respect was the age 
of the patients. Due to the inconsistency of diagnostic criteria used in the literature, it 
is not possible to provide a concise comparison of our results with those reported by 
other authors (Table 1). 
Of course these results do not permit us to draw definitive conclusions, but we would 
like to hypothesize that spinal abnormalities due to oral retinoid treatment only occur 
sporadically in predisposed subjects. DISH is "an extremely common" entity in the 
general population21 and spinal abnormalities as described in the literature are probably 
more a normal variation than a complication of retinoid treatment. 
There is no consensus on the guidelines for routine surveillance of patients during 
prolonged retinoid treatment, recommendations in the literature diverge from no X-ray 
screening at all l5,26 to pre-treatment and annual screening of spinal areas.7-8·27,28 Several 
authors recommend additional screening of extra-spinal areas.3,29 The present study 
does not lend support to the performance of annual routine spinal radiographs during 
retinoid treatment. It is important to ask for skeletal pains and mobility restriction on a 
regular basis during oral retinoid treatment and to focus on both spinal and extra-spinal 
regions.30 Additional controlled and prospective studies are required to develop defi-
nitive screening guidelines for patients submitted to long-term oral retinoid treatment. 
Further investigations should be focused on the basic mechanisms and specific locati-
ons of retinoid-induced bone changes and on defining "high-risk" patients in this 
respect. 
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Discussion, Conclusions and Summary 
The exploration on efficacy and side-effects of methotrexate (MTX) and acitretin 
proved that these drugs fulfil a major need for patients with severe psoriasis and 
disorders of keratinization. Their high efficacy, however, is associated with various 
side-effects. Some of these side-effects are subjective or interfere to a modest extent 
with the patient's general feeling of well-being, whereas others are potentially dange-
rous. In this respect it is of particular relevance that the diseases described in this 
thesis all have a chronic nature and require long-term systemic treatment. Therefore 
patients on treatment with MTX and acitretin should be monitored according to well 
defined treatment protocols. In appendix I and II an update of guidelines for the 
practical use of these drugs in dermatology is provided. Several observations on 
clinical effectivity and side-effects of MTX and acitretin in severe psoriasis and 
disorders of keratinization, as presented in this thesis, have been incorporated in these 
guidelines. An overview concerning several aspects of psoriasis, the investigated 
disorders of keratinization and the modes of action of MTX and acitretin is presented 
in the general introduction of this thesis. 
In brief, the most important observations of the thesis are summarized and discussed. 
Parti: 
Methotrexate (MTX) in severe Psoriasis 
1.1 
What is the effectivity and side-effect profile of long-term treatment with MTX in 
psoriasis? 
The answers to this question have been presented in chapter 2. The most important 
observation of this retrospective analysis was the fact that no deaths or life-threatening 
side-effects due to MTX treatment occurred in the observation period of 22 years, in 
which 113 patients were treated with long-term MTX at the Nijmegen Department of 
Dermatology. The high effectiveness of MTX is illustrated by the fact that in 81% of 
the patients, suffering from both erythematosquamous and pustular forms of severe 
psoriasis, a prolonged total or subtotal clearance was reached. In general the side-
effects were transient and disappeared following dose reduction or (temporarily) 
discontinuation of treatment. Another important observation in the present study was 
the absence of a significant correlation between the cumulative dose or duration of 
treatment and the histological classification of liver biopsies. No correlation could be 
shown between the liver biopsy classification and serum liver function tests. In this 
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study, the occurrence of liver fibrosis and cirrhosis was 13% and 4% respectively, 
which is relatively low compared to most other studies. We conclude that MTX is a 
very effective, universally applicable and relatively safe drug in the treatment of severe 
psoriasis. Its non-specific action spectrum is in line with the broad interference of 
MTX with inflammatory and epidermal growth characteristics. A liver biopsy during 
the first 3 months of treatment and subsequently after each 1.5 g of MTX, should 
remain part of the treatment protocol, until reliable non-invasive screening tests to 
assess liver damage are available. 
The development of adequate treatment guidelines is a dynamic process, requiring 
clinical studies over prolonged periods following the introduction of new drugs. Such, 
however, remains of equal importance for drugs which are already well-established in 
the treatment of psoriasis. 
1.2. 
Does interruption of long-term MTX treatment in psoriasis result in a substantial 
dose-reduction? 
In chapter 3 the results of interruption of long-term MTX treatment in 10 psoriatic 
patients are presented. Each patient was in a stable clinical condition before treatment 
interruption and the weekly MTX dose had been minimized according to tolerance and 
efficacy. Following discontinuation, MTX was reintroduced at the moment of a partial 
relapse, according to well-defined criteria. The mean MTX-free period that could be 
reached was 17 weeks and the mean reduction in cumulative dose was 76 mg. Seven 
patients had a MTX-free period of at least 11 weeks; the mean MTX-free period of 
these patients was 23 weeks with a mean reduction in cumulative dose of 117.5 mg. 
Two patients were still free of MTX after 6 months, one patient did not get a relapse 
at all. The number of MTX-free weeks was higher in patients with a low pre-study 
weekly MTX-dose. Only 3 of the 10 patients, however, preferred interval treatment to 
a continuous schedule, in most cases because of fear for a relapse or reluctance to 
extensive topical treatment. A remarkable observation was the significant decrease of 
the serum transaminases shortly after discontinuation of MTX treatment, indicating a 
direct toxic influence of MTX on the liver parenchyma. Other important laboratory 
parameters showed no significant changes. It can be concluded from this study that 
interruption of long-term MTX leads to a substantial reduction of the cumulative dose 
and reduces the hepatotoxic load of MTX. Apparently the "gain" in cumulative MTX 
dose due to treatment interruption was not annuled by high "loading-up" doses after 
reintroduction of treatment. Most patients are reluctant to interrupt a successful 
systemic treatment, therefore intensive guidance and persuasion to interrupt the MTX 
regimen at regular intervals are important. 
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1.3. 
Can we develop alternative approaches to detect early MTX-induced liver damage 
in psoriatic patients that are reliable, but less invasive compared to liver biopsies? 
In chapter 4 the results of a prospective study, concerning the value of dynamic 
hepatic scintigraphy (DHS) and serum aminoterminal propeptide of type III 
procollagen (PIIINP) for early detection of MTX-induced hepatic damage in psoriasis 
patients have been presented. By means of a DHS the portal contribution to the total 
liver flow can be computed. This portal contribution decreases if the hepatic flow-
resistance increases, which has been reported to occur in case of fibrosis and cirrhosis. 
Serum PIIINP levels have been reported to increase in conditions associated with 
increased synthesis and deposition of collagen as in hepatic fibrosis and cirrhosis, but 
also in other diseases like scleroderma and rheumatoid arthritis. These relatively non-
invasive procedures were compared with the liver biopsy as the gold standard 
procedure. Twenty-five MTX patients with a mean cumulative dose of 3.9 gram were 
studied and 7 patients with non-MTX related hepatic cirrhosis were included as disease 
controls. By means of DHS a clear-cut separation could be established between the 
patients with a normal liver histology and all other patients. This method, however, 
appeared not to be suitable to grade the severity of hepatic damage. A global 
relationship was demonstrated between serum PIIINP concentrations and hepatic 
damage, but individual values unfortunately were not reliable as a screening procedure. 
The combination of both screening tests had only a limited additional value above 
DHS alone. 
We conclude that isolated PIIINP measurements are probably not sufficiently reliable 
for the screening of individual patients. In contrast, DHS appeared to be very 
promising as a screening-method to detect early MTX-induced hepatic damage in 
psoriatic patients. The present study will be extended during the following years and a 
second evaluation will be performed when 60 MTX-treated psoriatics and 20 patients 
with non-MTX related cirrhosis have been included. Pending further studies, it is our 
opinion that regular liver biopsies have to remain part of the guidelines for long-term 
MTX treatment in dermatology. 
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Part II: 
Acitretin in Severe Psoriasis and Disorders of Keratinization 
2.1. 
What is the efficacy and side-effect profile of acitretin in severe psoriasis and 
disorders of keratinization and which are optimal dosage schedules? 
In chapter 2 an excellent therapeutic response of a patient with disabling Hallopeau's 
disease to acitretin monotherapy in a relatively low dosage of 35-45 mg/day (0.5-0.6 
mg/kg/day) is reported. The leukotriene B4-induced intraepidermal accumulation of 
polymorphonuclear leucocytes was markedly inhibited, illustrating the strong anti-
inflammatory potential of acitretin. 
We also achieved excellent results with acitretin (25-60 mg/day) in 6 patients with 
persistent palmoplantar pustulosis and in 2 patients with generalized pustular 
psoriasis.1,2 These observations confirm the efficacy of acitretin in recalcitrant forms of 
pustular psoriasis. 
In chapter 3 the response to acitretin in 5 patients with Darier's disease was 
investigated. In two patients complete clearance was achieved and 2 patients showed a 
marked improvement. In the fifth patient there was only a moderate clinical 
improvement. Two patients showed isomorphic reactions at 35 and 45 mg/day, which 
is generally considered as a relatively low dosage. These exacerbations resolved 
following reduction of the dosage. We conclude that acitretin is effective in Darier's 
disease, but that the initial dosage has to be low (10-25 mg/day). This dosage can be 
gradually increased up to the optimal level for each individual patient. The prompt 
clinical reaction to dosage reductions proved to be a major advantage of acitretin 
above its prodrug etretinate, which has a much longer half-life time. 
Chapter 4 comprises the first report on the effectivity of oral retinoids in ichthyosis 
bullosa Siemens. Two patients were treated with etretinate and two patients with 
acitretin. All patients showed excellent results on a maintenance dose of only 10-25 
mg/day. All symptoms, including the blistering, disappeared completely or almost 
completely. The dosage of acitretin was very low compared to the etretinate dosage of 
40-60 mg/day that was needed to treat a patient with bullous ichthyosiform erythro-
derma of Brocq. In this condition blistering may be aggravated during retinoid 
treatment. 
In chapter 5 the response of 7 patients with lamellar ichthyosis to acitretin is 
reported. Dosages of 25-55 mg/day proved to be required for an optimal clinical 
response. In two patients the maximal dose was limited by tolerance, but the effectivity 
improved following dose-increments. Four patients however, including a patient with 
erythrodermic lamellar ichthyosis, required low-dose acitretin treatment (< 25 mg), as 
higher dosages resulted in a marked clinical deterioration. This dichotomy with respect 
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to the response to acitretin supports the hypothesis that lamellar ichthyosis is a 
spectrum of distinct disease entities. 
In chapter 6 a beneficial response of two patients with invalidating keratoderma 
palmaris et plantaris transgrediera (Greither's disease) to acitretin 25-35 mg/day is 
reported. The maximal dose in these patients was only limited by tolerance. 
In chapter 7 a favourable response of two patients with Mal de Meleda to acitretin is 
reported. Treatment should be initiated with a relatively low dosage of 10 mg/day, as 
higher dosages resulted in increased tenderness, blistering and erythema. The dosage 
should be gradually increased up to an optimal dose for each individual patient. In 
both cases a concomitant fungal infection was present, requiring additional antifungal 
treatment. 
In chapter 8 a patient with persistent palmoplantar pustulosis is presented, who 
developed a severe hepatotoxic reaction with progression to cirrhosis during treatment 
with acitretin. This severe side-effect started after 4 months of treatment with a 
dramatic increase of the serum transaminases. Based on this observation and other case 
reports in the literature, we conclude that severe hepatotoxic reactions induced by oral 
retinoid treatment are extremely uncommon, but potentially dangerous. Liver 
transaminases elevate to high values in a short period of time (days to weeks). Regular 
screening of serum liver functions is a very important component of the retinoid 
treatment protocol. In case of a sudden elevation of the serum transaminases very 
frequent controls are mandatory. 
Side-effects of acitretin 
The side-effect profile of 37 patients of the Nijmegen study has been presented and 
compared to the literature in Chapter 1. It appeared that the side-effects of acitretin 
and etretinate are highly comparable. Dryness of skin and mucosae and (reversible) 
hair loss were frequently reported. These side-effects are not dangerous, but they 
strongly contribute to the relatively small therapeutic margin of acitretin. As increased 
serum cholesterol, triglyceride and transaminase levels were not uncommon, regular 
screening of these parameters is indicated. One patient developed a severe hepatotoxic 
reaction leading to cirrhosis. 
2.2. 
What is the influence of oral retinoid treatment on the prevalence and severity of 
bony abnormalities? 
In chapter 9 a patient with severe juvenile pityriasis pilaris is presented, who 
developed extensive extra-spinal hyperostoses after 13 years of oral retinoid treatment, 
whereas routine X-ray examinations of the spine during retinoid therapy had been 
completely normal. The patient suffered already during some months from progressive 
mobility restriction and pain in his left hip, but he did not connect these symptoms 
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with his retinoid treatment and therefore he did not communicate these complaints to 
us. The lesson that can be learned from this case report and from similar reports in the 
literature, is that normal spinal X-rays are no guarantee that a patient is free from 
hyperostoses and that dermatologists should actively ask their retinoid patients about 
skeletal pains or mobility restriction. The clinical management in patients with 
retinoid-induced hyperostoses is rather difficult. Discontinuation of retinoid therapy is 
indicated, but not always possible in severe affected patients. In the present case both 
PUVA and azathioprine treatment had been insufficiently effective. Low-dose oral 
MTX, fortunately, appeared to be a good alternative for acitretin. 
Most reports in the literature concerning extra-spinal skeletal abnormalities are 
casuistic reports and there is no consensus on the monitoring guidelines to detect 
spinal and extra-spinal skeletal abnormalities in retinoid patients. 
Chapter 10 describes the prevalence and severity of spinal abnormalities in our 
retinoid patient population. In this extensive study, comprising 135 patients with a 
"prospective" sample of 26 patients, no relationship between oral retinoid treatment 
and the frequency and severity of spinal abnormalities could be established. 
A review of the non-casuistic literature concerning retinoid-induced skeletal 
abnormalities is presented in a table in the introduction of chapter 10. It can be 
concluded from this table that the reported prevalence of bone abnormalities is widely 
variable and that controlled prospective studies have not been carried out. The 
summarized uncontrolled prospective studies have a maximum mean treatment period 
of only 24 months. Many methods were used in the available literature to define the 
different bone abnormalities and to establish their frequency and severity. Another 
problem is the differentiation of retinoid-induced changes from age-induced 
abnormalities. In our study we used definitions for diffuse idiopathic skeletal 
hyperostoses (DISH), degenerative changes and osteoporosis, that are now generally 
accepted in radiology. In addition a scoring system to estimate the severity of DISH 
and degenerative changes was developed. The investigated patient population 
comprised patients who had used no retinoids at all or only for a short period - from 
these patients pre-treatment radiographs were available - and patients who had used 
retinoids for longer periods. Fifty patients were treated for more than 24 months and 
30 patients for more than 48 months. The study design enabled us to relate the skeletal 
abnormalities to the duration of retinoid treatment. The prevalence and severity of 
DISH as well as degenerative abnormalities and the prevalence of osteoporosis were 
correlated with the age of the patients but not with the duration of retinoid use. 
Therefore we suggest that annual spinal radiographs can be excluded from the oral 
retinoid treatment protocol. Baseline spinal radiographs, however, should be performed 
in the initial phase of treatment if prolonged treatment of a patient is expected. 
Little is known about the basic mechanisms of retinoid-induced bone changes. Which 
patients are at "high-risk" in this respect? Further prospective and controlled studies 
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on retinoid-induced bone changes are necessary to establish definitive treatment 
guidelines. 
In summary: 
Methotrexate has a broad action spectrum as an antipsoriatic treatment. It is a very 
effective, universally applicable and relatively safe drug in this respect. Intermittent 
dosage schedules are more adequate compared to continuous long-term treatment. 
Dynamic hepatic scintigraphy is a very promising new tool for detection of early liver 
damage, compared to the more invasive liver biopsy procedure. 
The efficacy profile of acitretin proved to comprise highly inflammatory conditions 
such as pustular forms of psoriasis and also conditions with virtually no inflammation 
such as Darier's disease, several forms of ichthyosis and palmoplantar keratoderma. 
These results reflect the broad action spectrum of acitretin. The optimal dose, however, 
shows a considerable variation between the different diseases. In a part of the patients 
with Darier's disease, lamellar ichthyosis and Mal de Meleda a deterioration of clinical 
symptoms occurred at higher dosages. Especially in these diseases it is important to 
start with a low initial dose. 
The side-effect profile of acitretin appeared to be highly comparable to that of 
etretinate. With respect to retinoid-induced the bone changes, regular questioning about 
skeletal pains or mobility restriction provides more relevant information compared to 
repeated X-ray examination of the spine. 
Guidelines are of great importance to optimize the efficacy and safety of long-term 
systemic treatment with methotrexate and acitretin. A patient-oriented approach permits 
the selection of the most appropriate treatment for the individual patient in every stage 
of his disease and life. 
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Discussie, Conclusies en Samenvatting 
De exploratie op het gebied van werkzaamheid en bijwerkingen van methotrexaat 
(MTX) en acitretine heeft aangetoond dat deze medicijnen van groot belang zijn voor 
patiënten met ernstige psoriasis en verhoomingsstoomissen. De grote effectiviteit van 
deze middelen gaat echter gepaard met verschillende bijwerkingen. Sommige bijwer-
kingen zijn subjectief of interfereren slechts in beperkte mate met het gevoel van 
welbevinden, terwijl andere potentieel gevaarlijk zijn. Alle ziekten die beschreven 
worden in dit proefschrift zijn chronisch van aard en vergen lange termijn behandeling. 
Daarom moeten patiënten die behandeld worden met MTX en acitretine volgens goed 
gedefinieerde behandelingsprotocollen gecontroleerd worden. In appendix I en II 
worden aangepaste richtlijnen gepresenteerd voor gebruik van deze middelen in de 
dermatologische praktijk. Diverse observaties op het gebied van klinische effectiviteit 
en bijwerkingen van MTX en acitretine bij ernstige psoriasis en verhoomings-
stoomissen, zoals gepresenteerd in dit proefschrift, werden geïncorporeerd in deze 
richtlijnen. In de algemene introductie van het proefschrift wordt een overzicht 
gegeven over verschillende aspecten van psoriasis en de verhoomingsstoomissen die 
specifiek onderzocht werden, alsmede een korte verhandeling over de werkings-
mechanismen van MTX en acitretine. De belangrijkste bevindingen van het proef-
schrift worden hieronder kort samengevat en toegelicht. 
Deel I: 
Methotrexaat (MTX) bij Patiënten met Ernstige Psoriasis 
1.1. 
Hoe is de effectiviteit en wat zijn de bijwerkingen van lange termijn behandeling 
met MTX bij psoriasis? 
De antwoorden op deze vraag werden gepresenteerd in hoofdstuk 2. De belangrijkste 
observatie van deze retrospectieve analyse was het feit dat er geen patiënten zijn 
gestorven of levensbedreigende bijwerkingen doormaakten als gevolg van de MTX 
behandeling in de observatieperiode van 22 jaar waarin 113 patiënten van de 
Nijmeegse Dermatologie-afdeling langdurig behandeld werden met MTX. De goede 
werkzaamheid van MTX blijkt uit het feit dat langdurige gehele of vrijwel gehele 
genezing werd bereikt bij 81% van de patiënten met zowel erythematosquameuze als 
pustuleuze vormen van psoriasis. De bijwerkingen waren over het algemeen tijdelijk en 
verdwenen na vermindering van de dosis of (tijdelijke) stopzetting van de behandeling. 
Een andere belangrijke observatie in dit onderzoek was het ontbreken van een 
significante correlatie tussen de cumulatieve dosis of duur van de behandeling en de 
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histologische classificatie van de leverpuncties. Ook kon geen relatie worden aange-
toond tussen deze histologische classificatie en de leverfunctie waarden in het serum. 
De prevalentie van leverfibrose en -cirrhose in deze studie was respectievelijk 13% en 
4%; dit zijn vrij lage percentages vergeleken met de meeste gepubliceerde studies. We 
concluderen dat MTX een zeer effectieve, breed toepasbare en relatief veilige 
behandeling is voor patiënten met ernstige psoriasis. Het brede actiespectrum van MTX 
vloeit voort uit het feit dat ontstekingsmechanismen en epidermale groeiregulatie op 
diverse manieren door dit middel worden beïnvloed. Het uitvoeren van een lever-
biopsie tijdens de eerste 3 maanden van de behandeling en vervolgens na iedere 1.5 g 
MTX blijft noodzakelijk totdat betrouwbare niet-invasieve screeningstesten beschikbaar 
komen voor het beoordelen van leverschade. De ontwikkeling van goede behandelings-
protocollen is een dynamisch proces, waarbij langdurige klinische studies nodig zijn na 
de introductie van nieuwe medicijnen. Deze studies zijn evenzeer belangrijk voor 
medicijnen die inmiddels al een vaste plaats gevonden hebben bij de behandeling van 
psoriasis. 
1.2. 
Leidt onderbreking van langdurige MTX behandeling tot een substantiële 
dosisreductie? 
In hoofdstuk 3 worden de resultaten gepresenteerd van het onderbreken van lang-
durige MTX behandeling bij 10 patiënten met psoriasis. Alle patiënten waren in een 
stabiele klinische toestand vóór de behandelingsonderbreking en de wekelijkse MTX 
dosis werd al zo laag mogelijk gedoseerd op geleide van effectiviteit en tolerantie. Na 
de onderbreking werd MTX weer gereïntroduceerd als een gedeeltelijke relapse optrad, 
die gedefinieerd werd volgens duidelijke criteria. De gemiddelde MTX-vrije periode 
die bereikt kon worden was 17 weken en de gemiddelde reductie in de cumulatieve 
dosis was 76 mg. Zeven patiënten hadden een gemiddelde MTX-vrije periode van 
tenminste 11 weken; de gemiddelde MTX-vrije periode van deze patiënten was 23 
weken met een gemiddelde reductie in de cumulatieve dosis van 117,5 mg. Twee 
patiënten gebruikten nog steeds geen MTX na 6 maanden en één patiënt kreeg 
helemaal geen relapse. Het aantal MTX-vrije weken was hoger bij patiënten met een 
lage wekelijkse MTX dosis vóór de studie. Slechts 3 van de 10 patiënten gaven de 
voorkeur aan intervalbehandeling boven continue behandeling, meestal uit angst voor 
een relapse of door tegenzin in een uitgebreide lokale behandeling. Een opmerkelijke 
observatie was de significante daling van de serum transaminasen kort na het onder-
breken van de MTX behandeling; dit is een aanwijzing voor een direct toxisch effect 
van MTX op het leverparenchym. Andere belangrijke laboratoriumparameters lieten 
geen significante veranderingen zien. Uit dit onderzoek kan worden geconcludeerd dat 
onderbreken van langdurige MTX behandeling leidt tot een substantiële reductie van 
de cumulatieve dosis en dat hierdoor tevens de hepatotoxische belasting van MTX 
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afneemt. Blijkbaar wordt de reductie in de cumulatieve dosis a.g.v. de onderbreking 
niet opgeheven door een hoge oplaaddosis na reïntroductie van de behandeling. 
Intensieve begeleiding en aansporing zijn nodig om een succesvolle MTX behandeling 
met regelmatige tussenpozen te onderbreken, omdat de meeste patiënten hier nogal 
terughoudend tegenover staan. 
1.3. 
Kunnen we betrouwbare methoden ontwikkelen om bij patiënten met psoriasis 
MTX-gefnduceerde leverschade in een vroeg stadium op te sporen, die minder 
invasief zijn dan leverbïopsiën? 
In hoofdstuk 4 worden de resultaten besproken van een prospectieve studie over de 
waarde van dynamische hepatische scintigrafie (DHS) en serumspiegels van het 
aminoterminale propeptide van type III procollageen (PIIINP) voor vroege opsporing 
van MTX-gefnduceerde leverschade bij patiënten met psoriasis. Met behulp van DHS 
kan de portale bijdrage aan de totale leverflow worden berekend. Deze portale bijdrage 
vermindert als de stromingsweerstand in de lever toeneemt, zoals is aangetoond bij 
leverfibrose en cirrhose. Serum PIIINP spiegels stijgen als er een verhoogde synthese 
en depositie van collageen is zoals bij leverfibrose en cirrhose, maar ook bij andere 
ziekten zoals sclerodermie en rheumatoide arthritis. Deze relatief niet-invasieve 
procedures werden vergeleken met de leverbiopsie als gouden standaard. Vijfentwintig 
MTX patiënten met een gemiddelde cumulatieve dosis van 3,9 g werden onderzocht en 
7 patiënten met een niet-MTX gerelateerde levercirrhose werden geïncludeerd als 
"disease-controls". Met behulp van DHS werd een strikte scheiding gezien tussen de 
patiënten met een normale leverhistologie en alle andere patiënten. De methode bleek 
echter niet geschikt te zijn voor het beoordelen van de mate van leverschade. Welis-
waar werd een globale relatie aangetoond tussen serum PIIINP waarden en lever-
schade, maar eenmalige individuele waarden bleken niet betrouwbaar voor screenings-
doeleinden. De combinatie van DHS en PIIINP waarden had slechts een beperkte 
additionele waarde boven DHS alleen. 
We concluderen dat eenmalige PIIINP metingen niet voldoende betrouwbaar lijken 
voor het screenen van individuele patiënten. Daarentegen bleek DHS een zeer veelbe-
lovende screeningsmethode te zijn ter opsporing van vroege MTX-geïnduceerde lever-
schade bij psoriasispatienten. Deze studie zal in de komende jaren worden uitgebreid. 
Een tweede evaluatie zal volgen als 60 met MTX behandelde patiënten met psoriasis 
en 20 patiënten met een niet-MTX gerelateerde levercirrhose geïncludeerd zijn. In 
afwachting van toekomstige onderzoeken menen wij dat de leverbiopsie deel uit 
moeten blijven maken van het MTX-behandelingsprotocol in de Dermatologie. 
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Deel Π: 
Acitretine bij Patiënten met Ernstige Psoriasis en Verhoor-
ningsstoornissen 
2.1. 
Hoe is de effectiviteit en wat zijn de bijwerkingen van behandeling met acitretine 
bij ernstige psoriasis en verhoorningsstoornissen en wat zijn de optimale 
doseringen. 
In hoofdstuk 2 wordt een uitstekende therapeutische respons beschreven bij een 
patiënt met invaliderende acrodermatitis continua van Hallopeau op acitretine 
monotherapie in een relatief lage dosering van 35-45 mg/dag (0,5-0,6 mg/kg/dag). De 
door leukotriene B<-geïnduceerde intra-epidermale accumulatie van polymorfkemige 
granulocyten werd duidelijk geremd. Deze bevinding illustreert de sterke anti-
infiammatoire werking van acitretine. 
We bereikten ook uitstekende resultaten met acitretine 25-60 mg/dag bij 6 patiënten 
met persisterende palmoplantaire pustulosis en bij 2 patiënten met gegeneraliseerde 
pustuleuze psoriasis.1,2 Deze observaties bevestigen de effectiviteit van acitretine bij 
recalcitrante vormen van pustuleuze psoriasis. 
In hoofdstuk 3 wordt het resultaat beschreven van behandeling met acitretine bij 5 
patiënten met de ziekte van Darier. Bij 2 patiënten verdwenen de huidafwijkingen 
geheel en bij 2 andere patiënten werd een sterke verbetering bereikt. De verbetering bij 
de vijfde patiënt was slechts matig. Bij 2 patiënten traden isomorfe reacties op bij 
relatief lage doses van 35 en 45 mg/dag. Deze exacerbaties verdwenen na dosis-
reductie. We concluderen dat acitretine effectief is bij de ziekte van Darier, maar dat 
de aanvangsdosis laag moet zijn (10-25 mg/dag). Deze dosis kan geleidelijk worden 
opgehoogd tot een optimaal niveau voor iedere individuele patiënt. De snelle klinische 
reactie op dosisreductie bleek een belangrijk voordeel te zijn van acitretine boven zijn 
voorganger etretinaat, wat een veel langere halfwaardetijd heeft. 
Hoofdstuk 4 beschrijft de eerste resultaten van de werking van orale retinoiden bij 
ichthyosis bullosa Siemens. Twee patiënten werden behandeld met etretinaat en twee 
patiënten met acitretine. Bij alle patiënten werd een uitstekend resultaat bereikt met een 
onderhoudsdosis van slechts 10-25 mg/dag. Alle symptomen, waaronder ook de 
blaarvorming, verdwenen geheel of vrijwel geheel. De benodigde acitretine dosis was 
erg laag vergeleken met de etretinaat dosis van 40-60 mg/dag die nodig was om een 
patiënt te behandelen met een bulleuze ichthyosiforme erythrodermie van Brocq. Bij 
deze aandoening is beschreven dat de blaarvorming kan toenemen tijdens retinoid 
behandeling. 
In hoofdstuk 5 wordt de respons op acitretine beschreven van 7 patiënten met lamel-
laire ichthyosis. Doses variërend van 25-55 mg/dag bleken nodig te zijn voor een 
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optimale respons. Bij twee patiënten werd de maximale dosis alleen gelimiteerd door 
de tolerantie, terwijl de effectiviteit toenam bij verhoging van de dosis. Bij 4 patiënten, 
waaronder een patiënt met erythrodermische lamellaire ichthyosis, waren lage 
doseringen (<25 mg) echter noodzakelijk, daar bij hogere doseringen juist een 
verslechtering van de symptomen optrad. Deze dichotomie met betrekking tot de 
respons op acitretine geeft steun aan de hypothese dat lamellaire ichthyosis bestaat uit 
een spectrum van verschillende entiteiten. 
Hoofdstuk 6 beschrijft de gunstige reactie op acitretine in een dosis van 25-35 mg/dag 
bij twee patiënten met invaliderende keratoderma palmaris et plantaris transgrediens 
(ziekte van Greither). De maximale dosis bij deze patiënten werd alleen gelimiteerd 
door tolerantie. 
In hoofdstuk 7 wordt een gunstig resultaat van behandeling met acitretine bij twee 
patiënten met Mal de Meleda beschreven. De aanvangsdosering dient relatief laag te 
zijn (10 mg/dag), daar bij hogere doseringen een toename van pijnklachten, blaar-
vorming en erytheem kan optreden. De dosis dient geleidelijk te worden opgevoerd een 
optimaal niveau bereikt is. Bij beide patiënten was sprake van een bijkomende 
mycotische infectie, waarvoor antimycotische therapie nodig was. 
In hoofdstuk 8 wordt een patiënte gepresenteerd met persisterende palmoplantaire 
pustulosis, die tijdens behandeling met acitretine een ernstige hepatotoxische reactie 
doormaakte resulterend in het ontstaan van levercirrhose. Deze ernstige bijwerking 
ontwikkelde zich na 4 maanden behandeling met een plotselinge sterke stijging van de 
serum transaminases Naar aanleiding van deze observatie en andere casuïstische 
mededelingen in de literatuur, concluderen we dat ernstige door retinoid gebruik 
geïnduceerde hepatotoxische reacties weliswaar extreem zeldzaam zijn, maar wel 
potentieel gevaarlijk. De serum transaminasen stijgen meestal in zeer korte tijd tot 
hoge waarden (dagen tot weken). Regelmatige controle van de leverfuncties is een zeer 
belangrijk onderdeel van het retinoidprotocol. Bij plotselinge stijging van de serum 
transaminasen zijn zeer frequente controles noodzakelijk. 
Bijwerkingen van acitretine 
Het bijwerkingenprofiel van 37 patiënten uit het bovenbeschreven Nijmeegse onder-
zoek werd gepresenteerd en vergeleken met de literatuur in hoofdstuk 1. Het bleek dat 
de bijwerkingen van acitretine en etretinaat nauwelijks verschillen. Uitdroging van huid 
en slijmvliezen en (reversibele) haaruitval kwamen frequent voor. Deze bijwerkingen 
zijn niet gevaarlijk, maar zij dragen wel in hoge mate bij aan de relatief smalle 
therapeutische breedte van acitretine. Daar verhoging van het serum cholesterol en 
triglyceride gehalte en ook van de serum transaminasen niet zeldzaam is, is regel-
matige screening van deze parameters aangewezen. Een patiënt ontwikkelde een 
ernstige hepatotoxische reactie die resulteerde in cirrhose. 
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2.2. 
Wat is de invloed van orale retinoidbehandeling op de prevalentie en ernst van 
botafwijkingen? 
In hoofdstuk 9 wordt een patiënt gepresenteerd met ernstige juvenile pityriasis rubra 
pilaris, die uitgebreide extra-spinale Hyperostosen ontwikkelde na 13 jaar behandeling 
met orale retinoiden, terwijl bij routine röntgenonderzoek van de wervelkolom nooit 
afwijkingen waren gevonden. Deze patiënt had al gedurende enkele maanden last van 
progressieve bewegingsbeperking en pijn aan zijn linker heup, maar hij bracht deze 
klachten niet in verband met het gebruik van retinoiden en had ze daarom ook niet aan 
ons meegedeeld. Uit dit case report en uit overeenkomstige mededelingen in de 
literatuur blijkt dat normale röntgenfoto's van de wervelkolom geen garantie vormen 
dat een patiënt vrij is van Hyperostosen en dat dermatologen hun retinoidpati enten 
actief dienen te vragen naar skeletpijnen of bewegingsbeperking. Het klinische beleid 
bij patiënten met retinoid-geinduceerde hyperostosen is niet zo gemakkelijk. Stop-
zetting van de retinoidbehandeling is weliswaar geïndiceerd, maar niet altijd mogelijk 
bij ernstig aangedane patiënten. Bij de hier beschreven patiënt waren behandeling met 
PUVA en azathioprine beide onvoldoende effectief. Orale therapie met laag gedoseerd 
MTX bleek gelukkig een goed alternatief te zijn voor acitretine. De meeste berichten 
in de literatuur over extra-spinale botafwijkingen zijn casuïstisch van aard en er is geen 
algemene consensus met betrekking tot screeningsprotocollen ter detectie van spinale-
en extra-spinale botafwijkingen bij patiënten die langdurig met retinoiden behandeld 
worden. 
Hoofdstuk 10 beschrijft de prevalentie en ernst van spinale skeletafwijkingen in onze 
retinoid patiëntenpopulatie. In dit uitgebreide onderzoek bij 135 patiënten met een 
"prospectieve" subgroep van 26 patiënten, kon geen relatie worden aangetoond tussen 
orale retinoidbehandeling en de frequentie en ernst van spinale afwijkingen. 
Een overzicht van de niet-casuïstische literatuur over retinoid-geinduceerde skelet-
afwijkingen wordt gepresenteerd in een tabel in de introductie van hoofdstuk 10. Uit 
deze tabel kan geconcludeerd worden dat de gerapporteerde prevalentie van botafwij-
kingen sterk variabel is en dat gecontroleerde prospectieve studies niet verricht zijn. De 
beschikbare ongecontroleerde prospectieve studies betreffen een gemiddelde behande-
lingsduur van maximaal 24 maanden. In de literatuur werden diverse methodes 
gebruikt om de verschillende botafwijkingen te definiëren en om de prevalentie en de 
emst ervan vast te stellen. Een ander probleem is het differentiëren van retinoid-
geinduceerde afwijkingen van leeftijdsgebonden veranderingen. In ons onderzoek werd 
gebruik gemaakt van in de huidige radiologische literatuur algemeen geaccepteerde 
definities voor diffuse idiopatische skelethyperostosen (DISH), degeneratieve verande-
ringen en osteoporose. Tevens werd een scoringssysteem ontwikkeld om de emst van 
DISH en degeneratieve veranderingen te bepalen. De onderzochte patiëntenpopulatie 
bevatte zowel patiënten die geen retinoiden hadden gebruikt of slechts gedurende een 
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korte periode - van deze patiënten waren uitgangsfoto's van de wervelkolom beschik-
baar - als patiënten die gedurende langere tijd behandeld waren. Vijftig patiënten 
werden gedurende meer dan 24 maanden behandeld en 30 patiënten zelfs gedurende 
meer dan 48 maanden. Deze studie-opzet stelde ons in de gelegenheid om de skelet-
afwijkingen te relateren aan de duur van de retinoidbehandeling. De prevalentie en 
ernst van DISH, degeneratieve veranderingen en de prevalentie van osteoporose waren 
wel gecorreleerd met de leeftijd van de patiënten, maar niet met de duur van de 
retinoidbehandeling. Daarom menen we dat jaarlijkse röntgenonderzoeken van de 
wervelkolom geschrapt kunnen worden uit het behandelingsprotocol voor retinoïden. 
Als langdurige retinoidbehandeling verwacht wordt, dienen röntgenfoto's van de 
wervelkolom gemaakt te worden in de beginfase van de behandeling om de uitgangs-
situatie vast te leggen. 
Er is weinig bekend over de basale mechanismen van retinoid-gei'nduceerde botafwij-
kingen. Zijn er bepaalde patiënten die een verhoogde kans hierop hebben? Aanvullende 
prospectieve en gecontroleerde studies op het gebied van retinoid-gei'nduceerde 
botafwijkingen zijn nodig voor de ontwikkeling van definitieve behandelings-
protocollen. 
Samenvattend: 
Methotrexaat heeft een breed anti-psoriatisch actiespectrum. Het is een zeer effectief, 
algemeen toepasbaar en relatief veilig medicijn op dit gebied. Intermitterende dosis-
schemata zijn te prefereren boven langdurige continue behandeling. Dynamische 
hepatische scintigrafie is een veelbelovende nieuwe methode ter detectering van vroege 
leverschade. Deze methode wordt door de patiënten sterk geprefereerd boven de meer 
invasieve leverbiopsie procedure. 
Het effectiviteitsprofiel van acitretine bleek zowel aandoeningen met uitgebreide 
¡nflammatie te omvatten, zoals pustuleuze vormen van psoriasis, als ook aandoeningen 
zonder noemenswaardige inflammatoire component, zoals de ziekte van Darier, 
verschillende vormen van ichthyosis en palmoplantaire keratodermién. Deze resultaten 
reflecteren het brede actiespectrum van acitretine. De optimale dosis verschilt echter 
aanzienlijk tussen de verschillende aandoeningen. In een deel van de patiënten met de 
ziekte van Darier, lamellaire ichthyosis en Mal de Meleda trad een verslechtering op 
van de klinische symptomen bij hogere doseringen. Vooral bij deze aandoeningen is 
het belangrijk om te starten met een lage aanvangsdosis. De bijwerkingen van 
acitretine bleken sterk overeen te komen met die van etretinaat. Het regelmatig 
informeren naar skeletpij nen of bewegingsbeperking levert meer relevante informatie 
op over eventuele retinoid-gei'nduceerde skeletafwijkingen dan herhaalde routine-
röntgenonderzoeken van de wervelkolom. 
Behandelingsprotocollen zijn zeer belangrijk om de effectiviteit en veiligheid van 
langdurige systemische behandeling met methotrexaat en acitretine te optimaliseren. 
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Een patiënt-gerichte benadering biedt de mogelijkheid om de meest geschikte behande-
ling te selecteren voor de individuele patiënt in iedere fase van zijn ziekte en van zijn 
leven. 
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APPENDIX I 
Guidelines for Long-term Treatment with Methotrexate in Psoriasis 
Methotrexate (Ledertrexate®), tablets 2.5 mg 
Indications 
• severe psoriasis vulgaris/variants 
• erythrodermic psoriasis 
• (generalized) pustular psoriasis 
• severe psoriatic arthritis 
• severe nail psoriasis 
Contraindications (A= absolute; R= relative) 
• pregnancy/pregnancy wish <3 months, nursing (A) 
• fertile males contemplating conception <3 months (A) 
• significant disturbances of hepatic function (A) 
• renal inssufficience (dose adjustment) (R) 
• acute infectious disease (R) 
• severe anemia, leucopenia, trombopenia (R) 
• gastric ulcer, gastritis (A) 
• immunodeficiency states (R) 
• alcohol use (>l/day) (A) 
• use of other drugs that increase MTX toxicity (R) 
• history of arsenic use (A) 
• insufficient patient compliance (A) 
Most important side-effects 
• gastro-intestinal disturbances 
• subjective complaints (headaches, anorexia, fatigue etc) 
• hepatotoxicity 
• anemia, leucopenia, or thrombocytopenia 
• ulcerations of skin or mucous membranes 
• interstitial pneumonitis (rare but dangerous) 
• teratogenicity, mutagenicity 
¡S3 
Increased hepatotoxicity of MTX 
history of liver disease 
diabetes mellitus, obesitas, high age 
alcohol use 
high cumulative MTX dose? 
interactions with other drugs 
history of arsenic intake 
(Pre)treatment investigations 
pre 1-2 wks each 4-6 wks each 3-4 mths 
Hb, Ht, MCV, 
platelets, leuc, diff + + + + 
AST, ALT, gamma-GT, AF, bil + + + + 
LDH + + 
BSE + + + 
Creatinin + + + + 
Folic acid + - + 
Urine sed/prot О - О 
Liver biopsy + - - after each 
1.5 gr 
N.B.: О = optional 
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Important notes: 
• Before start of treatment it is strongly recommended to perform a creatinin-
clearance, or to estimate the creatinin-clearance according to the "Cockroft-Gault 
Formula" (CGF): 
(140-age) χ weight (kg)/ 0.81 χ fasting serum creat (μπιοΐ/ΐ) 
For female patients: X 0.85. 
CGF > 90: good renal function. 
CGF < 70: renal function seriously impaired. No MTX or adjustment of 
dosage (consult intemist/nefrologist). 
• Adequate anticonception is important in both male and female patients during 
treatment and £3 months after discontinuation. 
• In case of anemia it is important to determine the serum folic acid value. In case of 
low values: folic acid l-2x 5 mg/day, except on "MTX-days". 
• In case of gastrointestinal disturbances: folic acid 5 mg/day may be successful (not 
on "MTX-days").6 
• Alcohol use. In our department we have a "practical rule": <1 consumption/day and 
no alcohol on "MTX-days". 
• In case of acute fever, coughing, shortness of breath and cyanosis: CAVE 
interstitial pneumonitis! 
Diagnosis: chest X-ray. 
Therapy: STOP MTX, parenteral corticosteroids, intensive care treatment. 
• Combination with topical agents (and in some cases also UVB/PUVA) may reduce 
the weekly dosage. 
• Intermittent treatment schedule can result in a considerable reduction of the 
cumulative dose, even if the weekly dose has been "tapered off already! 
Information 
• Oral and written information on the effectivity and side-effects of MTX (patient 
leaflet). 
• Information on teratogenecity and adequate anticonception. 
• Information on potentially dangerous interactions with other drugs (drug 
registration card in wallet). 
• Informed consent in medical record. 
• Correspondence to general physician and other involved collegues. 
Liver biopsies 
• "Baseline" biopsy may be postponed 3-4 months in low-risk patients, untili the 
need for long-term treatment has been evaluated. 
• Liver biopsy after each cumulative dose of 1.5 gram. 
155 
Liver biopsy classification Consequence 
Grade I 
Grade II 
Grade IIIA 
Grade HIB 
Grade IV 
normal histology 
steatosis 
mild fibrosis 
severe fibrosis 
cirrhosis 
next biopsy after 1.5 g MTX 
next biopsy after 1.5 g MTX 
next biopsy after 6 months 
stop MTX 
stop MTX 
Weekly dosage MTX Cumulative dose 1.5 g after: 
7.5 mg 
15 mg 
50 months 
25 months 
Treatment schedule 
The most popular schedule is the "divided oral dose schedule" (Weinstein): 3 oral 
dosages/week at 12-hour intervals. One single oral dose/week is an alternative. 
Intramuscular or intraveneous treatment is possible, especially in case of gas­
trointestinal side-effects. 
In our department the maximum weekly dose is 15 mg/week, others consider 25-
30 mg/week as a maximum. Initial dosage 3x 2.5 mg/week, gradual increase (2.5-
5 mg/week) with monitoring of effectivity and side-effects. 
Interactions with other drugs 
Lethal complications were reported with the following concomitant medication: 
Sulfonamides 
Trimethoprim 
NSAID's 
Corticosteroids 
Cytostatics/ 
radiotherapy 
Retinoids 
Alcohol 
A 
+ 
+ 
В 
+ 
+ 
С 
+ 
+ 
+ 
D 
+ 
+ 
E 
+ 
+ 
+ 
A-
B= 
C= 
D= 
E = 
decrease of plasma protein binding 
competition of renal secretion 
hepatotoxicity 
folic acid antagonism 
bone marrow suppression/immunosuppression 
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MTX - intoxication 
• Determine serum MTX level: toxic range >10"* mol/1. 
• Immediately 20 mg folinic acid (Leucovorin·) or as many mg as the estimated 
MTX overdosage (parenterally). 
• Folinic acid every 6 hours during the first 48 hours or until serum MTX level <10"> 
mol/1 (orally or parenterally). 
• Folinic acid è 25 mg always IV or IM (maximal oral absorption), lower dosages 
can be given orally. 
• Always consultation of internist or rheumatologist. 
• Beyond 24 hr after MTX intoxication leucovorin is probably not effective anymore. 
Serum MTX concentration (mol/1) Dosage folinic acid (Leucovorin1") 
óhours 
< IO"' 
5x IO'7 20 
lx 10^ 100 
2x 10^ 200 
>2x 10"* proportionally higher 
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APPENDIX Π 
Guidelines for Long-term Treatment with Acitretin 
Acitretin (Neotigason*), capsules 10 and 25 mg 
Most important indications Initial Dose Estimation 
(mg/day) of Efficacy 
A Psoriasis spectrum 
• severe psoriasis vulgaris/variants 30-50 
• erythrodermic psoriasis 10-30 
• severe pustular psoriasis 50-75 
• persistent palmoplantar pustulosis 35-45 
• acrodermatitis continua Hallopeau 35-45 
В Monogenetic disorders of keratinization 
Ichthyosis 
• lammellar ichthyosis 
• bullous ichthyosis Brocq 
• ichthyosis bullosa Siemens 
• severe X-linked ichthyosis 
• Darier's disease 
• erythrokeratodermas 
• porokeratoses 
• Greither's disease 
• Mal de Meleda 
• other palmoplantar hyperkeratoses 
С Other skin diseases 
• pityriasis rubra pilaris 
• cutaneous lupus erythematodes 
• lichen planus 
• (pre)malignant skin conditions 
10-25 
10-25 
10-25 
25-35 
10-25 
25-35 
35-75 
35 
10 
10-35 
35-50 
35-50 
35-50 
50-100 
Contra-indications (A= absolute; R= relative) 
• pregnancy/pregnancy-wish <2 years, nursing (A) 
• severe hepatic dysfunction (A) 
• insufficient patient compliance (A) 
• moderate hepatic disturbances (R) 
• severe renal impairment (R) 
• strongly elevated serum levels of cholestérol/triglycérides (R) 
• concomitant treatment with tetracycline (risk factor for intracranial hypertension), 
or phenytoin (competition of plasma protein binding) 
• concomitant use of hepatotoxic drugs (R) 
Most important .side-effects (estimated prevalence) 
• cheilitis, dryness of eyes, nasal and oral mucosa (100%) 
• epistaxis (10%) 
• xerosis, pruritus (100%) 
• palmoplantar desquamation (60%) 
• hair loss (20-50%) 
• sticky skin (20%) 
• brittle nails (20%) 
• elevation of cholesterol /triglyderide gehalte (20%) 
• elevation of liver enzymes (20%) 
• severe liver damage (<1%) 
• spinal(?) and extra-spinal hyperostoses 
• teratogenicity 
(Pre)treatment investigations 
pre 2 wks each 4-12 wks each 12 mths 
+ 0 0 О 
+ + + + 
+ + + + 
+ + + + 
+ + + + 
+ О 
N.B.: О = optional 
Pregnancy-test 
Hb, Ht, platelets, 
leucocytes 
SGOT, SGPT, gamma-GT, 
AF, bil 
Chol, TG, HDL 
Creatinin 
Spinal X-ray 
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Important notes: 
1. The optimal therapeutic dose has to be individualized1; gradual adjustments 
according to effectivity and side-effects. 
2. Adequate anticonception from at least one month pre-treatment until two years 
post-treatment. 
3. Ask for skeletal pains and mobility restriction on a regular basis; radiographic 
control of symptomatic areas. 
4. Combination therapy with topical agents might reduce retinoid dose. 
5. Combination with UVB/PUVA in psoriasis is very effective. 
Patient information 
• Oral and written information concerning effectivity, side-effects and the need for 
adequate anticonception in fertile female patients (patient leaflet). 
• Informed consent in medical record. 
• Written information to general physician and other involved collegues. 
Use of Acitretin in children 
• Retinoids are only indicated in very severe disease 
• monitoring growth curves ( lx/ 6-12 months) 
• Annual radiographic control of spine, ankle, radius, skeletal age. 
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STELLINGEN 
behorende bij het proefschrift 
"Methotrexate and acitretin in severe psoriasis and disorders of keratinization: 
efficacy, side-effects and guidelines for long-term treatment" 
1. Methotrexaat is een zeer effectieve, breed toepasbare en relatief veilige 
behandeling voor patiënten met ernstige psoriasis, (dit proefschrift) 
2. Bij de behandeling van patiënten met ernstige psoriasis middels wekelijks 
methotrexaat is een kuursgewijs therapieschema te prefereren boven continue 
behandeling, maar hiervoor is intensieve begeleiding en motivatie van de patiënten 
door de behandelend dermatoloog noodzakelijk, (dit proefschrift) 
3. Dynamische hepatische scintigrafie is een veelbelovende onderzoeksmethode om 
vroege methotrexaat-geinduceerde leverschade bij patiënten met psoriasis op te 
sporen, (dit proefschrift) 
4. Het routinematig uitvoeren van leverbiopsiën zal waarschijnlijk binnen een tiental 
jaren verdwijnen uit het methotrexaat-behandelingsprotocol voor patiënten met 
psoriasis, (dit proefschrift) 
5. Het is belangrijk om bij de controle van patiënten die langdurig met orale 
retinoïden behandeld worden regelmatig te vragen naar skeletpijnen of bewegings-
beperking, (dit proefschrift) 
6. De prevalentie van spinale skeletafwijkingen is sterk gerelateerd aan de leeftijd 
van de patiënten en waarschijnlijk niet of nauwelijks aan de duur van een 
eventuele orale retinoi'dbehandeling. (dit proefschrift) 
7. Phototherapie met UVB is een goede behandelingsmogelijkheid voor chronisch 
cutané graft versus host ziekte, als PUVA therapie gecontraïndiceerd is of slecht 
verdragen wordt. 
8. De diagnose calciphylaxie wordt zelden op tijd gesteld. 
9. Bekkenklachten in relatie tot zwangerschap en partus zijn nog te weinig bekend 
bij artsen, fysiotherapeuten en verzekeraars. 
10. Het huidige co-schap dermatologie van twee weken is te kort om basisartsen 
adequaat op te leiden. 
11. Klinisch gericht wetenschappelijk onderzoek kan ook goed in de perifere praktijk 
worden uitgevoerd. Mede door een tekort aan specialisten wordt dit op 
onvoldoende grote schaal gedaan. 
12. Voor vrouwen met ambitie is effectiviteit veel belangrijker dan assertiviteit. 
13. Vijfendertig jaar is een goede leeftijd om te promoveren. 
14. Flexibiliteit dient niet te worden verward met chaos (P.M. Steijlen, proefschrift 
1994), maar ordelijkheid bevordert het functioneren van een flexibele geest. 
15. Een goede dressuurinstructeur kan belangrijke informatie verschaffen over het 
opvoeden van jonge kinderen. 
16. Aeque peccat, qui omnes fabulas a ritibus atque sacris et qui ritus omnes a fabulis 
repetit. (С.A.A.J. Greebe, proefschrift 1895) Vrij vertaald: Degene die alle 
verhalen ontleent aan de godsdienstige ceremoniën zondigt evenzeer als degene 
die alle ceremoniën ontleent aan de verhalen. 
17. Niet slechts bij motorrijtuigen op meer dan twee wielen doch ook bij tweewielige 
motorvoertuigen kan zich het geval voordoen, dat degene onder wiens toezicht het 
motorvoertuig wordt bestuurd, als "bestuurder" moet worden aangemerkt. 
(J.J.A.F. Greebe, proefschrift 1935) Deze stelling is sedert 14 augustus 1985 niet 
meer juist. 
18. De grote invloed van de publieke smaak op de programma's van symphonie-
concerten leidt tot onverantwoorde uitvoeringspraktijken. 
(C.A.A.J. Greebe, proefschrift 1962) 
Nijmegen, 10 november 1995 R.J. van Dooren-Greebe 


